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Abstract 
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature 
monocytes and granulocytes that are potent inhibitors of T cell activation. A role for MDSCs in 
bacterial infections has only recently emerged, and our laboratory was the first to demonstrate a 
functional role for MDSCs during Staphylococcus aureus (S. aureus) biofilm infection. Biofilm 
infections often lead to significant morbidity due to their recalcitrance to antibiotics and ability to 
subvert immune-mediated clearance by skewing the immune response toward an anti-
inflammatory, pro-fibrotic phenotype. Therefore, we examined whether MDSCs could play a role 
in this process. CD11b
+
Gr-1
+
 MDSCs represented the main cellular infiltrate during S. aureus 
orthopedic biofilm infection, and biofilm-associated MDSCs inhibited T cells proliferation and 
cytokine production, which correlated with a paucity of T cell infiltrates at the infection site. 
Importantly, tissues obtained from patients undergoing revision surgery for prosthetic joint 
infections (PJIs) revealed similar patterns of immune cell influx, with increased MDSC-like 
infiltrates and significantly fewer T cells compared to aseptic revisions. Depletion of MDSCs and 
improved bacterial clearance by enhancing the intrinsic proinflammatory attributes of infiltrating 
monocytes and macrophages.  However, the mechanisms responsible for MDSC homing to sites 
of biofilm infection and factors mediating immunosuppression remain unknown. In cancer, 
proinflammatory signals initially induce MDSC recruitment and activation, while the 
immunosuppressive functions of MDSCs are mediated through factors like IL-10, Arg-1 and 
iNOS. IL-12p40 and IL-10 are both significantly elevated during S. aureus biofilm infection. These 
studies demonstrate that IL-12 plays a key role in the recruitment of MDSCs into biofilm infection 
via a chemoattractant that remains to be identified, while IL-10 is produced by infiltrating MDSCs 
at the site of biofilm infection, whereupon it plays a critical role in polarizing 
monocyte/macrophages toward an anti-inflammatory phenotype. Loss of either IL-12 or IL-10 
during the early MDSC recruitment or effector phases, respectively, promotes biofilm clearance, 
implicating key roles for each cytokine at distinct stages of infection. Collectively, these studies 
demonstrate that MDSCs are key contributors to the chronicity of S. aureus biofilm infection, as 
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their immunosuppressive function prevents monocyte/macrophage proinflammatory activity, 
which facilitates biofilm persistence. 
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Chapter 1: Introduction 
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1) S. aureus biofilm infection 
a) Methicillin-resistant Staphylococcus aureus 
 Staphylococcus aureus (S. aureus) is a gram-positive bacterium known to colonize the 
skin and nasal mucosa of approximately one-third of people worldwide [1-4]. Since its discovery 
in the 1880s, S. aureus has been regarded as a serious threat to human health, causing a range 
of diseases from superficial skin and soft tissue infections to more invasive infections like 
bacterial pneumonia and sepsis [3]. Prior to the 1960s, these infections were routinely and 
successfully treated with antibiotics.  However, the marked ability of S. aureus to adapt to 
different environments, [5, 6] along with the misuse and overuse of antibiotics, aided bacterial 
evolution and resulted in the rise of methicillin-resistant S. aureus (MRSA) strains [7].  
The emergence of MRSA has not only complicated the treatment of S. aureus infections, 
but has led it to become one of the most frequent causes of hospital- and community-associated 
infection [8, 9] with the ability to cause disease in otherwise healthy individuals [9, 10]. In addition, 
many MRSA isolates have acquired resistance to other antibiotics, including erythromycin 
(macrolide), clindamycin (lincosamide), ciprofloxacin (fluoroquinolone) and tetracycline 
(polyketide) [7]. Due to this widespread resistance to antibiotics and a lack of other alternative 
therapeutics, the glycopeptide vancomycin has become the standard treatment for MRSA [4]. 
Although most MRSA strains are known to be susceptible to vancomycin, there are certain S. 
aureus isolates that are vancomycin intermediate-resistant (VISA) and are only susceptible to 
vancomycin at high concentrations [11]. Full vancomycin resistance is extremely uncommon and 
has developed much slower than resistance to β-lactam antibiotics. However, the continued 
increase of vancomyin use in the U.S. has raised concerns that selective pressure will cause 
vancomycin-resistant S. aureus (VRSA) strains to become more prevalent and result in a return 
to the pre-antibiotic era [3, 4, 6, 12]. Recent U.S. estimates indicate MRSA causes approximately 
95,000 invasive infections and 19,000 deaths per year, a mortality rate higher than that for HIV, 
viral hepatitis, tuberculosis and influenza combined, highlighting a need for more therapeutic 
options to target this elusive pathogen [6]. 
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The mechanism underlying methicillin resistance is the acquisition and insertion of the 
staphylococcal cassette chromosome mec (SCCmec) into the chromosome of susceptible 
strains, protecting these bacteria from the entire class of available β-lactam antibiotics [2, 11]. 
Currently there are 11 SCCmec types, all of which include the mecA gene that encodes for the 
low-affinity penicillin-binding protein PBP2a [13, 14]. β-lactam antibiotics are unable to inhibit 
PBP2a, in contrast to other S. aureus PBP proteins, which leads to resistance. While the high 
frequency of antibiotic resistant strains contributes to its ability to cause disease, S. aureus also 
expresses several other virulence factors that contribute to its ability to cause disease. For 
example, nearly all strains of S. aureus secrete α- and γ-hemolysins and some leukocidins, 
whereas a few secrete superantigen toxic shock syndrome toxin (TSST), and the pore-forming 
toxin Panton-Valentine leukocidin (PVL) [5, 15]. Not only do these virulence determinants aid the 
organism in evading the host immune system, but can also directly damage leukocytes and host 
tissues.  
 Until recently, MRSA cases were mainly the result of healthcare-associated (HA) 
infections and affected compromised hosts who were chronically ill or had implanted medical 
devices [16]. However, the incidence of community-acquired MRSA (CA-MRSA) is increasing and 
affects healthy persons who do not share the same associated risk factors as patients in the 
hospital [10, 13, 16]. CA-MRSA strains carry the smaller staphylococcal cassette chromosome IV, 
and many possess PVL genes [10, 17]. Populations at risk for CA-MRSA infection include 
intravenous drug users, prison inmates, athletes, military personnel, individuals in close contact 
with MRSA carriers as well as those with a history of boils or skin infections [18-20]. The most 
commonly isolated strain of CA-MRSA is pulse-field type USA300 [21], which a recent study 
estimates accounts for about 67% of all invasive CA-MRSA infections [9]. These CA-MRSA 
strains have been characterized for their increased virulence compared to HA-MRSA 
counterparts, allowing for their rapid rise and implication in several outbreaks in the U.S. [22, 23]. 
This increased virulence may be attributed to two prophages not found in other MRSA strains, 
namely prophages ΦSa2 and ΦSa3, with prophage ΦSa2 encoding for the PVL genes [24]. In 
particular, prophage ΦSa2 encodes for staphylokinase, staphylococcal complement inhibitor and 
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S. aureus chemotaxis inhibitory protein (CHIPS), which are all capable of neutralizing innate 
immune mechanisms for bacterial elimination [25].  
 Our laboratory has acquired a USA300 clinical isolate and has used this S. aureus strain 
to strengthen the translational impact of studies in our experimental mouse models of biofilm 
infection. Specifically, this USA300 LAC 13c strain was isolated from a skin and soft tissue 
infection in a detainee from the Los Angeles County Jail (LAC) and cured of the p01(cryptic 
plasmid) and p03 (confers erythromycin resistance) plasmids [9, 26]. The USA300-0114 strains 
are primarily responsible for CA-MRSA infections in the U.S. and  predominantly carry the IVa 
subtype of SCCmec, spatype YHGFMBQBLO, msrA-mediated macrolide resistance and a 
number of virulence genes, including lukS-PV/lukF-PV and arcA, coding for PVL and the arginine 
catabolic mobile element (ACME), respectively [22, 23].  
b) Biofilms 
 In addition to antibiotic resistance, staphylococci have alternative mechanisms of survival 
and virulence, among which is biofilm formation [1, 27-29]. Biofilms are defined as adherent 
communities of bacteria encased within a complex matrix composed of proteins, polysaccharides 
and eDNA [27-33] often surrounded by a host fibrotic response, and staphylococci are recognized 
as the most frequent cause of biofilm-associated infections [34]. Specifically, S. aureus is capable 
of forming biofilms on both natural body surfaces, including the lung and heart, as well as medical 
devices, such as indwelling catheters and prostheses [27, 32, 33, 35]. Although CA-MRSA strains 
are able to form biofilms, and show recalcitrance to antibiotics, it is believed that the biofilm offers 
additional protection against antimicrobial agents, and indeed microorganisms within biofilms 
have a greater resistance to antimicrobial killing than planktonic cells of the same species [32, 
36]. This increased resistance may be related to the reduced growth rate of biofilm 
microorganisms. Cells encased within the biofilm matrix grow much more slowly than planktonic 
cells, and as a result, take up antimicrobial agents more slowly. In addition, many antibiotics 
target cell wall synthesis, which is reduced during biofilm growth, causing them to be less 
effective [28, 33, 36]. Furthermore, the structure of the biofilm and its secreted products interfere 
with host innate immune responses and proper recognition of biofilm-associated bacteria [32]. 
23 
 
Taken together, the resistance to available therapies and evasion of host immune responses has 
made biofilm infections a significant human health problem. 
 Biofilm development is a multi-step process that involves initial attachment of bacterial 
cells to biotic or abiotic surfaces, followed by accumulation or maturation of the biofilm before 
single cells or larger cell clusters detach from the biofilm mass [29, 34, 37, 38]. Each of these 
phases are thought to be physiologically different from one another and require phase-specific 
gene regulation [34]. During initial attachment, an individual planktonic cell will reversibly 
associate with a surface, and if the cell does not dissociate, it will bind irreversibly to the surface 
[30]. S. aureus has the ability to attach to nearly any indwelling medical device, and this is 
thought to occur through direct interaction with the device’s polymer surface and host matrix 
proteins that coat implanted devices [37]. Attachment to the plastic or metal surface of an 
indwelling medical device is driven mostly by hydrophobic or electrostatic interactions initially [38]. 
However, almost immediately after implantation these devices are coated in host matrix material 
which greatly enhances bacterial attachment. Staphylococci express microbial surface 
components recognizing adhesive matrix molecules (MSCRAMMs), surface-anchored proteins 
that allow for adherence and colonization of devices and host tissue [29, 38]. In addition to 
MSCRAMMs, teichoic acids and the surface protein autolysin have also been described as being 
involved in the attachment phase of staphylococcal biofilm development [38].  
 Once attachment has occurred, proliferation proceeds through the production of an 
extracellular matrix (ECM) that contributes to intercellular aggregation [29, 37, 38]. 
Polysaccharide intercellular adhesion (PIA), which covers most staphylococcal cells, is a major 
component of the ECM and directly mediates biofilm accumulation [34, 38, 39]. PIA is 
synthesized, exported, and modified by products of the ica locus and its importance in biofilm 
development has been demonstrated in numerous studies [40-43]. Most S. aureus strains have 
the ability to produce PIA; however, some S. epidermidis strains lack the ica genes and thus do 
not produce PIA. These strains are able to form biofilms in vitro and in vivo [39, 44, 45]. In these 
cases, it is apparent that other surface-associated proteins such as protein A, fibrinogen-binding 
proteins (FnBPA and FnBPB), S. aureus surface protein (SasG), biofilm-associated protein (Bap), 
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and clumping factor B (Clf B) are also involved in attachment and accumulation [30]. In addition, 
Aap, teichoic acids, or DNA released from lysed bacteria (eDNA) facilitate cell-cell adhesion [45-
47], further demonstrating the complexity of the biofilm maturation process.  
 Detachment represents the final stage of biofilm development and is often the cause of 
bloodstream infection, emboli and metastatic spread of bacteria [27, 34]. In clinical settings, 
biofilms are often thought of as a reservoir for dissemination of microorganisms to other sites in 
the host. This phase is facilitated by mechanical forces, cessation of the production of biofilm 
adhesion molecules, or enzymes that destroy the matrix [34]. In S. aureus, the rate of biofilm 
dissemination is thought to be primarily controlled by the accessory gene regulator (Agr), a 
quorum-sensing system that controls gene expression in a cell-density dependent manner [38]. 
Agr upregulates the expression of toxins and proteases while downregulating the expression of 
surface adhesion proteins upon entry into the stationary phase of growth through sensing of a 
peptide pheromone, autoinducing peptide (AIP) [38]. Detachment is the result of Agr activation 
expression in the outer layers of the biofilm, while expression in deeper layers could be required 
for efficient formation of channels necessary for nutrient access [37, 48]. 
c)  Prosthetic Joint and Catheter-Associated Infections 
 The risk of infection is increased by the presence of foreign materials [4], and infections 
associated with indwelling medical devices are typically caused by microorganisms that grow in 
biofilms [36]. It is known that only a small number of organisms are needed to colonize an implant 
[49]. Thus, bacterial strains that are able to form biofilms have an advantage in this setting, as 
once they adhere they can proliferate and mature to form a biofilm while avoiding detection by the 
host innate immune system. Often organisms associated with these devices are skin flora 
inoculated at the time of implantation [49]. Indeed, staphylococcal species like S. aureus are 
among the most common etiologic agents of device-related infections [38, 50], with the incidence 
of infection due to resistant strains of staphylococci accounting for up to 50% of prosthetic joint 
infection (PJI) in one study [16]. In some cases, organisms can seed implants hematogenously or 
through compromised local tissues, particularly during indwelling catheter implantation [49, 51].  
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 The number of joint replacement surgeries has been continuously increasing, and as with 
any surgical procedure, complications can arise, including failure due to infection. Currently, the 
rates of PJI following primary procedures range from 1-9% [52]. The seriousness of this 
complication is due to the formation of biofilms on prosthetic devices and their inherent 
recalcitrance to traditional antibiotic therapy. Therefore, these chronic infections often require 
device resection arthroplasty, and two-stage replacement is the current standard-of-care 
treatment in North America [16, 49]. The two-stage exchange begins with removal of the infected 
prosthesis and implantation of an antibiotic-impregnated spacer to control infection during the 
prosthesis-free interval, during which antibiotic therapy is also administered systemically. Six 
weeks to three months following the first stage, a new prosthesis is inserted during a second 
procedure [16, 49]. Despite this lengthy process and continued administration of antimicrobial 
agents, these devices often fail again due to infection. It is estimated that infection rates reach 
40% following revision procedures [52]. This failure can be attributed not only to recurrence of the 
primary organism, but also to infection by novel organisms [16].  
Catheters of all types are used in clinical practice to improve the quality of life of 
chronically and critically ill patients. However, biofilm formation and bloodstream infections are 
major risks associated with catheter placement [53], and can result in CSF shunt infections [54-
56] or catheter-related bloodstream infections in the case of central venous catheters (CVCs). 
Since the presence of a biofilm on the implant subjects the host to constant dispersal of biofilm-
associated cells through the blood stream coupled with the biofilm’s resistance to antibiotic 
therapy, catheter removal is the conventional management for these infections [53]. Although 
removing CVCs and reinserting another in a different vascular access site carries its own 
complications, there are currently a limited number of alternative therapeutic options for 
physicians [53, 57]. 
d) Mouse models of biofilm infection 
 Currently, the two most commonly employed animal models for the study of S .aureus 
biofilm infection are catheter-associated and orthopedic implant-associated infections. These two 
models have been employed in many different tissues and cavities to examine host-pathogen 
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interactions under static or dynamic conditions, including subcutaneous, venous and CNS 
catheter-associated infections [32, 42, 43, 55, 58] as well as orthopedic implants associated with 
the femur or tibia [28, 59-62].  
In general, the orthopedic implant-associated models explore static biofilm growth and 
host-pathogen interactions at the site of a chronic infection with direct access to the bone marrow, 
which could have important immunological implications on the course of infection. Furthermore, 
this model can be used to examine the incidence of implant-associated osteomyelitis, of which S. 
aureus is a leading cause [61]. Careful attention was paid during the development of this model to 
use materials that would allow for accurate representation of several facets of human disease 
seen in the clinical setting. Titanium alloys are the most common metals used in total joint 
arthroplasties, and thus, nickel-titanium wire was selected for the implant material in the 
orthopedic model utilized in the Kielian laboratory [63].  
 The subcutaneous catheter model of S. aureus biofilm infection used in our laboratory is 
a static model, which does not recapitulate the sheer forces that a biofilm would encounter in an 
indwelling intravascular catheter, but does allow for the investigation of various aspects of host-
pathogen interactions. This model can also be highly advantageous due to its easy tissue 
accessibility to monitor infection, straightforward device placement and relatively high-throughput 
nature compared to orthopedic implant models that require much more laborious surgery [60]. 
Collectively, these mouse models of infection have allowed for a better understanding of the 
mechanisms governing the innate immune response to S. aureus biofilm infection [32, 59, 60, 62] 
as well as ways in which bacteria evade this response through the use of bacterial mutant strains 
and mice deficient for various immune-related molecules. Continued use of these models could 
potentially allow for the identification of critical disease determinants as well as therapeutic 
targets to reduce patient morbidity and mortality associated with bacterial biofilm infection.   
2) Innate Immune response to S. aureus infection 
a) Innate immune recognition of S. aureus 
 Innate immunity represents the first line of defense against invading pathogens and all 
cells of the innate immune system rely on a set of germ-line encoded pattern recognition 
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receptors (PRRs) directed against highly conserved pathogen-associated molecular patterns 
(PAMPs) to elicit a rapid immune response [64]. Perhaps the most common class of PRRs are 
Toll-like receptors (TLRs), of which thirteen have been identified in humans, and ten in mice [64, 
65]. Despite the differences in ligands for each of the TLRs, most utilize a common signaling 
pathway through MyD88 and NF-κB/MAPK that leads to the transcriptional activation of 
proinflammatory cytokines and chemokines [66-69]. In terms of gram-positive bacteria and 
staphylococcal species, TLR2, expressed on the surface of innate immune cells such as 
monocytes/macrophages and neutrophils, is involved in the recognition of peptidoglycan (PGN) 
and lipoproteins [70], while TLR9 is an intracellular receptor that recognizes unmethylated CpG 
motifs characteristic of bacterial DNA [31].  
 The involvement of TLRs has been implicated in mediating innate immune recognition 
and elimination of staphylococcal species during planktonic growth [71-75]. TLR2-deficient mice 
exhibit increased mortality rates during S. aureus-induced sepsis, due to a failure in bacterial 
recognition and decreased proinflammatory cytokine production [72]. However, patients with 
mutations inactivating TLR2 have no increased risk of developing post-arthroplasty S. aureus 
infection, which agrees with reports from our laboratory and others that have determined biofilms 
circumvent TLR2 and TLR9 recognition [32, 62].  Unlike during planktonic S. aureus infection, 
TLR2 and TLR9 KO mice display similar biofilm burdens as WT animals and all display 
attenuated inflammatory mediator expression. These observations indicate that, in the context of 
indwelling device-associated biofilm infection, bacteria circumvent traditional PRR recognition 
strategies of innate immune cells and thus also deter downstream proinflammatory responses to 
invading pathogens [32, 62]. Although TLR2 is essential for S. aureus recognition during 
planktonic infection, the altered growth state S. aureus assumes during biofilm infection could 
determine whether these sensing mechanisms are effective.  
Further hindering TLR engagement is the observation that host leukocytes do not form 
intimate associations with biofilms, both in vitro and in vivo. This could be due to the fact that 
biofilms are encased within a complex structure, with few free bacteria exposed on the outer 
surface, thereby avoiding detection by PRRs [32, 61]. In addition, the biofilm matrix contains 
28 
 
complex polysaccharide polymers that may interfere with engagement of TLR ligands [76]. S. 
aureus is known to produce staphylococcal superantigen-like (SSL) proteins, of which SSL3 has 
been shown to block TLR2 activation through direct extracellular interaction with the receptor [77]. 
However, it is possible that S. aureus biofilms may be recognized by alternative PRRs. For 
example, both AIM2 and DNA-dependent activator of IFN-regulatory factors (DAI) can sense 
eDNA which is a major component of the S. aureus biofilm ECM [78, 79]. Muramyl peptide, the 
degradation production of staphylococcal PGN, can be sensed by the cytoplasmic PRR 
nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and elicit proinflammatory 
mediator release independent of TLR signaling [80, 81].  
Although TLR2 and TLR9 do not appear to be involved during staphylococcal biofilm 
infections, a role for IL-1β has been revealed in controlling early bacterial burdens during PJI [62]. 
IL-1β KO mice displayed enhanced biofilm formation and decreased neutrophil recruitment, which 
was most pronounced during early time points. This indicates the proinflammatory properties of 
IL-1β may have a protective role early before a robust biofilm has gained a foothold on the 
associated implant. Interestingly, both the IL-1 receptor (IL-1R) and TLRs share a common 
downstream adaptor, myeloid differentiation factor 88 (MyD88), that when activated leads to NF-
κB-mediated transcription. Studies from our laboratory have shown that MyD88 greatly influences 
the course of biofilm infections, as MyD88 KO mice have significantly higher bacterial burdens 
and decreased expression of several proinflammatory mediators necessary for mounting a robust 
immune response against S. aureus [31]. Taken together, in the context of what is known about 
TLR and IL-1β signaling during S. aureus biofilm infection, MyD88 appears to play a dual role 
during biofilm infection. Early MyD88 signals are responsible for biofilm containment and MyD88 
loss decreases the proinflammatory capacity of effector cells, such as macrophages, that 
participate in the clearance of planktonic bacteria that would be encountered during biofilm 
dispersal and dissemination to distant sites in the host [31, 62].  
Altogether the understanding of innate immune signaling to biofilm infection and the 
timing of these signals is poorly understood. There is likely a very concerted series of events 
following inoculation of planktonic bacteria, adherence and maturation into a robust biofilm 
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infection. A better understanding of the innate immune recognition mechanisms that are important 
during all stages of biofilm development is needed in order to determine alternative ways to target 
the innate immune system and develop alternative therapeutics to combat these persistent biofilm 
infections. 
b) Neutrophil response to S. aureus 
 In models of planktonic S. aureus infection, it has been shown that association of TLR2, 
MyD88 and the subsequent production of cytokines and chemokines is involved in the 
recruitment of neutrophils that mediate innate immune responses at infection sites [82]. 
Neutrophils are a phagocytic cell of the innate immune system and are often considered the first 
responder to staphylococcal infection, as they rapidly migrate to sites of inflammation [83, 84]. 
Mediators such as CXCL1 and CXCL2, among others, are produced in response to damage or 
invading pathogens and bind specific surface receptors on neutrophils directing their 
extravasation from the circulation. Specifically, S. aureus surface components like LTA, and 
secreted molecules such as staphylococcal enterotoxins and toxic shock syndrome toxin (TSST)-
1, have been shown to elicit chemokine production by monocytes and epithelial cells, thereby 
recruiting neutrophils to the site of S. aureus infection [83, 85, 86]. In addition, the complement 
component C5a is another potent neutrophil chemotactic molecule and S. aureus PGN has been 
shown to directly activate the complement cascade [87].  
Once at the site of planktonic infection, neutrophils have the capability to phagocytose 
bacteria, including S. aureus. As mentioned previously, all cells of the innate immune system 
express PRRs. In terms of neutrophil responses, engagement of these receptors activates 
pathways critical to microbicidal activity and prolonged cell survival. Neutrophils are perhaps best 
known for their production of large amounts of reactive oxygen species (ROS) and degranulation. 
However, they also secrete proinflammatory cytokines and chemokines, including TNF-α, IL-1β, 
CXCL2, CXCL11 and CCL3 [31, 88, 89], and have a vast arsenal of anti-microbial peptides such 
as α-defensins, cathelicidins, cathepsins, and lysozyme that also play a role in neutrophil-
mediated immunity [83, 90]. Because these cells possess high cytotoxic capacity and 
proinflammatory potential, regulation of cell turnover is essential for maintaining homeostasis. 
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This is accomplished through apoptosis [83]. In the context of infection, where neutrophils are 
recruited and activated, apoptosis is accelerated and the clearance of apoptotic neutrophils by 
macrophages is thought to play a key role in the resolution of the inflammatory response [83, 91].  
Despite the large arsenal of weapons neutrophils possess to combat invading bacteria, 
many pathogens have evolved mechanisms to evade neutrophil-mediated host defense 
strategies. Indeed, S. aureus can actively avoid destruction by neutrophils and survive to cause 
devastating disease. One of the most fundamental features of S. aureus’ ability to cause infection 
is the secretion of toxins. α-hemolysin (Hla) is the major cytotoxic exotoxin secreted by S. aureus, 
and functions by binding to a disintegrin and metalloprotease 10 (ADAM10), initiating cytolytic 
pore formation [92]. In addition, γ-hemolysin and PVL are known to preferentially target and lyse 
leukocytes [3, 93]. Furthermore, S. aureus expresses extracellular adherence proteins (Eap) that 
bind and inhibit intercellular adhesion molecule-1 (ICAM-1), the endothelial receptor required to 
initiate leukocyte adhesion and diapedisis from the vasculature [93, 94], and about 60% of S. 
aureus strains are known to secrete the chemotaxis inhibitory protein of staphylococci (CHIPS), 
which binds to chemokine receptors and inhibits neutrophil recruitment to sites of infection [3, 93]. 
S. aureus blocks complement activation and resists phagocytosis through the production of 
surface-associated anti-opsonic proteins, like protein A, and a polysaccharide capsule [3, 93]. 
There is also evidence to suggest that CA-MRSA strains can induce programmed necrosis of 
neutrophils following phagocytosis, which some consider to be a component of enhanced 
virulence, since a large proinflammatory response to lysed neutrophils is avoided and the bacteria 
can go undetected longer within the intracellular compartment [95].  
Although S. aureus possesses a wide variety of subversion strategies, neutrophils can 
still exert bactericidal activity under planktonic conditions [70, 96, 97]. However, the direct role of 
these cells in modulating S. aureus biofilm infection is less understood. Some in vitro studies, 
using both static and flow cell biofilms, have suggested that neutrophils are capable of migrating 
toward and clear the biofilm by phagocytosis [98, 99]. But, the extent of clearance depended on 
the maturation state of the biofilm, with developing young biofilms being more sensitive to 
neutrophils than more mature biofilms [99]. It is possible that immature biofilms have more 
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associated planktonic bacteria, as the structure is still developing, which could account for the 
effectiveness of a neutrophils. It would be presumed then that a mature biofilm has fewer 
planktonic cells associated with it and is thereby protected from this response. In addition, many 
of these studies have only been performed in vitro, and our laboratory has shown that several 
inflammatory signals responsible for recruitment and activation of innate immune cells are 
attenuated in vivo and biofilm-infected tissues have limited numbers of infiltrating neutrophils [32, 
59, 60, 100]. This calls into question the in vivo relevance of an effective neutrophil response to 
biofilms. Indeed, studies in our laboratory using adoptive transfer of neutrophils into tissues 
surrounding catheter-associated biofilms in vivo showed these cells were not able to clear biofilm-
associated bacteria. Although there have been reports that increasing numbers of neutrophils are 
present during S. aureus post-arthroplasty infection [62], neutrophils were quantified based on 
H&E staining or EGFP-fluorescent signals from LysM-GFP mice [62]. Furthermore, the use of 
Ly6G alone is not a good marker for neutrophil populations, due to overlap with immature 
precursor populations like MDSCs. Therefore, many of these methods have resulted in possible 
inaccurate quantitation of neutrophil cell numbers present at the site of S. aureus infection.   
c) Macrophage response to S. aureus 
 Along with neutrophils, macrophages are an important innate immune effector cell critical 
for defense against acute planktonic staphylococcal infection. To date, however, the majority of 
studies investigating innate immunity to S. aureus have focused on neutrophils, and therefore 
much less is known about macrophage responses during staphylococcal infection. Neutrophils 
have potent microbicidal activity, but are short-lived and require rapid cell turnover in addition to a 
limited capacity to produce inflammatory cytokines and chemokines. Macrophages, on the other 
hand, have important and diverse roles in regulating tissue homeostasis by eliminating apoptotic 
cells and recycling nutrients by eliminating waste products from tissues [101-103]. Additionally, 
they are critical for an effective immune responses and produce high levels of proinflammatory 
mediators that amplify immune cell recruitment/activation cascades [32, 104, 105]. Macrophages 
are derived from bone marrow precursors of the granulocytic-monocytic lineage that develop into 
monocytes. Monocytes remain in the bone marrow < 24 h before entering the systemic 
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circulation. Only after monocytes cross endothelial venules and enter tissue do they transition into 
macrophages [103]. Unlike neutrophils, nearly all tissues contain resident macrophages and 
these cells can serve as critical first line defenders against invading microbes [32, 106, 107]. 
Normally resident macrophages are relatively quiescent, but they can be readily activated by a 
variety of stimuli during the immune response, in part through their Toll-like and scavenger 
receptors [103].  
 Macrophages can exhibit both pro- and anti-inflammatory properties and are generally 
characterized based on gene expression patterns and cytokine secretion. But these phenotypes 
are driven largely by the environment in which a macrophage is found and stimuli they encounter, 
which results in a great deal of plasticity within a macrophage population [101, 103]. Some 
polarization signals may include apoptotic cells, hormones, immune complexes, cytokines and 
bacteria-associated PAMPs [103]. It is thought that stimulation by microbial products elicits the 
production of proinflammatory cytokines like IL-1, IL-6, IL-12, and TNF-α, as well as nitric oxide 
(NO) and various chemokines, which are generally associated with protective responses and 
bacterial clearance [101, 108-110]. However, inflammation is a tightly regulated process, and 
macrophages can become more anti-inflammatory and pro-fibrotic, producing multiple inhibitors 
and antagonists, like IL-10 and arginase-1 (Arg-1), which suppress activation and 
proinflammatory mediator production in addition to lowering microbicidal activity [111]. Further 
compounding this complexity, pathogenic bacteria have developed mechanisms, including biofilm 
formation, to interfere with or alter macrophage phenotypes in an effort to enhance survival and 
promote persistence within the host, as described below. 
 Previous reports have shown that mixed leukocyte and purified neutrophil populations are 
capable of infiltrating biofilms [98, 112], and our laboratory has demonstrated that macrophages 
are also able to invade these structures to some extent [32]. However, macrophages displayed a 
limited ability to phagocytose S. aureus biofilm-associated bacteria in vitro and in vivo. In fact, the 
majority of macrophages that invaded S. aureus biofilms in vitro were dead compared to those 
that remained above the biofilm surface [31, 32]. The reasons for this could be due to several 
factors. First, biofilms appear to secrete factors that limit the phagocytic potential of 
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macrophages. Macrophages incubated with conditioned supernatants from S. aureus biofilms in 
vitro were unable to phagocytose latex beads or planktonic bacteria, which were readily 
internalized by untreated macrophages [31]. Second, the sheer size and complex organization of 
the biofilm structure could inhibit phagocytosis of biofilm-associated bacteria, as it exceeds the 
size of a macrophage by several orders of magnitude, and macrophages were capable of 
phagocytosing bacteria from mechanically disrupted biofilms [32]. Even if macrophages do 
phagocytose some bacteria, S. aureus gene products have been associated with the 
detoxification of ROS and RNS. Thus, S. aureus can survive and grow within macrophages [113]. 
These phenomena could have significant implications during biofilm infections, as macrophages 
would be impaired in their ability to scavenge dead cell/debris or contribute to tissue remodeling 
in the vicinity of the biofilm and contribute to biofilm persistence in vivo [31].  
 There is also emerging evidence that suggests staphylococcal biofilms actively skew host 
immunity toward an anti-inflammatory, pro-fibrotic response that favors bacterial persistence [31, 
32, 114]. Studies from our laboratory have shown preferential accumulation of anti-inflammatory 
macrophages in the S. aureus biofilm milieu, both in vitro and in vivo [31, 32, 61]. These cells 
have decreased inducible nitric oxide (iNOS) expression, while Arg-1 is increased. Both iNOS 
and Arg-1 compete for arginine to initiate their respective biosynthetic pathways, and a 
preferential induction of Arg-1 in biofilm-associated macrophages likely results in skewing the 
immune response away from bacterial killing [31, 32]. Increased Arg-1 activity has implications 
beyond innate immune responses as well. For example, Arg-1 leads to L-proline production, 
which is a precursor in the collagen biosynthetic pathway [115, 116], and studies from our 
laboratory have shown increased Arg-1 expression associated with pro-fibrotic macrophage 
responses to S. aureus biofilms in vivo [32, 117].  Arginine can regulate T cell proliferation and 
effector functions; therefore, arginine depletion from the environment results in defective TCR 
signaling through inhibition of CD3ζ expression, cell cycle, and cytokine production. Indeed, our 
laboratory has found few T cell infiltrates associated with different models of biofilm infection, 
including human post-arthroplasty implants and cranial bone flap biofilm infection [32, 59, 100, 
118]. Currently, there is still a lot to learn regarding the bacteria- and host-derived factors that 
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play a role in eliciting macrophage dysfunction and its greater impact on the whole immune 
response to S. aureus biofilm infection. 
3) Myeloid-derived suppressor cells 
 Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of myeloid 
progenitor cells, including immature monocytes and granulocytes [119-123]. MDSCs are known 
for their ability to augment Arg-1 expression, which inhibits T cell effector responses, and also 
anti-inflammatory cytokine production that polarizes macrophages toward an immunosuppressive 
phenotype. Our laboratory has shown that S. aureus biofilms augment Arg-1 expression in vivo 
and skew macrophages toward an anti-inflammatory state that correlates with a failure to recruit T 
cells to the site of infection [32]. In addition, T cells are not recruited to sites of PJIs in humans 
[59]. Therefore, MDSC infiltrates could be responsible for promoting the anti-inflammatory milieu 
during S. aureus biofilm infection. 
The role of MDSCs in cancer has been extensively studied; however, accumulation of 
these cells has also been reported during other pathologic conditions, including bacterial, 
parasitic and viral infection, acute and chronic inflammation, and traumatic stress [124, 125], and 
is considered essential to immune regulation [126]. MDSCs can be generated in response to a 
wide variety of cytokines, which has made deciphering the signals required for their induction very 
difficult to ascertain and often context-specific. For example, it has been demonstrated in cancer 
that the precise nature of an MDSC population depends on the tumor itself and host tumor-
derived factors [127]. Some studies have shown that the phenotype and suppressive ability of 
MDSCs is context dependent, and in our studies we have determined that although MDSCs are 
suppressive when recovered from the site of biofilm infection, MDSCs from the spleen of infected 
mice do not have the ability to inhibit T cell proliferation [60]. Therefore, understanding of the 
mechanisms involved in MDSC induction during staphylococcal infection and the role these cells 
play in the local environment as opposed to systemic sites will be critical to developing novel 
targets and therapeutics that limit bacterial persistence.  
a)  History, nomenclature and definition of phenotypic markers 
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There has been an emerging interest in the past five decades in understanding the role of 
suppressor cells as a critical mediator of health and disease, although this has not been without 
some debate. Natural suppressor (NS) cells were first reported in tumor-bearing mice in the mid-
1960s [128, 129], as they actively suppressed anti-tumor responses like T cell proliferation, 
antibody production and CTL induction to promote immune evasion [129]. Interestingly, NS 
activity was a characteristic of multiple cell populations from different hematopoietic sites, 
including the spleen and bone marrow. NS cells were found to be increased by tumor secretions 
as well as exogenous administration of growth factors like GM-CSF and G-CSF, and were 
observed in the bone marrow of naïve mice, although they lacked suppressive activity.  
Over time, similar observations were made in other tissues and types of cancer, which 
led NS cells to also be identified by several other monikers, including immune myeloid cells, 
suppressor macrophages, immature myeloid cells, and most recently MDSCs [130]. This led to 
controversy over whether they really existed at all [129]. Suppressor cells had started to gain 
appreciation in extramedullary hematopoiesis and increased neutrophil numbers in tumor-bearing 
animals, and were later shown to inhibit lymphocyte numbers and cytotoxic activity [131]. But the 
lack of a defined set of markers surface to positively identify MDSCs caused confusion. After the 
Gr-1
+
CD11b
+
 phenotype was suggested a general agreement was reached that these cells do in 
fact exist and are distinct from monocytes and granulocytes based on their suppressive activity 
[32, 132-134]. Finally in 2007, a letter was published by Gabrilovich et al [125] in an effort to end 
the nomenclature controversy for good, and MDSC was chosen as the term for this immature, 
immunosuppressive cell population. 
 Despite the amount of heterogeneity, all MDSCs in mice lack markers of mature myeloid 
cells, but express both Gr-1 and CD11b [120-123, 126, 130, 131, 135, 136]. Although the Gr-
1
+
CD11b
+
 population as a whole displays properties characteristic of MDSCs, this surface marker 
combination makes it difficult to discern the phenotype of the suppressive cell population in a 
given pathologic condition. This is because the Gr-1 epitope encompasses both Ly6G and Ly6C 
molecules, and therefore cannot distinguish between monocyte- and granulocyte-like subsets 
within the whole Gr-1
+
 population [126]. 
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 Based on this differential expression of Ly6G and Ly6C, MDSCs in mice can be divided 
into two main subsets: granulocytic and monocytic MDSCs (G-MDSCs and M-MDSCs, 
respectively). In general, G-MDSCs have a CD11b
+
Ly6G
+
Ly6C
low
 phenotype, whereas monocytic 
MDSCs are CD11b
+
Ly6G
-
Ly6C
high
, although there is some variability in the degree to which these 
markers are expressed [119, 124, 129-131]. In addition to their different surface marker 
expression, it is thought that these two subsets also have alternate mechanisms of suppressing T 
cell responses, utilizing NOS2 and Arg-1 differentially to induce immunosuppression [129, 137].  
b) Human MDSCs 
 MDSCs have also been described in humans, initially in patients with head and neck 
cancer that were identified by CD24 expression and T cell suppression [138-140]. But ultimately, 
this classification of MDSCs rendered them indistinguishable from hematopoietic progenitor cells 
[129]. Unlike mice, humans do not express Gr-1, Ly6G or Ly6C, and therefore, the markers for 
human MDSCs are different and not as straightforward as in the murine system. For quite some 
time the human MDSC phenotype was described by negative expression of human leukocyte 
antigen D-related (HLA-DR) and either or both of the common myeloid markers CD11b or CD33 
[139]. Recently, more specific marker subsets have been defined allowing G- and M-MDSCs to 
be identified in humans. The G-MDSC phenotype in humans is identified as HLA-DR
-
CD11b
+
CD33
+
CD14
-
CD15
+
, whereas M-MDSCs correspond to HLA-DR
-/low
CD11b
+
CD33
+
CD14
+
 
[129, 131].  
c)  Function of MDSCs in health and disease  
 MDSCs are the intermediates of normal myeloid development and differentiation stages. 
The hematopoietic system continually cycles through a small population of pluripotent 
hematopoietic stem cells (HSCs) to balance self-renewal and differentiation [129] as the numbers 
of functionally mature myeloid cells must be maintained. [130]. Immature cells expressing the Gr-
1
+
CD11b
+
 phenotype are maintained at relatively low levels in murine bone marrow (i.e. 20-30%) 
[130, 131]. In healthy individuals MDSCs do not expand, instead, HSCs and immature myeloid 
cells are generated primarily in the bone marrow and quickly differentiate into mature 
granulocytes, macrophages or DCs [129-131, 137]. However, excessive inflammatory mediator 
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production leads to increased mobilization of mature myeloid cells, which creates niche spaces in 
the bone marrow reservoir and skews differentiation from mature myeloid cells toward MDSC 
expansion.  Therefore, dysregulated myelopoiesis is considered a prerequisite for MDSC 
expansion [130]. 
 Disturbances in cytokine homeostasis induced by cancer, infection, or other immune 
stresses can alter the equilibrium of MDSCs, leading to their accumulation in lymphoid organs 
and blood [120, 130]. Instead of one factor, GM-CSF for instance, being responsible for both the 
differentiation and activation of MDSCs, it is now though that two signals are responsible for 
these processes and are governed by different signal transduction pathways [121, 137]. The first 
process of MDSC expansion is induced by various cytokines and growth factors produced by 
tumors, cells responding to infectious agents, or chronic stimulation. These factors can include 
GM-CSF, M-CSF, G-CSF, IL-6, VEGF, and signals are primarily directed through signal 
transducer and activator of transcription 3 (STAT3) and STAT5. MDSCs then require a second 
activating signal that endows their functional characteristics, which manifests as increased Arg-1, 
NO, and production of immune suppressive cytokines [121]. This type of signaling is provided by 
proinflammtory molecules like IFN-γ, IL-1β, IL-13, TLR ligands, etc., and utilizes STAT1 and NF-
κB transcription factors as well as COX2 [121]. The two-signal model for MDSC expansion and 
activation explains why steady-state activation of STAT3 and STAT5 in response to growth 
factors required for normal hematopoiesis does not result in MDSC accumulation in the absence 
of strong proinflammatory signals, and also explains why acute inflammation, associated with 
release of proinflammatory factors in the absence of growth factors, also does not augment 
MDSC recruitment [121].  
 Activation of MDSCs in pathologic conditions results in their ability to suppress immune 
responses in vitro and in vivo [127, 131, 137], including the inhibition of T cell activation and 
polarization of macrophages toward an anti-inflammatory phenotype .  The mechanisms 
underlying the inhibitory activity of MDSCs range from those requiring cell-cell contact to others 
that are mediated through the modification of the microenvironment. Indeed, MDSCs have been 
shown to suppress immune responses through direct and indirect mechanisms [141].  
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In terms of direct MDSC inhibition, the main proposed mechanisms are NO and  ROS 
production, arginine depletion, secretion of immunosuppressive cytokines such as TGF-β and IL-
10 as well as induction of apoptosis meditated by the FAS-FASL  pathway [119, 124, 132, 142-
145]. In particular, increased iNOS or Arg-1 activity in MDSCs leads to enhanced arginine 
catabolism, thereby depleting this non-essential amino acid from the environment. A shortage of 
L-arg inhibits T cell proliferation through several different mechanisms, including decreasing 
expression of CD3ζ and preventing T cell upregulation of the cell cycle regulators cyclin D3 and 
cyclin-dependent kinase 4 [137]. Furthermore, the hyperproduction of ROS by MDSCs has been 
shown to directly disrupt antigen-specific CD8 T cell responses through nitration of tyrosines that 
interfere with TCR-CD8 complex interaction with MHC [146].  
MDSCs are able to suppress indirectly by inducing the development of other cell types 
with immune suppressor function, including regulatory T cells (Tregs) and anti-inflammatory 
macrophages [120, 147, 148]. The secretion of immunosuppressive cytokines, like IL-10, by 
MDSCs can transform the environment in a way that favors the development of these cell types. 
Tregs and anti-inflammatory macrophages can then go on to produce more anti-inflammatory 
cytokines, including IL-10, representing a positive feedback loop to propagate immune 
suppressive activity. MDSC secretion of IL-10 in other models has been shown to downregulate 
IL-12 production in macrophages [135]. Additionally, cell contact-dependent cross-talk between 
MDSCs and macrophages has also been reported to occur in tumors [135].  
d) MDSCs and S. aureus biofilm infection 
 As MDSCs are found to be involved in more and more areas of health and disease, the 
debate over whether they are beneficial or deleterious to host immunity against invading 
pathogens continues [130]. It is apparent that the immunosuppressive, anti-inflammatory 
properties of MDSCs could be beneficial under certain circumstances but, to date, no one has 
identified the tipping point of when these responses become harmful or ways to intervene. During 
infection it is believed that immature myeloid cells in the bone marrow are recruited to sites of 
inflammation to replace damaged or exhausted cells, but factors within the local environment, 
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host- or pathogen-derived, arrest these cells in an immature state and the inflammatory signals 
present lead to their acquisition of immunosuppressive properties [130]. 
 Our laboratory was the first to demonstrate a role for MDSCs during S. aureus infection 
[60]. MDSCs infiltrating S. aureus biofilms were capable of inhibiting T cell proliferation and 
expressed genes typical of MDSCs described under other pathologic conditions, including Arg-1, 
iNOS and IL-10. Manipulation of MDSCs with Ab depletion strategies demonstrated that their 
immunosuppressive function prevents monocytes/macrophages from eliminating biofilm-
associated bacteria by attenuating their proinflammatory properties. More recent studies have 
shown that IL-12 is critical for MDSC recruitment to the site of S. aureus PJI and that IL-10 is one 
mechanism used by MDSCs to exert immunosuppressive functions. Additional details regarding 
these studies can be found in Chapters 3, 4 and 5 of the dissertation. 
 During initial stages of infection MDSCs could be protective by limiting tissue damage 
during potentially overwhelming inflammation [130, 149]. Indeed, a study has shown that 
depletion of MDSCs during early severe sepsis reduced survival, suggesting they do play an 
immunoprotective role this this disease setting [150]. However, while early sepsis is 
proinflammatory, late sepsis is characterized as an anti-inflammatory state and MDSCs contribute 
greatly to this shift. MDSCs have been observed to secrete copious amounts of IL-10 during late 
sepsis [123]. Furthermore, it has been reported that T cells play a protective role in a model of 
systemic S. aureus infection. However, they lose their ability to respond to bacterial Ags with the 
transition from acute infection to persistence and exhibit a dysfunctional state characteristic of 
suppression by MDSCs [149]. All of these findings demonstrate that MDSCs have a very dynamic 
role during infection and it is not surprising that bacteria have evolved mechanisms to manipulate 
immune-regulatory mechanisms to promote their long-term survival [149, 150].   
4) Overview of Dissertation 
Initial experiments from our laboratory demonstrated that biofilm infections skew the host 
innate immune response toward an anti-inflammatory phenotype that allows them to subvert 
immune clearance mechanisms [32]. Not only do the bacteria circumvent traditional bacterial 
recognition pathways mediated through TLRs, but also alter the macrophage response leading to 
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significant Arg-1 production, which has been associated with bacterial persistence. In addition to 
Arg-1
+
 macrophages being found in close proximity to the catheter surface, other non-
macrophage cells were also Arg-1
+
. This led us to investigate the possibility that biofilms induce 
the immature, immunosuppressive population of MDSCs to accumulate at the site of infection. In 
addition, we have also attempted to augment macrophage proinflammatory responses to biofilm 
infection through therapeutic approaches, including treatment with EP67 and administration of 
pro-inflammatory macrophages to biofilm-infected tissues. 
During the course of my research, I have identified a bona fide MDSC infiltrate during S. 
aureus biofilm infection, which could be a result of the biofilm hijacking the immune response to 
inhibit the formation of mature antimicrobial leukocyte effectors and instead polarize endogenous 
monocytes and macrophages toward an anti-inflammatory phenotype [59, 60, 129]. There is 
evidence to suggest that the combination of MDSC recruitment and anti-inflammatory 
macrophages during S. aureus biofilm infection likely contributes to the biofilm persistence. 
Indeed, we have demonstrated that anywhere from 10
3
-10
5
 viable organisms can be detected 3 
months after infection in both the mouse orthopedic implant- and catheter-associated biofilm 
infection models, which accurately recapitulates the persistent nature of implant-associated 
biofilm infections in humans [59, 60]. Our laboratory has demonstrated that our mouse model of 
orthopedic biofilm infection mimics several aspects of human PJI. For example, very few T cells 
are associated with PJI, whereas the main cellular infiltrate into aseptic tissues are T cells. 
Furthermore, a population of MDSC-like cells expressing genes characteristic of MDSC described 
in other models has been found in human PJI tissues [59]. However, the main objective of this 
research is to identify the mechanisms used by MDSCs to exert their immunosuppressive 
functions. My research demonstrates the complexity of MDSC responses and highlights the role 
of both pro- and anti-inflammatory mediators (IL-12 and IL-10, respectively) during different 
phases of biofilm development.  
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Chapter 2: Materials and Methods 
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1) Mouse strains 
A breeding colony of C57BL/6 mice was established in Dr. Kielian’s laboratory upon purchasing 
animals from the National Cancer Institute (Frederick, MD) or Jackson Laboratories (Bar Harbor, 
ME). These studies were performed in strict accordance with recommendations found in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH) and 
were reviewed by the Institutional Animal Care and Use Committee of the University of Nebraska 
Medical Center.  
 
IL-12p40 KO mice were purchased from The Jackson Laboratory (Bar Harbor, ME, stock number 
002693, B6.129S1-Il12b
tm1Jm
/J). A targeting vector containing a PGK-neomycin cassette was 
used to disrupt part of exon 3 in the Il12b gene. Homozygous mice have a severely restricted 
ability to mount Th1 responses while Th2 responses are enhanced.  
 
IL-12p35 KO mice were purchased from The Jackson Laboratory (Bar Harbor, ME; stock number 
002692, B6.129S1-Il12a
tm1Jm
/J) and were generated by replacing exons 1 and 2 of the gene with 
a neomycin resistance cassette. These KO mice fail to show any delayed-type hypersensitivity 
(DTH) reaction, and are therefore useful in studying resistance to infection. 
 
IL-23p19 KO mice were provided by Genentech (South San Francisco, CA) 
 
IL-10 KO (stock number 002251, B6.129P2-Il10
tm1Cgn
/J) and IL-10-GFP reporter mice (stock 
number 008379, B6.129S6-Il10
tm1Flv
/J) were purchased from The Jackson Laboratory (Bar 
Harbor, ME). The IL-10 gene was disrupted in 129/Ola-derived embryonic stem (ES) cells by 
replacing codons 5-55 of the first exon by a linker, providing a termination codon and a neo gene, 
and by introducing a termination codon into exon 3. Transfected cells were injected into C57BL/6 
blastocysts. Mice homozygous for the Il10 gene mutation do not produce IL-10 and completely 
lack IL-10 activity [151], which impacts immunosuppressive mechanisms of the innate and 
adaptive immune systems. IL-10-GFP mice have an internal ribosome entry site-green 
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fluorescent protein (IRES-GFP) cassette followed by a loxP-flanked neomycin cassette between 
the stop codon and polyadenylation signal of exon 5 of the gene. This allows for the detection and 
monitoring of cells committed to IL-10 production. 
 
MyD88 KO mice were originally obtained from Dr. S. Akira (Osaka University, Suita, Osaka, 
Japan) and were backcrossed with C57BL/6 mice for > 10 generations [152-154]. The Myd88-
deficient allele encodes a deletion of exon 3 of the myeloid differentiation primary response 88 
gene. MyD88 is a cytosolic adaptor protein that plays a central role in the innate and adaptive 
immune response, and is required to limit bacterial burdens and prolong survival during infection.  
 
CXCR2 KO (stock number 006848, B6.129S2(C)-Cxcr2
tm1Mwm
/J) mice were purchased from The 
Jackson Laboratory (Bar Harbor, ME). The CXCR2 gene was knocked out with a neomycin 
selection cassette that replaced the entire coding sequence of the gene. Homozygous mice have 
several abnormalities, including neurological defects, impaired wound healing, impaired 
angiogenesis, altered growth of induced/implanted tumors, splenomegaly and increased 
susceptibility to various pathogens due to impaired granulocyte recruitment and decreased 
pathogen clearance during innate immune responses.  
 
2) Bacterial strains and microbiological techniques 
Bacterial strains 
The USA300 LAC strain of Staphylococcus aureus (S. aureus) is a community-acquired 
methicillin-resistant (CA-MRSA) isolate kindly provided by Dr. Frank DeLeo (National Institute of 
Allergy and Infectious Diseases Rocky Mountain Laboratories, Hamilton, MT). This strain was 
isolated from the Los Angeles county (LAC) jail inmate with a skin and soft tissue infection and 
was also responsible for the CA-MRSA outbreak of 2002 [26]. This S. aureus strain contains two 
plasmids, p01 and p03 and the USA300 LAC 13c strain used in the Kielian laboratory has been 
cured of the erythromycin-resistance plasmid.  
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For in vitro biofilms, USA300 LAC was transformed with the plasmid pCM11 to express GFP 
driven by the sarA P1 promoter (USA300 LAC-GFP), and plasmid expression was maintained 
with erm selection (10 μg/ml). For in vivo studies, USA 300 LAC 13c chromosomally transduced 
with the bacterial luciferase gene lux was used and will be referred to as USA300 LAC::lux 
throughout. 
Bacterial storage 
Bacterial strains were stored at -80°C in the form of glycerol stocks, prepared by growing bacteria 
to exponential phase in brain-heart infusion broth (BHI, Fisher Scientific, Pittsburgh, PA) followed 
by centrifugation at 2,400 rpm for 10 min, 4°C. The pellet was resuspended in 10ml of ice-cold 1X 
PBS and washed by centrifuging again at 2,400 rpm for 10 min, 4°C. After discarding the 
supernatant, the pellet was resuspended in 20% glycerol in 1X PBS and this bacterial-glycerol 
suspension was aliquoted into appropriately labeled cryovials and stored at -80°C.  
A new streak plate was made prior to each experiment in an effort to avoid mutation of bacteria 
by prolonged dormancy at 4°C.  
Preparation of bacteria for in vitro experiments 
For experimental purposes, overnight cultures were grown by selecting a single bacterial colony 
from the streak plate using a sterile disposable loop and inoculating BHI in a baffled flask at a 
10:1 flask:volume ratio. Inoculations were incubated at 37°C with constant shaking at 250 rpm for 
12-16 h. The following day, bacterial titers were determined by plating onto blood agar plates and 
heat-inactivated bacteria was prepared by incubating a portion of the stock at 55°C for 60 min, 
with vortexing every 15 min. This heat-inactivated stock was aliquoted and stored at -80°C for 
future use. In addition, the heat-killed bacterial suspension was plated onto blood agar plates to 
confirm the absence of growth before being used for experiments. 
In vitro S. aureus biofilms 
Overnight cultures were grown by selecting a single colony from a streak plate and inoculating 4 
ml Complete Biofilm Media (RPMI 1640, 10% FBS, L-glut, Erm10 [for GFP bacteria only], 
HEPES) with overnight incubation at 37°C with constant shaking (250 rpm). Two-well glass-
chamber slides (Nunc, Rochester, NY) were coated with 2 ml per well of 20% human plasma in 
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sterile carbonate-bicarbonate buffer (Sigma-Aldrich, St. Louis, MO) and incubated overnight at 
4°C. The following day, plasma-coating buffer was removed, chambers were inoculated with 
bacteria (diluted to an OD600 of 0.05 in 2 mls) and incubated at 37°C under static aerobic 
conditions for 6 days. Each day following slide inoculation, 700 μl of spent medium was removed 
from each well and 1 ml of fresh biofilm medium was added.  
Preparation of bacteria for in vivo experiments 
A single colony of from a streak plate was grown overnight for 12-16 h at 37°C in a 250 ml baffled 
flask containing 25 ml of autoclaved BHI broth (10:1 flask:volume ratio) with constant shaking 
(250rpm). The overnight culture was diluted 1:10 in BHI and the following day the number of 
planktonic bacteria present was determined by measuring the O.D. (BioMate 3S 
Spectrophotometer, Thermo Scientific, Waltham, MA) at 620 nm. In addition, 1 ml of the overnight 
culture was transferred into a 1.5 ml Eppendorf microcentrifuge tube and centrifuged at 14,000 
rpm, 4°C for 5 min to pellet the bacteria. The supernatant was removed and the pellet was 
resuspended in 1 ml PBS and subsequently washed two more times by centrifuging at 14,000 
rpm for 5 min, 4°C. To prepare inoculum for injection, the washed culture was diluted in sterile 
PBS after estimating the CFU/ml of the overnight culture. If the overnight culture was estimated at 
3.2 x 10
9
 CFU/ml, two subsequent 1:100 dilutions would follow: 
1:100 dilution = 3.2 x 10
7
 CFU/ml 
1:100 dilution = 3.2 x 10
5
 CFU/ml 
 
An equation was then used to determine the amount of diluted culture needed to inject 1 x 10
3
 
CFU in 20 µl (5x10
4
/ml): 
(3.2 x 10
5
 CFU/ml) * x = 5 x 10
4
 CFU/ml * 1ml 
x = 0.156 ml in 0.844ml PBS 
or  
x = 156 µl of diluted 10
5
 culture + 844 µl PBS 
 
The exact concentration of cells/ml in the overnight culture was determined following preparation 
of bacteria for infection by diluting the washed culture in triplicate as follows: 
10
-2
  20µl of the 1ml washed overnight culture into 180 µl PBS 
10
-3 
20 µl of 10
-2
 dilution into 180 µl PBS 
10
-4 
20 µl of 10
-3
 dilution into 180 µl PBS 
10
-5 
20 µl of 10
-4
 dilution into 180 µl PBS 
10
-6 
20 µl of 10
-5
 dilution into 180 µl PBS 
10
-7 
20 µl of 10
-6
 dilution into 180 µl PBS 
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10
-8 
20 µl of 10
-7
 dilution into 180 µl PBS 
 
100 µl of the 10
-7
 and 10
-8
 dilutions were plated onto blood agar plates and counted the following 
day. The number of bacteria was enumerated and plate counts were averaged to determine the 
actual CFU used for infection. 
 
3) Cell culture techniques 
Primary mouse bone marrow-derived macrophage (BMDMΦ) culture 
Adult C57BL/6 WT and MyD88 KO were euthanized with an overdose of inhaled isoflurane 
(Isothesia, VetUS, Dublin, OH) using a euthanasia chamber and cervical dislocation was 
performed as the secondary form of euthanasia. The abdominal surface of the mouse was 
flooded with 70% EtOH, to prevent fur from contaminating specimens and a subcutaneous 
incision was made near the midline of the abdomen. Skin was separated from the peritoneum 
until all hind limbs were exposed and excess muscle was dissected away. Hind limbs were 
removed at the hip joint and immediately submerged in a petri dish containing 70% EtOH before 
being kept  in 1X PBS on ice. Using Kimwipes, excess connective tissue and muscle was 
removed from the bone surface and clean bones were placed in fresh 1X PBS. At this point, the 
entire procedure was carried out under aseptic conditions in a biological safety cabinet with sterile 
autoclaved instruments. Both ends of the bones were cut with scissors and bone marrow was 
flushed with sterile DMEM and a 26-gague needle. The bone marrow effluent was collected in a 
50 ml conical tube. Once all bones were flushed, cells were pipetted to disrupt cell aggregates, 
filtered through a 70 μm cell strainer and centrifuged at 1,200 rpm for 5 min, 4°C. The 
supernatant was aspirated and red blood cells were lysed by adding 500 μl sterile water for 5 sec, 
followed by immediate addition of 100 μl 10X PBS. Next, cells were washed with medium, 
centrifuged, and counted using trypan blue (Lonza, Walkersville, Germany) on a hemacytometer. 
Cells were seeded in 175 mm tissue culture dishes at a density of 1 x 10
7
 cells / plate in 20 mls of 
media. BMDMΦ media was composed of Dulbecco’s modified eagle’s medium (DMEM, 4.5 g/L 
glucose supplemented with 4mM L-glutamine) containing heat-inactivated fetal bovine serum 
(10% v/v FBS, HyClone, Logan, UT; inactivated at 55°C for 30 min, with swirling at 10 min 
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intervals), 20% sL929 (ATCC) supernatant as a source of macrophage colony stimulating factor 
(M-CSF) (Whetton et al Biochim Biophys Acta, 1989), 1% v/v HEPES (1 M stock), 1% v/v 
Glutamine (200 mM stock, both HyClone, South Logan, UT), 0.1% v/v 50 mM Beta-
mercaptoethanol (Fisher Scientific, Pittsburgh, PA) and antibiotic-antimycotic solution (10,000 
IU/ml Penicillin, 10,000 μg/ml Streptomycin, 25 μg/ml Amphotericin B, final 1% v/v, Mediatech 
Inc., Manassas, VA). Medium was replaced on cultures at days 2, 4 and 6 after initial plating and 
cells were harvested on day 7 for subsequent experimentation. 
Primary mouse bone marrow-derived neutrophil culture 
Adult C57BL/6 or MyD88 KO mice were euthanized, bone marrow was isolated as previously 
described and placed on a three-layer Percoll gradient (Amersham Pharmacia Biotech, Uppsala, 
Sweeden). After filtering, cells were centrifuged at 400g for 10 min, 4°C, resuspended in 3ml of 
78% Stock Isotonic Percoll (SIP, 100% SIP [9 parts Percoll to 1 part 10X PBS] in 1X PBS). Next, 
3 ml of 69% SIP was layered on top followed by 3 ml of 52% SIP. This three-layer gradient was 
centrifuged at 1500g for 30 min, 15°C with no brake. Cells from the upper phases were discarded 
and neutrophils were collected from the 68% / 78% interface and upper part of the 78% layer. 
Harvested cells were washed with PBS, centrifuged (400g, 10 min, 4°C), resuspended in 1 ml 1X 
Lysing Buffer (BD Pharm Lyse, BD Biosciences, Franklin Lakes, NJ) and incubated at room 
temperature for 2 min. HBSS with 10% FBS was added to stop lysing reaction and cells were 
centrifuged (400g, 10 min, 4°C) before being  resuspended in 2 ml buffer for magnetic-activated 
cell sorting (MACS, PBS without Ca, Mg, + 2% FBS), vortexed and counted with trypan blue on a 
hemacytometer. Magnetic labeling was done using the Miltenyi anti-Ly6G MicroBead Kit (Miltenyi 
Biotec, San Diego, CA) according to the manufacturer’s instructions. Magnetic separation was 
performed using an MS column on a MACS Separator. Columns were prepared by rinsing with 
500 μl buffer, whereupon the cell suspension was added onto the column. Unlabeled cells were 
collected by washing the column 3X with 500 μl of buffer, then the column was removed from the 
separator and placed over a collection tube. Buffer was flushed through the column with a 
plunger to elute the fraction of labeled cells. Cells were counted and at least 600,000 Ly6G
+
 cells 
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were removed to check purity by flow cytometry, while the remaining cells were used for co-
cultures with S. aureus biofilms. 
Primary mouse bone marrow-derived MDSC culture 
Adult C57BL/6, IL-10 KO or IL-12p40 KO mice were euthanized and bone marrow was isolated 
as previously described. After lysing RBCs, cells were washed and resuspended RPMI-1640 
medium supplemented with 10% v/v HI FBS, 1% v/v HEPES, 1% v/v L-Glut, 0.1% v/v antibiotic-
antimycotic solution, 40 ng/ml G-CSF and 40 ng/ml GM-CSF (both from Peprotech, Rocky Hill, 
NJ). 10
7 
bone marrow cells were plated into 175mm dishes in 20 mls of media and incubated for 
4 d at 37°C, 5% CO2. The Ly6G
+
Ly6C
+
 MDSC population was purified from the mixed cell 
population by FACS and verified to possess T cell inhibitory activity.  
 
4) Immune cell co-culture with S. aureus biofilms in vitro 
BMDMΦs and neutrophils were labeled with either 5 μM CellTracker Orange or CellTracker Blue 
(both from Molecular Probes, San Diego, CA) depending on the experimental set up. Labeling 
was conducted following the manufacturer’s instructions. After labelling, some BMDMΦ were 
activated toward an M1 phenotype by treating with 10 ng/ml IFN-γ or 100 ng/ml TNF-α and 10 
μg/ml S. aureus-derived peptidoglycan (PGN) for 6 h. Cells were co-cultured with S. aureus 
biofilms by first removing 700 μl of spent medium and then adding 1 ml of fresh biofilm media 
containing 10
7
 neutrophils, nonactivated MΦ or M1-activated MΦ to the biofilms. Co-cultures 
were incubated at  37°C under static conditions and imaged using a Zeiss 510 META laser 
scanning microscope (Carl Zeiss, Oberkochen, Germany) at 2 and 24 h following the addition of 
immune cells. Neutrophil- and MΦ-biofilm co-cultures were harvested 24 h after immune cell 
addition by mechanical disruption, whereupon bacterial enumeration was performed by serial 
dilution on tryptic soy agar plates supplemented with 5% sheep blood (Hemostat Laboratories, 
Dixon, CA).  
  
5) Mouse models of S. aureus biofilm infection 
Subcutaneous catheter-associated biofilm infection 
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Age and sex-matched mice (8-10 weeks old) were used to examine the immune response to S. 
aureus catheter-associated biofilm infection. Mice were weighed and anesthetized with Avertin 
(15 µl/g, 2.5% solution, Sigma-Aldrich, St. Louis, MO) by intraperitoneal (i.p.) injection. Once 
anesthetized, the left flank was shaved and the skin was cleaned and disinfected with povidone-
iodine. Next, a small subcutaneous (s.c.) incision was made in the left flank and a blunt probe 
was used to create a pocket for the insertion of a sterile, 14-gauge teflon intravenous catheter, 1 
cm in length (Exel International, St. Petersburg, FL). The incision was sealed using Vetbond 
Tissue Adhesive (3M, St. Paul, MN) and 10
3
 CFU USA300 LAC::lux in 20 µl of sterile PBS was 
slowly injected through the skin, directly into the catheter lumen using a 27 gauge x ½” needle. 
Eye ointment (LubriFresh™ P.M., Major Pharmaceuticals, Livonia, MI) was placed on all mice 
before they were returned to clean cages and kept under heat lamps to maintain core body 
temperature until fully recovered from anesthesia. Cages were labeled with orange biohazard 
cards and monitored daily throughout the course of infection.  
Orthopedic implant biofilm infection 
Age and sex-matched mice (8-10 weeks old) were used to simulate infectious complications in 
patients following surgical device placement. Animals were weighed and anesthetized with 
ketamine/xylazine (100 mg/kg and 5 mg/kg, respectively) by i.p. injection before the surgical site 
was shaved and disinfected with povidone-iodine. A medial parapatellar arthrotomy with lateral 
displacement of the quandriceps-patella was performed to access the distal femur. Next, the 
femoral intercondylar notch was located and a burr hole was drilled into the intramedullary canal 
using a 26-gague needle, whereupon an orthopedic-grade Kirschner wire (0.6 mm diameter, 
Nitinol [nickel-titanium]; Custom Wire Technologies, Port Washington, WI) precut to 0.8-cm was 
inserted. Approximately 1 mm of K-wire was left protruding into the joint space and a total of 10
3
 
CFU of the USA300 LAC::lux isolate was inoculated at the implant tip. The quadriceps-patellar 
complex was reduced to the midline and the fascia was sutured with 6-0 metric absorbable 
sutures before the skin of the surgical site was closed with 6-0 metric nylon sutures (both from 
Covidien, Mansfield, MA). In some experiments, control mice received sterile implants using an 
identical procedure. All animals received Buprenex, (0.1 mg/kg s.c.; Reckitt Benckiser, Hull, U.K.) 
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for pain relief immediately following the surgical procedure, before being returned to clean cages 
to under a heat lamp to ensure maintenance of core body temperature until fully recovered from 
anesthesia. Cages were labeled with orange biohazard cards and monitored daily. A second 
dose of Buprenex was administered 24 h after surgery and after this interval, all mice exhibited 
normal ambulation and no discernable pain behaviors. 
 
6) Computed tomography 
Bone integrity in the context of aseptic implants, S. aureus biofilm infection and Gr-1
+
 cell 
depletion was monitored using live computed tomography (CT) scans. Mice were first 
anesthetized with 1.5% isoflurane in a 70% nitrous oxide/30% oxygen mixture and imaged using 
a FLEX Triumph x-ray CT/single photon emission CT system and software (TriFoil Imaging, 
Northridge, CA). One thousand twenty-four CT projections for each image were acquired at 75 
kVp and reconstructed using Truimph X-0 4.1. CT images were generated using the three-
dimensional image visualization and analysis software VIVID, which is based on Amira 4.1 
(TriFoil Imaging).  
 
7) Recovery of implant-associated tissues for S. aureus enumeration 
Recovery of subcutaneous catheters and surrounding tissues 
Animals were sacrificed by overdose of inhaled isoflurane, followed by cervical dislocation. The 
left flank was sterilized with a povidone-iodine prep pad to prevent potential sample 
contamination with skin microflora. The section of the flank containing the catheter and 
associated tissue was removed, whereupon the catheter was separated from the surrounding 
host tissue and placed in 1 ml PBS on ice. Tissue surrounding the catheter was also collected, 
weighed and placed in 500 μl homogenization buffer (25 ml of 1X PBS q.s., pH 7.4, 1 Complete™ 
protease inhibitor cocktail tablet) on ice. In some experiments, the kidney and heart were also 
collected. These organs were excised, weighed and kept on ice in 500 μl PBS to determine the 
amount of bacterial dissemination. Once all tissues were removed catheters were sonicated for 5 
min on ice while catheter-associated tissue and any organs collected were homogenized using a 
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Bullet Blender (Next Advance, Averill Park, NY). Serial dilutions of the effluents and homogenates 
were plated on TSA supplemented with 5% sheep blood to determine bacterial colonization. 
Bacterial titers were expressed as Log10 CFU/ml for catheters or Log10 cfu/g wet tissue weight for 
catheter-associated tissues and other organs. 
Recovery of orthopedic implants and surrounding tissues 
For collecting inflamed soft tissue surrounding the infected knee joint, animals were euthanized 
by overdose of inhaled isoflurane, followed by cervical dislocation. The flank and left leg were 
then flooded with 70% EtOH and an incision was made in the skin so the skin of the left leg could 
be removed. Next, the subcutaneous tissue dorsal to the patellar tendon was excised, weighed 
and placed in 500 µl 1X PBS + 2% FBS on ice. Muscle and tendon tissues were excluded from 
the analysis. This tissue was dissociated with the blunt end of a plunger from a 30-cc syringe and 
passed through a 35 μm filter (BD Falcon, Bedford, MA). An aliquot of 150 μl was removed at this 
point for quantitation of bacterial burdens and Milliplex analysis of the supernatant. The remaining 
filtrated was further processed for flow cytometer as described below. Next, the muscle was 
cleaned away from the knee joint and femur. The knee joint was separated from the femur 
allowing for removal of the implant, which was extracted from the femur and sonicated for 5 min 
in 1 ml 1X PBS on ice to dislodge adherent bacteria. Both the knee joint and femur were weighed 
and placed in 500 µl homogenization buffer before being homogenized using two sequential 
procedures. First, tissues were homogenized with a Polytron homogenizer at the highest setting 
for approximately 30 s. Then tissues were further dissociated using a Bullet Blender. Serial 
dilutions of effluents from the tissue, joint, femur and implant were plated on TSA supplemented 
with 5% sheep blood to determine bacterial colonization. For some experiments, the spleen, heart 
and kidneys were collected to determine the degree of splenomegaly or bacterial dissemination 
as described above. 
Tissues from human prosthetic joint infections (PJIs) 
Excess tissues from patients undergoing joint revisions for PJI, or aseptic loosening as controls, 
were procured by orthopedic surgeons at the University of Nebraska Medical Center. Informed 
consent was obtained during the presurgical visit and the protocol was approved by the 
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Institutional Review Board (IRB) of the University of Nebraska Medical Center. Upon excision, 
tissues were placed in sterile PBS on ice and dissociated using Nitex mesh and a mortar and 
pestle, before being washed and subsequently stained for FACS analysis as described below. 
 
8) Scanning electron microscopy 
Mice were sacrificed and the whole femur harboring the titanium implant was fixed in 0.1 M 
Sorenson’s phosphate buffer containing 2% glutaraldehyde and 2% paraformaldehyde for 1 h at 
room temperature and held in fixative overnight at 4°C. Fixed specimens were washed three 
times in TBS followed by three rinses in double distilled (dd)H20 and decalcification in 14% EDTA 
for 2d. After rinsing in ddH20, specimens were dehydrated using a graded series of ethanol 
washes and critical point dried in a Pelco CPD2 critical point dryer (Tel Pella, Redding, CA). Dried 
specimens were mounted on aluminum stubs with carbon tabs and colloidal silver paste before 
being sputter coated with gold-palladium using a Hummer VI sputter coater (Anatech, Battle 
Creek, MI). Samples were viewed using a Quanta 200 scanning microscope (FEI, Hillsboro, OR) 
operated at 25 kV. 
 
9) Immunohistochemistry 
Decalcification of femurs for histological evaluation 
In order for histological analysis to be performed in the S. aureus orthopedic implant model of 
infection tissues first had to be decalcified. To this end, the whole right leg (femur/knee/tibia) was 
excised, leaving muscle and soft tissue intact, placed into a tube containing enough 10% formalin 
to completely cover the tissue and fixed for at least 72 h at room temperature. Formalin was 
discarded and tissues were washed thoroughly in distilled water. After washing, tubes were filled 
with enough decalcifier solution (Super Decalcifier I: Delicate, Polysciences, Warrington, PA), to 
cover the tissue and placed on a rocker at room temperature for 4-6 h to completely decalcify 
tissue. Following decalcification, tissue was washed 3X with water, before an incision was made 
in the quadriceps and femur to access and remove the implant. Decalcified tissues were placed in 
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a histo-cassette and kept in 10% formalin or PBS before being embedded in paraffin and cut into 
4 μm sagittal sections.  
Deparaffinizing and antigen retrieval  
Mice were sacrificed and the section of the flank containing the catheter and associated tissue 
was removed as previously described. The catheter and associated tissues were cut in half with a 
razor blade, left intact, and transferred to a cassette. Tissues were fixed in 10% formalin and 
embedded in paraffin, whereupon 10-µm thick sections were cut by the UNMC Histology Core. 
Embedded sections were deparaffinized using the protocol described in Table 9.1.  
Table 2.1. Tissue deparaffinization protocol 
STATION REAGENT TIME 
1 Xylene 5 min 
2 Xylene 5 min 
3 Xylene 5 min 
4 100% EtOH 1 min 
5 100% EtOH 1 min 
6 95% EtOH 1 min 
7 70% EtOH 5-10 dips 
8 Water Clear 
 
This process was followed by antigen retrieval, whereupon deparaffinized slides were placed in 
sodium citrate solution (10 mM sodium citrate [1.47g sodium citrate in 500 ml dH20], 0.05% 
Tween 20, pH 6). Slides were completely submerged in the buffer and placed in a plastic bowl 
filled 1/3 with water and microwaved for 14 min at power 7. Cooled slides were placed in PBS. 
Hematoxylin and Eosin (H&E) staining  
Rapid H&E staining was performed on deparaffinized tissue using the protocol described in Table 
9.2. Coplin jars with screw caps were used for the procedure. 
Alcohol-formalin-acetic acid solution (Fixative) was prepared with 10 ml of 37% formalin, 90 ml of 
80% EtOH and 5 ml of glacial acetic acid. Alcoholic eosin stock (Fisher Scientific, Pittsburgh, PA) 
was diluted 1:3 with 70% EtOH to prepare the working solution. Harris Modified Hematoxylin 
(Fisher Scientific, Pittsburgh, PA) was used undiluted.  
For evaluation of pathological conditions during S. aureus orthopedic biofilm infection H&E-
stained tissues were evaluated for inflammatory changes by a board certified pathologist (Jessica 
54 
 
A. Kozel, University of Nebraska Medical Center) with the degree of inflammation determined 
using a scoring scale (0, no observable pathology; 1, minimal pathology; 2, moderate pathology; 
3, severe pathology). Splenic architecture following Ab-mediated cell depletion was also 
performed. Spleens were fixed in 10% formalin, paraffin-embedded and sectioned for H&E 
staining as described above.  
Table 2.2. Rapid Hematoxylin and Eosin staining protocol 
 
 
 
 
 
 
 
 
Gram-staining 
Bacteria associated with infected joints were visualized on deparaffinized tissue sections using 
the protocol described in Table 9.3. 
Table 2.3. Gram-staining protocol 
STATION REAGENT TIME 
1 Crystal Violet 1 min 
2 Water Rinse 
3 Gram’s Iodine Solution 5 min 
4 Water Rinse 
5 100% EtOH 5-6 dips 
6 Water Rinse 
7 Safranin 30-60 sec 
8 Water Rinse 
9 100% EtOH Rinse 
10 100% EtOH Rinse 
11 Xylene Clear 
 
Fluorescence staining and confocal microscopy 
Tissues surrounding infected catheters were processed for immunofluorescence staining using 
primary antibodies specific for the MΦ marker Iba-1 (Biocare Medical, Concord, CA) and 
STATION REAGENT TIME 
1 Fixative 30-60 seconds 
2 70% EtOH Rinse briefly 
3 Water Rinse briefly 
4 Harris hematoxylin 10-15 seconds 
5 Water Rinse briefly 
6 Alcoholic eosin Counterstain 2 min 
7 95% EtOH (fresh) Dehydrate 5-10 dips 
8 95% EtOH (fresh) Dehydrate 5-10 dips 
9 Absolute EtOH Dehydrate 5-10 dips 
10 Absolute EtOH Dehydrate 5-10 dips 
11 Xylene Clear 
12 Xylene Clear 
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arginase-1 (Arg-1, Santa Cruz Biotechnology, San Diego, CA). First, a pap pen was used to mark 
around sections and slides were blocked in 10% donkey serum/PBS for 30 min. Blocking serum 
was drained, primary antibodies were added to sections following dilution in 2% donkey serum 
(Arg-1, 1:50; Iba-1, 1:100) and slides were incubated overnight, 4°C.  The following day, slides 
were washed three times in PBS for 5 min and donkey anti-rabbit FITC (1:100), donkey anti-
rabbit biotin (1:500) (Jackson ImmunoResearch Laboratories, West Grove, PA) with a 
streptavidin-594 conjugate (Invitrogen, Carlsbad, CA) and Hoescht (1:100) secondary antibodies 
were added. Slides were incubated for 30 min in the dark, whereupon the fluorescence labeling 
was shaken off and 0.1% Sudan Black solution was put on top of each section for 15 min in the 
dark. Subsequently, slides were washed 3X with PBS + 0.3% Tween 20 for 10 min per wash and 
then coverslipped with Slow Fade® (Life Technologies, Carlsbad, CA). Confocal imaging was 
performed using a Zeiss 510 META laser scanning microscope (Carl Zeiss). Staining specificity 
was confirmed by incubating tissues with a primary isotype-matched control antibody and 
appropriate secondary antibody. Quantitation of Arg-1 or Iba-1 fluorescence was calculated from 
at least 10 random fields of view using AxioVision software 4.8 (Carl Zeiss). 
 
10) Flow cytometry 
Mouse tissues 
Fluorescence-activated cell sorting (FACS) was used to characterize leukocyte infiltrates in 
inflamed soft tissues surrounding subcutaneous catheter or orthopedic implants during S. aureus 
biofilm infection. Animals were sacrificed with an overdose of inhaled isoflurane, tissues were 
excised as previously described and placed in 500 µl FACS buffer (2% FBS in PBS) on ice. 
Tissues were dissociated with the blunt end of a plunger from a 30cc syringe, and passed 
through a 35 µm filter (BD Falcon, Bedford, MA). Following removal of an aliquot for bacterial 
quantitation and Milliplex analysis, the filtrate was washed with 1X PBS and cells were collected 
by centrifugation (1200rpm, 5 min, 4°C), whereupon RBCs were lysed using BD Pharm Lyse (BD 
Biosciences, San Diego, CA) per manufacturer instructions. After lysis, cells were resuspended in 
500 µl 1X PBS followed by incubation in Fc Block (2 µl / sample, eBioscience, San Diego, CA) for 
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20 min at 4°C to minimize nonspecific antibody binding.100 µl of each sample was pooled and 
subsequently aliquoted into compensation and isotype control tubes to identify gating thresholds 
and assess the degree of nonspecific staining, respectively. The remaining 400 µl was split into 
two tubes and q.s. to 500 µl with 1X PBS. Cells were then stained with directly-conjugated 
antibodies for multi-color flow cytometry analysis, which included two separate panels to identify 
innate immune populations or T cells. Antibodies in the innate immune cell panel included: CD45-
APC, Ly6G-PE, Ly6C-PerCP-Cy5.5, and F4/80 PE-Cy7. Antibodies in the T cell panel included: 
CD3ε-APC, CD4-Pacific Blue, CD8a-FITC, Ly6C-PerCP-Cy5.5, and TCR γδ-PE. All fluorchrome-
conjugated antibodies were purchased from either BD Biosciences or eBioscience. To exclude 
dead cells from analysis, a Live/Dead Fixable Stain Kit (Life Technologies, Eugene, OR) was also 
used, following the manufacturer’s instructions. Analysis was performed using BD FACSDiva 
software with cells gated on the life CD45
+
 leukocyte population. 
Human tissues 
Immediately post-excision, surgical specimens were placed in isotonic saline on ice and rapidly 
processed. Tissues were weighed, and placed on a piece of 250 µm Nitex mesh and dissociated 
with a mortar and pestle in HBSS + 10% FBS. Cells were collected and washed 2X with HBSS + 
10% FBS, whereupon they were resuspended in 4 mls HBSS and layered over 3 ml of Ficoll-
Paque gradient and centrifuged according to manufacturer’s instructions (GE Healthcare, 
Uppsala, Sweden) Leukocytes were collected from the interface, washed 2X in HBSS + 10% 
FBS, resuspended in 500 µl HBSS and counted. Cells were then incubated with Human FcR 
Receptor Binding Inhibitor (eBioscience, San Diego, CA) to minimize non-specific antibody 
binding for 20 min, 4°C. Next, cells were stained with directly-conjugated antibodies for multi-color 
flow cytometry analysis for 30 min, 4°C. Antibodies included anti-human CD66b-FITC 
(BioLegend, San Diego, CA), CD14-PE, CD16-allyphycocyanin, CD33-PECy5, HLA-DR-PE-Cy7, 
CD45-eFluor450, CD3-APC-Cy7, CD11b-BV510 and CD11c-BV605. All fluorochrome-conjugated 
antibodies were purchased from either BD or eBioscience unless otherwise noted. To exclude 
dead cells from analysis, a Live/Dead Fixable Stain Kit (Life Technologies, Eugene, OR) was 
used according to the manufacturer’s instructions. Controls included cells stained with isotype 
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control antibodies to assess the degree of non-specific staining and compensation beads stained 
with the same antibodies were used to identify gating thresholds. Analysis was performed using 
BD FACSDiva software with cells gated on the live CD45
+
 leukocyte population. 
 
11) Recovery of biofilm-associated MDSCs and in vitro assays 
Cells were collected from the soft tissue surrounding infected knee joints as described above, and 
MDSCs were purified by FACS using either Gr-1-PE and CD11b-FITC or Ly6G-PE, Ly6C-PerCP-
Cy5.5 and CD11b-eFluor450 depending on the experimental setup. CD11b
+
Gr-1
+
 MDSCs were 
also FACS-purified from the spleens of naïve and S. aureus-infected animals for comparisons. 
The purity of MDSC populations was not examined after sorting owing to limiting cell numbers. 
However, cytospins and gene expression analysis on sorted populations revealed that sorted 
MDSCs were highly enriched, as they displayed characteristic markers and nuclear morphologies 
consistent with those reported for MDSCs in the literature.  
 In vitro MΦ and MDSC experiments 
To assess differences in proinflammatory responses of MΦ and MDSCs, Ly6G
+
Ly6C
+
 MDSCs 
were isolated from S. aureus implant-associated tissues or spleens at day 14 by FACS as 
described above, while BMDMΦ were prepared as previously outlined. MΦ, tissue MDSCs or 
splenic MDSCs were plated at 5 x 10
4
 cells / well in a round bottom 96-well plate and stimulated 
with either peptidoglycan (10 μg/ml) or heat-inactivated S. aureus (10
7
 / well) for 24 h at 37°C, 
5%CO2. After the 24 h incubation period, supernatants were collected and stored at -80°C until 
Milliplex analysis. 
Polyclonal CD4
+
proliferation assays 
Naïve C57BL/6 WT mice were euthanized with an overdose of inhaled isoflurane, whereupon 
their flanks were flooded with 70% EtOH and spleens were isolated from the peritoneal cavity and 
placed into PBS + 10% FBS on ice. Spleens were then pressed through a 250 µm Nitex filter 
(Genesee, San Diego, CA) to generate a single cell suspension, centrifuged at 1200 rpm for 10 
min, 4°C and RBCs were lysed using BD Pharm Lyse (BD Biosciences, San Diego, CA) per the 
manufacturer’s instructions. After lysis, cells were washed, resuspended in 1X PBS + 2% FBS 
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and incubated in Fc Block (2 µl / 1 x 10
6
 cells) for 20 min, 4°C. Splenocytes were subsequently 
stained with CD4-Alexa700 (BD Biosciences) and the Live/Dead Fixable Stain Kit, per the 
manufacturer’s instructions, for 30 min, 4°C. Viable CD4
+
 T cells were purified by FACS and then 
labeled with eFluor 670 cell proliferation dye (eBioscience) according to the manufacturer’s 
instructions.  
For establishing the functional activity of MDSCs associated with S. aureus orthopedic biofilm 
infections, T cell proliferation assays were performed. eFluor 670-labeled CD4
+
 T cells were 
plated at 1.5 x 10
6
 cells/well in a 96-well round bottom plate in RPMI 1640 with 10% FBS, 
supplemented with 100 ng/ml recombinant mouse IL-2 (Invitrogen, Frederick, MD). FACS-purified 
CD11b
+
Gr-1
+
, Ly6G
high
Ly6C
+
, Ly6G
low
Ly6C
low
, or Ly6G
-
Ly6C
+
 cells were obtained from S. aureus-
infected tissues as described above and added at 1:1 or 5:1 ratios to CD4
+
 T cells. Co-cultures 
were subjected to polyclonal stimulation by adding 4 µl / well CD3/CD28 Dynabeads (Life 
Technologies, Oslo, Norway). Negative controls of labeled T cells only or labeled T cells 
incubated with Dynabeads were also included. Cells were incubated at 37°C for 72 h, whereupon 
the extent of T cell proliferation was determined by flow cytometry and supernatants were saved 
for cytokine evaluation by Milliplex analysis.  
 
12) Adoptive Transfer Experiments 
Macrophage adoptive transfer into biofilm infections in vivo 
The subcutaneous catheter model of S. aureus biofilm infection was used, as previously 
described, to assess the ability of BMDMΦ and neutrophils to attenuate biofilm growth in vivo. 
WT or MyD88 KO BMDMΦ were isolated as previously described. After 7 d of culture, an aliquot 
of WT MΦ was reserved in BMDMΦ media for nonactivated treatment. The remaining WT and 
MyD88 KO MΦ were then activated toward an M1 phenotype by incubating with 10 ng/ml IFN-γ 
and 10 μg/ml S. aureus-derived PGN for 6 h in BMDMΦ media. Meanwhile, neutrophils were 
isolated from WT bone marrow as described above. Mice then received injections of 10
6
 
neutrophils, nonactivated MΦ, or M1-activated WT or MyD88 KO MΦ at four distinct sites (Fig 
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2.1) surrounding infected catheters beginning at 12 h post-infection, with repeat administration at 
24 and 48 h post-infection.                                              
                                                  
Figure 2.1. Subcutaneous injection sites for treatment of S. aureus biofilms in vivo. 
 
To determine the longevity of early MΦ treatment on inhibiting biofilm growth, a separate cohort 
of animals received injections of M1-activated MΦ at only 48 h post-infection. Furthermore, in 
some experiments, the numbers of injected neutrophils was increased by 1-log (i.e., 10
7
) to 
confirm their inability to impact biofilm clearance.                                              
For treatment of established biofilms, mice received injections of vehicle (PBS), 10
6
 nonactivated 
MΦ, 10
6
 M1-activated MΦ or antibiotic (i.p.; rifampicin and daptomycin; 0.125 and 0.25 mg/kg, 
respectively) on days 7 and 9 post-infection. Animals were sacrificed on day 14 post-infection as 
described above. 
Quantum Dot Labeling of MΦ 
To determine the longevity of M1-activated MΦ following transfer into biofilms in vivo near-
infrared Quantum dots (Qtracker 800; Molecular Probes) were used. BMDMΦ were isolated and 
activated as described above before being labeled with Qdots according to the manufacturer’s 
instructions. Once labeled, mice were given a single s.c. injection of 10
7
 M1-activated MΦ at the 
ends of the catheter at 24 h or 7 d post-infection for the early and established biofilm paradigms, 
respectively. Mice were monitored daily using an in vivo imaging system (IVIS Spectrum; Caliper 
Life Sciences, Hopkinton, MA).    
MDSC Adoptive Transfer Experiments 
MDSCs were generated from the bone marrow of C57BL/6 WT or IL-10 KO mice and the 
Ly6G
+
Ly6C
+
 population was purified by FACS as previously described. Ly6G
+
Ly6C
+
 MDSCs 
60 
 
were washed and resuspended in 1X PBS at 2.5 x 10
6
 cells / 5 μl. Depending on the 
experimental setup, WT MDSCs were injected s.c. into IL-12p40 KO mice at the site of implant-
associated infection one day post-infection, or WT and IL-10 KO MDSCs were injected into IL-10 
KO mice at day 7 post-infection. Implant associated tissues from IL-12p40 animals that received 
adoptively transferred MDSCs were recovered at day 7 post-infection, while tissues from IL-10 
KO animals receiving WT or IL-10 KO MDSCs were collected at day 14 post-infection for analysis 
of immune infiltrates by FACS and quantitation of bacterial burdens as described above. 
 
13) EP67 synthesis and treatment 
EP67 is a peptide derived from the C-terminal portion of human C5a and is a well-characterized 
agonist for the mouse C5aR (CD88). EP67 [YSFKDMP(meL)aR] and its inactive scrambled 
sequence [sEP67; (meL)RMYKPa FDS] were generated by a solid-phase Fmoc method of 
orthogonal synthesis and purified by analytical and preparative reverse-phase HPLC in the 
laboratory of Dr. Sam Sanderson at the University of Nebraska Medical Center. The peptide was 
characterized by electrospray mass spectrometry according to previously published methods 
(Phillips et al 2009 Bioconjug Chem). Animals were treated with either 200 μg EP67 or the 
inactive scrambled derivative (sEP67) directly into the catheter lumen at the time of S. aureus 
infecteion followed by 800 μg peptide distributed equally at four different sites surrounding the 
catheter at 24 and 48 h post-infection (Figure 2.1). To limit animal numbers, sEP67 was not used 
in all experiments, because initial studies established that this control peptide did not exert any 
biological activity. Animals were sacrificed at days 3 or 14 post-infection for quantitation of 
bacterial burdens, as well as Milliplex analysis as described above. 
 
14) In vivo depletion studies 
MDSCs were depleted in vivo during S. aureus orthopedic biofilm infection using two approaches. 
Either 1A8 (anti-Ly6G), which effectively depletes neutrophils and MDSCs, or RB6-C85 (anti-Gr-
1), which targets both Ly6G and Ly6C epitopes thereby targeting monocytes, neutrophils, MΦ, 
plasmycytoid dendritic cells and some T Cell populations, antibodies were used. Antibodies were 
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administered i.p. (100 µg / each) 1 d prior to S. aureus infection and continued every 72 h 
thereafter until animals were sacrificed. Control mice received equivalent amounts of isotype-
matched control antibodies (rat IgG2a and IgG2b, respectively) using the same treatment 
regimen. All antibodies were purchased in low endotoxin, azide-free form from BioLegend (San 
Diego, CA).  
Animals were euthanized at 7 or 14 days post-infection to determine the impact of cell depletion 
on S. aureus persistence and tissue-associated leukocyte infiltrates. Bone marrow and 
splenocytes were also collected to determine the efficiency of antibody-mediated depletion. 
 
15) RNA isolation and Quantitative Real-time Polymerase Chain Reaction (qRT-PCR) 
RNA isolation from FACS-purified cell populations 
MDSCs or monocytes were purified from S. aureus-infected tissues by FACS, whereupon total 
RNA was immediately isolated using the TaqMan gene expression cell-to-CT kit (Ambion, Austin, 
TX). RT and Preamplification reactions were conducted according to the manufacturer’s 
instructions using a Bio-Rad CFX Connect™ thermocycler. 
RNA isolation from whole tissue 
RNA isolation was performed on tissue isolated from catheter-associated tissue or orthopedic 
implant associated-tissue and knee joints. Tissues were excised from animals following 
euthanasia and immediately placed in 0.5 ml TriZol reagent (Life Technologies, Grand Island, 
NY), whereupon they were homogenized using a Polytron homogenizer at the highest setting for 
approximately 30 s and immediately cooled on ice. Once homogenized, samples were incubated 
at room temperature for 10 min to disrupt nuclear complexes. Next, 200 μl of chloroform was 
added to each tube, and samples were vortexed for 30 s and incubated at room temperature for 5 
min. Samples were then centrifuged at 10,500 rpm for 15 min, 4°C. Three distinct layers were 
visible, with the top aqueous phase containing RNA. This layer was carefully transferred to a new 
1.5 ml tube and the RNA was precipitated by adding 500 μl of isopropanol to each tube. Samples 
were vortexed for 30 s, incubated at room temperature for 10 min, and centrifuged at 10,500 rpm 
for 10 min, 4°C, which resulted in a compact, white RNA pellet at the side of each tube. The 
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supernatant was carefully removed and the RNA pellets were subsequently washed by adding 
900 μl cold 75% EtOH to each tube, followed by centrifugation at 6,500 rpm for 5 min, 4°C. 
Supernatants were again removed and pellets were air-dried on ice for 5 min before being 
resuspended in 30 μl of Diethylpyrocarbonate (DPEC) water or molecular grade RNase-free 
water. RNA was heated at 55°C for 10 min on a heating block to dissolve the RNA, whereupon 
samples were stored at -80°C. RNA quantification was performed using a NanoDrop Lite 
spectrophotometer (Thermo Scientific, Waltham, MA). 
Fold-changes in gene expression were evaluated by qRT-PCR. First, 2 μg of total RNA was 
treated with DNase (Invitrogen, San Diego, CA). Reaction buffer and RNase-free water was 
added and samples were incubated at room temperature for 15 minutes to degrade any 
contaminating DNA. DNase was inactivated by adding 1 μl of 25 mM EDTA and heating at 65°C 
for 10 min. Reverse transcription (RT) reactions were performed using the iScript™ cDNA 
synthesis kit (Bio-Rad, Hercules, CA) per the manufacturer’s instructions. A Bio-Rad CFX 
Connect™ thermocycler (Bio-Rad, Hercules, CA) was used for cDNA synthesis with the following 
parameters: 5 min, 25°C; 30 min, 42°C; 5 min, 85°C; and hold at 4°C until samples were 
removed. 
qRT-PCR 
cDNA samples or preamplified products were diluted 1:2 or 1:4, depending on number of cells 
recovered by FACS, in molecular grade water. qRT-PCR was performed on diluted samples 
using ABI “Assays on Demand” Taqman primer/probe sets for each specified gene. Universal 
PCR cycling conditions optimized for ABI primer/probe sets were utilized (95°C, 10 min; 95°C, 15 
s; 60°C, 1 min – 40 cycles of steps 2 and 3). For accurate calculation of expression levels, the 
cycle threshold for a particular gene was normalized against the housekeeping gene GAPDH, 
and was represented as a fold-induction (2
-ΔΔCt
) value relative to the control sample for a 
particular experiment. 
 
16) MILLIPLEX multi-analyte bead array 
Mouse 
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To evaluate a variety of cytokines/chemokines in the supernatants of catheter-associated tissues, 
or orthopedic implant-associated tissues, knee joints and femurs, a custom-designed microbead 
array was utilized according to the manufacturer’s instructions (Milliplex; Millipore, Billerica, MA). 
The particular array used allows for the simultaneous detection of 25 different inflammatory 
molecules in a single homogenate, and include: G-CSF (Granulocyte colony-stimulating factor), 
GM-CSF (Granulocyte macrophage colony-stimulating factor), IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, 
IL-6, IL-7, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, CCL2 (Monocyte chemoattractant protein 1, 
MCP-1), CCL3 (Macrophage inflammatory protein 1α, MIP-1α), CCL5 (Regulated upon activated 
T cell expressed and secreted, RANTES), CXCL1 (Keratinocyte chemoattractant, KC), CXCL2 
(MIP-2), CXCL9 (Monokine induced by IFN-γ, MIG), CXCL10 (IFN-induced protein 10, IP-10), 
TNF-α, and VEGF (Vascular endothelial growth factor). Results were analyzed on the Bio-Plex 
workstation (Bio-Rad, Hercules, CA) and adjusted based on the total amount of protein extracted 
from tissue homogenates, determined by a Bicinchoninic acid assay (BCA, Bio-Rad).  
Human 
For analysis of human PJI tissue specimens, a human 38-plex panel was used to evaluate a 
variety of cytokines/chemokines in the supernatants of tissue associated with aseptic or infected 
implants and included: epidermal growth factor, fibroblast growth factor-2, Flt-3L, G-CSF, GM-
CSF, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-
12p40, IL-12p70, IL-13, IL-15, IL-17, CX3CL1, CCL2, CCL3, CCL4, CCL7, CCL11, CCL22, 
CXCL1, CXCL10, soluble CD40L, TGF-α, TGF-β, TNF-α, and vascular endothelial growth factor. 
Results were analyzed using a Bio-Plex Workstation (Bio-Rad, Hercules, CA) and normalized 
based on the amount of total protein to account for differences in tissue sampling size. The level 
of sensitivity for most analytes in the array was 3.2 pg/ml. 
 
17) Enzyme-linked Immunosorbent Assay (ELISA)  
In addition to the MILLIPLEX assay, cytokine detection was also performed using ELISAs. For 
these assays, samples were diluted to fall within the standard curve and the procedure was 
conducted according to the manufacturers protocol (DuoSet, R&D Systems, Minneapolis, MN; 
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OPtEIA set, BD Pharmingen, San Diego, CA). In general, 96-well ELISA plates were coated with 
antibody diluted in a coating solution and incubated overnight at 4°C. The following day, the 
coating solution was removed and the plate was washed 3X using the appropriate washing buffer 
specified for each ELISA kit. After a blocking step, wells were washed and samples or standards 
were added for 2 h at room temperature. The solutions were decanted and the plate was 
thoroughly washed before incubation with a secondary antibody preparation in combination with 
streptavidin-horseradish peroxidase (HRP) enzyme solution diluted in assay buffer for 1 h. 
Following another thorough wash, the enzyme substrate (TMB substrate reagent, BD OPtEIA, 
San Diego, CA) was added, resulting in color change within 15-20 min. The reaction was stopped 
by adding 50 µl of 2N H2SO4 (Fisher Scientific, Pittsburgh, PA) and the plate was read at 
specified wavelengths using a spectrophotometer (iMark plate reader, Biorad, Hercules, CA). For 
PGE2 ELISAs, a pre-coated plate, washing buffer and other reagents were provided by the 
manufacturer (Enzo Life Sciences, Inc,. Farmingdale, NY), and the provided protocol was 
followed. All ELISA values were corrected for total protein content of homogenates.  
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Abstract 
 Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature 
monocytes and granulocytes that are potent inhibitors of T cell activation. A role for MDSCs in 
bacterial infections has only recently emerged, and nothing is known about MDSC function in the 
context of Staphylococcus aureus (S. aureus) infection. Because S. aureus biofilms are capable 
of subverting immune-mediated clearance, we examined whether MDSCs could play a role in this 
process. CD11b
+
Gr-1
+
 MDSCs represented the main cellular infiltrate during S. aureus orthopedic 
biofilm infection, accounting for >75% of the CD45
+
 population. Biofilm-associated MDSCs 
inhibited T cell proliferation and cytokine production, which correlated with a paucity of T cell 
infiltrates at the infection site. Analysis of FACS-purified MDSCs recovered from S. aureus 
biofilms revealed increased arginase-1, inducible NO synthase and IL-10 expression, key 
mediators of MDSC suppressive activity. Targeted depletion of MDSCs and neutrophils using the 
mAb 1A8 (anti-Ly6G) improved bacterial clearance by enhancing the intrinsic proinflammatory 
attributes of infiltrating monocytes and macrophages. Furthermore, the ability of 
monocytes/macrophages to promote biofilm clearance in the absence of MDSC action was 
revealed in significantly increased S. aureus burdens both locally and in the periphery, because 
effector Ly6C monocytes and, by extension, mature macrophages were also depleted. 
Collectively, these results demonstrate that MDSCs are key contributors to the chronicity of S. 
aureus biofilm infection, as their immunosuppressive function prevents monocyte/macrophage 
proinflammatory activity, which facilitates biofilm persistence.  
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Introduction 
 Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature 
monocytes and granulocytes that are potent inhibitors of T cell activation [122]. In mice, MDSCs 
are characterized by their expression of CD11b and Gr-1, but can be further subdivided into 
monocyte- and granulocyte-like subsets based on their differential expression of Ly6C and Ly6G, 
which are referred to as M-MDSC and G-MDSCs, respectively [120, 135]. CD11b
+
Gr-1
+
 cells 
normally reside in the bone marrow prior to their differentiation into mature granulocytes, 
macrophages or dendritic cells. However, MDSCs can be recruited into lymphoid and inflamed 
tissues during pathologic conditions by the actions of growth factors, such as G-CSF, GM-CSF, 
and VEGF, where disturbances in cytokine homeostasis block their differentiation into mature 
myeloid effector cells, resulting in MDSC expansion [135, 137].Several factors influence MDSC 
activation, including proinflammatory cytokines driven by MyD88-dependent signaling (i.e. IL-6), 
reactive oxygen species (ROS), and cyclooxygenase-2 (COX-2). These proinflamatory molecules 
induce the expression of arginase-1 (Arg-1) and several anti-inflammatory cytokines that not only 
contribute to the inhibition of T cell responses, but may also play a role in macrophage 
polarization towards an alternatively activated M2 phenotype [137]. Although MDSCs are well-
recognized for their role in tumor immunosuppression [122, 137, 155], recent evidence suggests 
that MDSCs can also regulate immune responses during bacterial infections [123, 156-159]. 
 Staphylococcus aureus (S. aureus) is a leading cause of community-acquired and 
nosocomial infections [29, 160]. Infection risk is increased by the presence of foreign materials, 
and S. aureus is a leading cause of biofilm infections on indwelling medical devices and 
orthopedic implants [28]. Biofilms are heterogeneous bacterial communities encased in a self-
produced matrix that represent a serious health care concern based on their chronicity and 
recalcitrance to antibiotic therapy [33]. Previous work from our laboratory has shown that S. 
aureus biofilms skew macrophages toward an alternatively activated M2 anti-inflammatory 
phenotype, typified by robust Arg-1 expression that correlates with the failure to recruit T cells to 
the site of infection[32]. However, Arg-1 expression was also detected in other cell types, leading 
us to examine the identity of alternative Arg-1
+ 
cells associated with S. aureus biofilms. In the 
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current study, we have identified a predominant CD11b
+
Gr-1
+
Arg-1
+
 MDSC infiltrate that 
contributes to the anti-inflammatory environment typical of S. aureus biofilm-associated 
infections. 
 Here we sought to examine the functional role of MDSCs in shaping the anti-
inflammatory milieu during S. aureus orthopedic biofilm infection. Although we identified MDSCs 
using well-established markers [121, 126, 161], their ability to attenuate T cell proliferation was 
required to establish their identity as a bona fide MDSC population. Indeed, we found that 
MDSCs infiltrating S. aureus biofilms were capable of inhibiting T cell proliferation, which 
represents the first report of MDSCs in any type of staphylococcal infection. Furthermore, qRT-
PCR analysis of FACS-purified MDSCs revealed increased expression of typical MDSC 
molecules, including Arg-1, iNOS, and IL-10. Administration of mAb 1A8 (anti-Ly6G), which 
specifically depleted the immunosuppressive MDSC population and mature neutrophils, 
significantly increased monocyte and macrophage proinflammatory activity, which translated into 
decreased S. aureus burdens in the infected joint. Independent evidence to support the 
importance of monocytes/macrophages in biofilm containment in the absence of MDSCs was 
demonstrated by the finding that RB6-C85 (anti-Gr-1 or anti-Ly6G/Ly6C) treatment, which 
depleted effector monocytes and macrophages in addition to MDSCs and granulocytes, 
significantly increased S. aureus burdens and proinflammatory mediator expression as well as 
bacterial dissemination to peripheral organs. These results indicate that MDSCs establish an anti-
inflammatory milieu during S. aureus biofilm infection that thwarts monocyte and macrophage 
proinflammatory activity, leading to persistent colonization. This prominent MDSC infiltrate also 
explains the paucity of T cells associated with S. aureus biofilms. Collectively, these studies 
demonstrate a role for MDSCs during staphylococcal biofilm infection and preventing their 
immunosuppressive actions may offer novel treatment strategies to thwart these devastating, 
chronic infections. 
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Results 
Accumulation of CD11b
+
Gr-1
+
 cells during S. aureus orthopedic biofilm infection. We 
recently reported that S. aureus biofilms skew infiltrating macrophages toward an alternatively 
activated M2 state typified by Arg-1 expression [31, 32]. However, other Arg-1
+
 cells distinct from 
macrophages were also observed, which led us to investigate their identity. A likely candidate 
was MDSCs based on their robust Arg-1 expression and well-described anti-inflammatory 
attributes in cancer [120, 137, 155]. In the present study, we used a mouse model of orthopedic 
biofilm infection [162] to demonstrate the presence and functional importance of MDSCs in 
shaping the anti-inflammatory biofilm milieu in an immunocompetent host. Biofilm formation on 
the orthopedic implant was confirmed by scanning electron microscopy, which revealed S. aureus 
attachment to a dense matrix deposited on the implant surface and bacterial tower formation (Fig. 
3.1). A prominent CD11b
+
Gr-1
+
 infiltrate was observed, which accounted for ~75% of the total 
CD45
+
 leukocyte population by day 14 post-infection (Fig. 3.2A, 2B). Coexpression of CD11b and 
Gr-1 is used to define MDSCs, and cytospin preparations of FACS-purified CD11b
+
Gr-1
+
 cells 
recovered from the site of S. aureus biofilm infection confirmed their heterogeneous composition 
of both granulocytic and monocytic morphologies (Fig. 3.2C). In particular, cells with ringed nuclei 
suggested the presence of immature granulocytes, and immature monocytes with large rounded 
nuclei and little cytoplasm were also observed (Fig. 3.2C). CD11b
+
Gr-1
+
 cells were also detected 
in mice receiving sterile implants, which was not unexpected, because MDSCs have been 
reported in virtually every inflammatory environment and are associated with wound healing 
responses under normal conditions [150, 161]; however, their numbers were significantly lower 
compared with S. aureus-infected animals (Fig. 3.2B). The abundance of CD11b
+
Gr-1
+
 cells 
during early S. aureus orthopedic infection may be one mechanism that contributes to the 
establishment of chronic disease.  
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Figure 3.1 
 
                    
 
Demonstration of S. aureus biofilm formation in vivo on orthopedic implants. Titanium 
orthopedic implants were isolated from C57BL/6 mice at day 45 following S. aureus infection and 
processed for scanning electron microscopy analysis. Left, Biofilm formation is visible on the 
concave surface of the implant (original magnification X300) demonstrating the irregular pattern 
of the biofilm surface with tower structures visible (arrows). Right, Higher magnification of the 
biofilm surface revealing numerous cocci interspersed with matrix material (original magnification 
X20,000). The image has been pseudocolored to highlight S. aureus (gold).  
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Figure 3.2
 
 
Accumulation of CD11b
+
Gr-1
+
 cells during S. aureus orthopedic biofilm infection. Implant-
associated tissues were collected from sterile and infected mice and analyzed by flow cytometry 
for CD11b
+
Gr-1
+
 cells at the indicated time points. (A) Representative contour plots and (B) 
CD11b
+
Gr-1
+
 infiltrates expressed as a percentage of the total CD45
+
 leukocyte population. (C) 
Cytospin preparations of FACS-purified CD11b
+
Gr-1
+
 cells from infected tissues at day 14 were 
stained with Wright-Giemsa (original magnification X20). Arrowheads and arrows indicate cells 
suggestive of immature granulocytes and monocytes, respectively. Results are representative of 
three sterile and five infected mice per group. ***p < 0.001, unpaired two-tailed Student t test.  
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CD11b
+
Gr-1
+
 MDSCs recruited to the site of S. aureus orthopedic biofilm infection inhibit T 
cell activation. A hallmark of MDSCs is their ability to inhibit Ag-specific and polyclonal T cell 
activation [121, 137]. This is a critical attribute based on the promiscuity in surface marker 
expression between MDSCs and other myeloid lineages [150, 163]. To determine whether S. 
aureus biofilm-associated CD11b
+
Gr-1
+
 infiltrates were bona fide MDSCs, we examined their 
ability to inhibit polyclonal CD4
+
 T cell activation, because S. aureus immunodominant TCR 
epitopes have not yet been identified. MDSCs were recovered from tissues at day 14, which 
coincided with maximum cell numbers at the infection site (Fig. 3.2B). CD11b
+
Gr-1
+
 cells from S. 
aureus-infected tissues significantly expressed T cell proliferation (Fig. 3.3A), establishing their 
identity as MDSCs. The inhibitory activity of biofilm-associated MDSCs was further demonstrated 
by their ability to significantly impair T cell cytokine secretion, including TNF-α, IFN-γ, IL-17, and 
IL-4 (Fig. 3B-E).  
 We next determined whether the immunosuppressive nature of MDSCs was restricted to 
the biofilm site or whether they were also suppressive in the periphery, which has been reported 
for MDSCs in tumor-bearing animals [164]. CD11b
+
Gr-1
+
 cells from the spleens of either naïve or 
infected animals were unable to suppress CD4
+
 T cell proliferation (data not shown). It was not 
unexpected that MDSCs from naïve animals failed to inhibit T cell activation, as pathologic 
conditions are known to elicit MDSC expansion and activation [120, 127, 136, 137]. Several 
groups have reported that MDSCs only acquire suppressive function after exposure to factors in 
inflammatory environments [150, 164, 165], and our results suggest that these signals are only 
present in the local biofilm milieu. 
 Because the Gr-1 Ab RB6-C85 recognizes both Ly6G and Ly6C epitopes [166], we 
stained for both markers and identified three distinct populations associated with S. aureus 
orthopedic biofilms, namely Ly6G
high
Ly6C
+
, Ly6G
low
Ly6C
low
, and Ly6G
-
Ly6C
+
 (Fig. 4A). Each 
subset was purified by FACS to determine which was responsible for the observed CD4
+
 T cell 
proliferation in a ratio-dependent manner, confirming their identity as MDSCs (Fig. 3.4E). Similar 
to the observations with the bulk CD11b
+
Gr-1
+
 population (Fig. 3), Ly6G
high
Ly6C
+
 cells decreased 
TNF-α and IL-17 expression (Fig. 3.4F and 3.4G, respectively). Cytospins of the Ly6G
high
Ly6C
+
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population revealed an immature granulocytic morphology characterized by numerous ringed 
nuclei (Fig. 3.4B), which, when taken together with their suppressive action is highly suggestive of 
these cells as granulocytic MDSCs. The Ly6G
-
Ly6C
+
 population was typified by a relatively 
homogenous monocyte-like morphology that was unable to suppress CD4
+
 T cell activation (Fig. 
3.4D, 3.4E), suggesting that these cells are inflammatory monocytes. Collectively, these results 
demonstrate the recruitment of a bona fide MDSC population in staphylococcal biofilm infection.  
 Studies by other groups have reported neutrophil infiltrates in mouse models of S. aureus 
orthopedic infection [167-169]. However, these reports used either immunostaining with Ly6G, 
Ly6G depletion or LysM-GFP mice to identify neutrophils and, as our results demonstrate, these 
approaches cannot differentiate between neutrophils and MDSCs [170]. It is possible that the 
Ly6G
low
Ly6C
low
 cells observed in our model of S. aureus orthopedic biofilm infection are 
neutrophils based on their cytospin morphology, revealing fewer immature cells compared with 
the MDSC population (Fig. 3.4C and 3.4B, respectively) and lack of T cell suppressive activity 
(Fig. 3.4E).  
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Figure 3.3  
 
 
CD11b
+
Gr-1
+
 infiltrates from the site of S. aureus biofilm infection inhibit T cell 
proliferation. FACS-purified CD11b
+
Gr-1
+
 cells recovered from infected joint tissues at day 14 
were immediately cultured ex vivo with eFluor 670-labled CD4
+
 T cells at a 1:1 ratio for 
proliferation assays. (A) Representative histograms of fluorescence intensity, with percentage 
proliferation reported. (B-E) Supernatants from MDSC/CD4
+
 T cell cocultures were collected at 
72 h to quantitate TNF-α (B), IFN-γ (C), IL-17 (D), and IL-4 (E) by Milliplex. Results are 
representative of three to nine independent experiments *p < 0.05, ***p < 0.001, unpaired two-
tailed Student t test. (-), T cells only; (+) T cells incubated with CD3/CD28 Dynabeads; ND, not 
detected. 
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Figure 3.4 
 
 
Ly6G
high
Ly6C
+
 cells infiltrating S. aureus biofilms are bona fide MDSCs. Leukocyte infiltrates 
associated with S. aureus-infected joints were collected at day 14 and analyzed for Ly6C and 
Ly6G expression by flow cytometry. Representative conour plot (A) and Wright-Giemsa-stained 
cytospin preparations of FACS-purified Ly6G
high
Ly6C
+
 (B), Ly6G
low
Ly6C
low
 (C), and Ly6G
-
Ly6C
+
 
(D) cells are shown (original magnification X100). (E) Analysis of ex vivo polyclonal CD4
+
 T cell 
proliferation following a 1:1 and 1:5 coculture with Ly6G
high
Ly6C
+
, Ly6G
low
Ly6C
low
, Ly6G
-
Ly6C
+
 
cells for 72 h, whereupon conditioned supernatants were assessed for TNF-α (F) and IL-17 (G) 
expression by Milliplex. Results are representative of three to nine replicates. *p < 0.05, ***p < 
0.001, one-way ANOVA with Bonferroni’s multiple comparison post hoc analysis. (-), T cells only; 
(+), T cells incubated with CD3/CD28 Dynabeads; ND, not detected.  
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Ly6G
high
Ly6C
+
 cells recruited to sites of S. aureus orthopedic biofilm infection express 
genes characteristic of MDSCs. Owing to the differential immunosuppressive properties of the 
Ly6G
high
Ly6C
+
 and Ly6G
-
Ly6C
+
 subsets associated with S. aureus orthopedic biofilm infection, 
we next examined gene expression profiles of FACS-purified populations immediately ex vivo by 
qRT-PCR as further confirmation of their identity. The Ly6G
high
Ly6C
+
 MDSC subset displayed 
increased iNOS, Arg-1, COX-2, and IL-10 concomitant with reduced IL-12p40 expression 
compared with the Ly6G
-
Ly6C
+
 monocytic fraction (Fig. 3.5), similar to MDSC profiles described 
in other disease models [122, 171-174].  
 MDSCs play an important role in regulating inflammatory processes through their 
production of several pro- and anti-inflammatory cytokines [123, 150]. To assess the inflammatory 
status of MDSCs, cells were recovered from the site of biofilm infection or the spleen and 
immediately stimulated ex vivo with heat-inactivated S. aureus or peptidoglycan. We found that 
regardless of their origin, Ly6G
high
Ly6C
+
 MDSCs were inherently less proinflammatory than 
macrophages (Supplemental Fig. S3.1). Collectively, these results provide further evidence to 
support the identity of infiltrating Ly6G
high
Ly6C
+
 cells into S. aureus orthopedic biofilm infections 
as MDSCs. 
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Figure 3.5 
 
 
Ly6G
high
Ly6C
+
 biofilm-associated infiltrates express genes characteristic of MDSCs. FACS-
purified Ly6G
high
Ly6C
+
 MDSCs and Ly6G
-
Ly6C
+
 inflammatory monocytes were recovered from 
infected joint tissues at day 14, whereupon RNA was immediately isolated for qRT-PCR analysis. 
Gene expression levels in Ly6G
high
Ly6C
+
 MDSCs were calculated after normalizing signals 
against GAPDH and are presented as the fold change relative to the Ly6G
-
Ly6C
+
 monocyte 
population. Results represent the means ± SEM of three independent experiments. 
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Depletion of Ly6G
+
 MDSCs increases monocyte infiltrates and their intrinsic 
proinflammatory activity, resulting in enhanced S. aureus biofilm clearance. To assess the 
functional role of Ly6G
high
Ly6C
+
 MDSCs in orchestrating the anti-inflammatory biofilm milieu to 
facilitate bacterial persistence, mice were treated with the mAb 1A8 to target Ly6G
+
 cells [171, 
175, 176]. This approach would deplete MDSCs, leaving the Ly6C
+
 monocyte and macrophages 
populations intact and able to combat S. aureus infection, presumably in the absence of 
immunosuppression. We confirmed that 1A8 was effective at depleting the Ly6G
high
Ly6C
+
 MDSC 
population, which was more robust at day 7 compared with day 14 (Fig. 3.6A, 6B). Interestingly, 
the frequency of Ly6C
+
 monocytes was significantly increased at day 7 (Fig. 3.6C), and we 
predicted that the absence of immunosuppressive Ly6G
+
 MDSCs would promote the 
proinflammatory attributes of these Ly6C
+
 mononuclear phagocytes. To address this possibility, 
we examined the activation state of FACS-purified Ly6G
-
Ly6C
+
 cells from the infection site of 
1A8-treated versus isotype control mice by qRT-PCR. In the context of MDSC depletion with 1A8, 
expression of iNOS, IL-12p40, and IL-6 was increased in Ly6G
-
Ly6C
+
 cells at day 7 (Fig. 3.7). 
Increased Arg-1 and IL-10 expression was also observed in Ly6G
-
Ly6C
+
 cells (Fig. 3.7), and 
although both possess anti-inflammatory properties, they may be important in maintaining a 
balanced inflammatory environment at the site of infection owing to the absence of normally 
immunosuppressive MDSCs. 
 Because Ly6C
+
 monocyte infiltrates were increased in the context of MDSC depletion 
and displayed intrinsic proinflammatory activity, we next examined whether this would translate 
into superior anti-biofilm activity. This prediction was confirmed, because Ly6G
+
 cell depletion 
with 1A8 significantly reduced S. aureus burdens in both the tissue and knee joint at days 7 and 
14 compared with isotype control animals (Fig. 3.8B), which correlated with less gross evidence 
of exudate formation in MDSC-depleted mice (Fig. 3.8A). Ly6G
+
 cell depletion did not cause S. 
aureus dissemination from the primary site of infection (Fig. 3.8C), and histopathologic analysis of 
H&E-stained tissues showed no dramatic differences in the degree of joint inflammation or 
splenic architecture (as a measure of extramedullary hematopoiesis) between 1A8-treated and 
istoype control animals (data not shown).  
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 To investigate the impact of Ly6G
+
 cell depletion on the inflammatory milieu during S. 
aureus orthopedic biofilm infection, soft tissues surrounding the knee, knee joint, and femur were 
analyzed using Milliplex arrays. Several cytokines (G-CSF, IL-1β, and IL-6) and chemokines 
(CXCL1, CXCL9, and CCL3) were dramatically reduced in 1A8-treated compared with isotype 
control mice primarily at day 7 (Fig. 3.9), in agreement with increased bacterial clearance in the 
former (Fig. 3.8B). Collectively, these results demonstrate that during S. aureus orthopedic biofilm 
infection, Ly6G
high
Ly6C
+
 MDSCs elicit a local microenvironment that restricts 
monocyte/macrophage proinflammatory activity, facilitating the establishment of an anti-
inflammatory environment that favors bacterial persistence. We propose that these effects were 
not significantly influenced by neutrophil loss following 1A8 treatment, because most Ly6G
+
 
leukocytes infiltrating infected joints (i.e., ~75%) were MDSCs. 
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Figure 3.6 
 
 
MDSC depletion augments monocyte recruitment during S. aureus orthopedic biofilm 
infection. Implant-associated tissues from 1A8- and isotype control-treated mice were collected 
at the indicated time points after infection and analyzed by flow cytometry. (A) Representative 
contour plots of Ly6C and Ly6G staining and (B) quantitation of Ly6G
+
Ly6C
+
 MDSCs and (C) 
Ly6C
+
 inflammatory monocytes. Results are presented as a percentage of the total leukocyte 
infiltrate and are representative of two independent experiments (n = 10 mice/group). **p < 0.01, 
***p < 0.001, unpaired two-tailed Student t test. 
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Figure 3.7 
 
 
MDSC depletion enhances intrinsic proinflammatory gene expression in Ly6C
+
 monocytes 
during S. aureus biofilm infection. Ly6G
-
Ly6C
+
 monocytes were purified from tissues 
surrounding the infected joints of 1A8- and isotype control-treated mice at days 7 and 14 post-
infection by FACS, whereupon RNA was immediately isolated for qRT-PCR analysis. Gene 
expression levels in Ly6G
-
Ly6C
+
 monocytes recovered from MDSC-depleted animals were 
calculated after normalizing signals against GAPDH and are presented as the fold change 
relative to Ly6G
-
Ly6C
+
 cells from isotype control mice. Results represent the means ± SEM of two 
independent experiments. 
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Figure 3.8  
 
 
MDSC depletion reduces S. aureus burdens during orthopedic biofilm infection. (A) Gross 
appearance of infected tissues from animals receiving 1A8 or an isotype-matched IgG. (B) 
Bacterial burdens associated with the knee joint, surrounding soft tissue, femur, and orthopedic 
implant and (C) heart and kidney of IgG control- or 1A8-treted animals at days 7 and 14 post-
infection. Results are expressed as the number of CFU per milliliter for orthopedic implants or 
CFU per gram tissue to correct for alterations in tissue sampling sizes. Significant differences in 
bacterial burdens between IgG- and 1A8-treated mice are denoted as *p < 0.05 and **p < 0.01 
(unpaired two-tailed Student t test). 
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Figure 3.9 
 
 
1A8 treatment attenuates proinflammatory mediator production during S. aureus 
orthopedic biofilm infection. Tissue homogenates surrounding orthopedic implants were 
prepared at days 7 and 14 postinfection from 1A8- and isotype-treated mice, whereupon 
expression of G-CSF (A), IL-1β (B), IL-6 (C), CXCL1 (D), CXCL9 (E), and CCL3 (F) was 
quantitated by Milliplex. Results were normalized to the amount of total protein recovered to 
correct for alterations in tissue sampling size. Results are representative of five mice per group. 
*p < 0.05, unpaired two-tailed Student t test. 
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Gr-1
+
 cell depletion confirms the inhibitory action of MDSCs on monocyte/macrophages to 
prevent S. aureus biofilm clearance. Our results have established that MDSC depletion with 
1A8 facilitated S. aureus biofilm clearance, in part due to decreased immunosuppressive effects 
that promoted the proinflammatory attributes of infiltrating monocytes and macrophages. To 
further demonstrate that monocyte/macrophages were critical for anti-biofilm activity in the 
absence of an MDSC infiltrate, we treated mice with the mAb RB6-C85. Similar to 1A8, RB6-C85 
depletes Ly6G
+
 MDSCs and neutrophils, but it also targets monocytes based on its reactivity with 
Ly6C, which would also impact macrophage numbers by default [136, 171, 175-177]. Therefore, 
any differences between 1A8 and RB6-C85 depletion would further support a role for 
monocytes/macrophages in mediating biofilm clearance without the suppressive MDSC 
population. As previously demonstrated, Ly6G/Ly6C staining detected three cell populations in 
implant-associated tissues of isotype control animals at days 7 and 14 following infection, namely 
Ly6G
high
Ly6C
+
 MDSCs, a Ly6G
low
Ly6C
low
 granulocyte-like population, and a Ly6G
-
Ly6C
+
 
inflammatory monocyte subset (Fig. 3.10A). However, at day 7 RB6-C85-treted animals only 
displayed one cell population that shifted from Ly6G
low
Ly6C
low
 to Ly6G
high
Ly6C
+
 at day 14 post-
infection (Fig. 3.10B). The percentage of Ly6G
low
Ly6C
low
 cells in RB6-C85-treated animals was 
significantly higher than isotype-treated controls at day 7; however, no differences were apparent 
at day 14, because the population had shifted to Ly6G
high
Ly6C
+
 (Fig. 3.10B). Although Ly6C
+
 
infiltrates were increased in RB6-C85-treated animals at day 14 post-infection (Fig. 3.10B), they 
were unable to inhibit T cell proliferation (Supplemental Fig. S3.2), and as such they do not 
represent a true MDSC phenotype. Therefore, we suggest that the presence of Ly6G
low
Ly6C
low
 
and Ly6G
high
Ly6C
+ 
populations in the infected joint of RB6-C85-treated mice results from 
increased demand from the overwhelming infection (Fig. 3.11), which agrees with the results to 
follow that demonstrate extensive extramedullary hematopoiesis in the spleens of these animals. 
This is supported by the finding that Ly6G
+
Ly6C
+
 cells were significantly lower in RB6-C85-
treated mice receiving sterile implants compared with isotype control Ab (data not shown). 
 We also examined CCR2 and F4/80 expression as markers for inflammatory monocytes 
and macrophages, respectively [178-180]. Because RB6-C85 also recognizes the Ly6C epitope, 
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we expected both of these populations to be decreased, as CCR2
+
 inflammatory monocytes 
express Ly6C and differentiate into F4/80
+
 macrophages once they have migrated into tissues 
[179]. As expected, the percentage of Ly6C
+
CCR2
+
 cells was significantly decreased in RB6-
C85-treated animals compared with isotype controls at days 7 and 14 postinfection (Fig. 10C). 
Likewise, there were significantly fewer F4/80
+
 macrophages in RB6-C85-depleted mice at day 7 
post-infection, and only a very small percentage of cells remained at day 14 (Fig. 3.10C). 
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Figure 3.10 
 
 
RB6-C85 administration alters leukocyte infiltrates during S. aureus orthopedic biofilm 
infection. Implant-associated tissues from RB6-C85- and isotype control-treated mice were 
collected at the indicated time points after infection and analyzed by flow cytometry. (A) 
Representative contour plots of Ly6C and Ly6G staining and quantitation of (B) Ly6G
high
Ly6C
+
 
MDSCs and Ly6G
low
Ly6C
low
 neutrophils and (C) inflammatory monocytes (CCR2
+
) and 
macrophages (F4/80
+
) present in infected animals receiving RB6-C85 or isotype control Ab. 
Results are expressed as a percentage of the total CD45
+
 leukocyte population. Results are 
representative of 10 mice per group from two independent experiments. *p < 0.05, **p < 0.01, 
unpaired two-tailed Student t test. 
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Gr-1
+
 cell depletion exacerbates S. aureus orthopedic biofilm infection owing to the loss of 
monocyte/macrophage effectors. Strikingly, S. aureus-infected mice treated with RB6-C85 
displayed grossly visible caseous exudate (Fig. 3.11A), which was typified by significantly 
increased bacterial burdens in the knee joint, surrounding soft tissue, and femur at days 7 and 14 
postinfection compared with infected animals receiving an isotype-matched control Ab (Fig. 
3.11B). Histological analysis of tissues collected from RB6-C85-treated mice revealed increased 
inflammation in the joint space, surrounding soft tissue, and bone compared with isotype control 
animals (Table 3.1). Furthermore, the degree of osteolysis was more severe in RB6-C85-treated 
animals, as evidenced by CT imaging (Fig. 3.12), and femurs were more brittle upon harvest. 
These results are in stark contrast with those obtained during 1A8 depletion where biofilm 
burdens were reduced, indicating that monocytes and macrophages are able to promote bacterial 
clearance in the absence of an immunosuppressive MDSC population, because the only 
difference between the Ab depletion strategies was the targeting of monocyte/macrophages.  
 
Table 3.1 Degree of inflammation and extramedullary hematopoiesis associated with RB6-
C85 mAb treatment during S. aureus orthopedic infection. 
 
RB6-C85 administration not only increased bacterial burdens and inflammation at the site 
of S. aureus orthopedic biofilm infection, but it also led to significant systemic effects. First, Gr-1
+
 
depletion enhanced S. aureus dissemination, as bacterial burdens in the heart, kidney, and 
spleen of RB6-C85-treated animals were significantly elevated at day 7 post-infection compared 
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with the isotype control group (Fig. 3.11C). Second, RB6-C85-treated animals displayed 
significant splenomegaly (Fig. 3.13A, 13B). Histopathology revealed marked expansion of the 
splenic sinuses and red pulp with extensive extramedullary hematopoiesis, typified by numerous 
erythroid islands, megakaryocytes, and leukocyte islands in RB6-C85-treated animals, which was 
not observed in infected isotype control mice (Fig. 3.13C). 
To examine changes in the inflammatory milieu after RB6-C85 treatment, inflammatory 
mediator expression was assessed. Numerous cytokines (IL-1β, G-CSF, and IL-17) and 
chemokines (CXCL1, CXCL2, and CCL3) were significantly increased at days 7 and 14 in RB6-
C85-treated animals compared with isotype controls (Fig. 3.14). Similar changes were observed 
in the infected knee joint and femur (data not shown). Taken together with the results from 1A8 
depletion, these finding demonstrate that MDSCs are critical for limiting the proinflammatory 
activity of monocytes and macrophages during S. aureus biofilm infection, which sets the stage 
for bacterial persistence. 
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Figure 3.11 
 
RB6-C85 treatment enhances S. aureus biofilm burdens and dissemination. (A) Gross 
appearance of infected tissues from animals receiving RB6-C85 or an isotype-matched IgG 
revealed a marked caseous exudate in the former. (B) Bacterial burdens associated with the 
knee joint, surrounding soft tissue, femur and orthopedic implant and (C) heart, kidney, and 
spleen of control IgG- or RB6-C85-treated animals at days 7 and 14 postinfection. Results are 
expressed as CFU per milliliter for orthopedic implants or CFU per gram of tissue to correct for 
differences in tissue sampling size. Results are representative of 10 mice per group from two 
independent experiments. Significant differences between IgG and RB6-C85 animals are denoted 
as *p < 0.05, **p < 0.01, and ***p < 0.001 (unpaired two-tailed Student t test). 
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Figure 3.12 
 
 
RB6-C85 administration results in increased osteolysis during S. aureus orthopedic 
biofilm infection. CT images (dorsal view) are presented at day 14 postinfection from mice 
receiving RB6-C85 or isotype control Ab. Arrows indicate the region of bone loss near the implant 
tip at the patella. Color intensity is indicative of bone density, where white indicates most dense 
and dark orange indicates least dense. Images are representative of four individual animals per 
group. 
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Figure 3.13  
 
 
RB6-C85 treatment leads to splenomegaly and extramedullary hematopoiesis during S. 
aureus orthopedic biofilm infection. Gross appearance (A) and weight (B) of spleens from 
RB6-C85- or IgG-treated mice at days 7 and 14 after S. aureus orthopedic biofilm infection (n = 
10/group). (C) H&E-stained sections of spleens from IgG- and RB6-C85-treated mice at day 14 
postinfection (n = 3/group; original magnification X40; zoomed images [original magnification, 
X60] depict areas delineated by rectangles in the X40 field of view). Arrows indicate presence of 
megakaryocytes in RB6-C85-treated spleens. Significant differences between IgG and RB6-C85 
animals are denoted as ***p < 0.001 (unpaired two-tailed Student t test). 
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Figure 3.14  
 
 
RB6-C85 administration exacerbates inflammatory mediator production during S. aureus 
orthopedic biofilm infection. Tissue homogenates surrounding orthopedic implants were 
prepared at days 7 and 14 postinfection from RB6-C85- and isotype control-treated mice, 
whereupon IL-1β (A), G-CSF (B), IL-17 (C), CXCL1 (D), CXCL2 (E), and CCL3 (F) expression 
was quantitated by Milliplex. Results were normalized to the amount of total protein recovered to 
correct for alterations in tissue sampling size. Results are representative of five mice per group. 
*p < 0.05, **p < 0.01, ***p < 0.001, unpaired two-tailed Student t test). 
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Supplemental Figure S3.1 
 
 
MDSCs exhibit less inherent proinflammatory activity than macrophages. Bone marrow-
derived macrophages (MΦ) and FACS-purified Ly6G
high
Ly6C
+
 MDSCs recovered from the site of 
S. aureus orthopedic biofilm infection (tissue MDSC) or the spleen (spleen MDSC) of infected 
animals were stimulated with 10
7
 heat-inactivated (HI) S. aureus or PGN (10 μg/ml). 
Supernatants were collected at 24 h, whereupon G-CSF (A), CCL5 (B), CCL3 (C) and IL-6 (D) 
expression was quantitated by Milliplex. Significant differences are denoted by asterisks (*p < 
0.05; **p < 0.01; ***p < 0.001; one-way ANOVA with Bonferroni’s multiple comparison post-hoc 
analysis) and are representative of three independent replicates. 
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Supplemental Figure S3.2 
 
 
RB6-C85 treatment reduces Ly6G
high
Ly6C
+
 MDSC infiltrates in mice receiving sterile 
orthopedic implants. Implant-associated tissues, blood and spleens from RB6-C85- and isotype 
control-treated mice were collected at the indicated time points after placement of sterile 
orthopedic devices and analyzed by flow cytometry. Ly6G
high
Ly6C
+
 or Gr-1
+
 MDSCs are 
expressed as a percentage of the total CD45
+
 leukocyte infiltrate. Significant differences are 
denoted by asterisks (*p < 0.05; unpaired two-tailed Student t test) and are representative of two 
mice per group. 
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Supplemental Figure S3.3  
 
 
CD11b
+
Gr-1
+
 MDSC infiltrates are observed during S. aureus catheter-associated biofilm 
infection. Mice (n = 4 per time point) were infected with 10
3
 CFU of USA300 LAC::lux in the 
lumen of surgically implanted catheters to establish biofilm infection. Catheter-associated tissues 
were collected from mice at the indicated time points, whereupon CD11b
+
Gr-1
+
 infiltrates were 
quantified by flow cytometry. Results are presented as the percentage of the total CD45
+
 infiltrate. 
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Supplemental Figure S3.4
 
 
RB6-C85 treatment during S. aureus catheter-associated biofilm infection results in 
increased bacterial burdens and dissemination. Mice (n = 4 IgG and 5 RB6-C85 per time 
point) were infected with 10
3
 CFU of USA300 LAC::lux in the lumen of surgically implanted 
catheters to establish biofilm infection. Animals received i.v. injections of 100 μg RB6-C85 or IgG 
isotype control Ab at days -1, 2, and 5 following S. aureus exposure, whereupon bacterial 
burdens associated with infected catheters, surrounding tissue, and dissemination to the kidney 
were quantitated at day 7 post-infection. Significant differences between groups are denoted by 
asterisks (*p < 0.05, **p < 0.01; unpaired two-tailed Student t test). 
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Discussion 
 An emerging role for MDSCs has been described in several diseases aside from cancer, 
most recently to include bacterial infections [123, 157-159, 176, 181]. Using a mouse model of S. 
aureus orthopedic biofilm infection, we demonstrate that a population of CD11b
+
Gr-1
+
 MDSCs 
accumulates in the joint tissue and depletion of this population results in improved bacterial 
clearance by promoting the proinflammatory attributes of infiltrating monocytes and 
macrophages. These findings suggest that MDSCs are key contributors to the chronicity of S. 
aureus biofilms through their modulation of the host immune response. 
 Our previous studies have shown that S. aureus biofilms augment Arg-1 expression and 
polarize macrophages toward an M2 anti-inflammatory state [32]. The present study has 
expanded the repertoire of immune suppressive effectors to include MDSCs. MDSCs are notable 
for their robust Arg-1 expression, which depletes extracellular arginine, causing T cell dysfunction 
at multiple levels, including cell cycle arrest, reduced expression of the CD3ζ chain, and a global 
reduction in several proteins essential for T cell activity [182-184]. Limited numbers of CD4
+
 T 
cells were detected in implant-associated tissues during S. aureus biofilm infection (i.e., 2-5%). 
We expected T cell infiltrates to be enhanced following Gr-1 and Ly6G depletion originating from 
the loss of MDSC activity; however, this was not the case. One possibility to explain this finding is 
that the combined action of MDSCs and regulator cytokines serve to limit T cell numbers at the 
site of biofilm infection, which remains to be determined. Besides actions on T cells, arginine 
depletion via MDSC Arg-1 activity reduces its availability for iNOS, which thwarts M1 classical 
macrophage activation, as we have previously shown in S. aureus biofilms [32]. By extension, the 
significant MDSC infiltrate associated with S. aureus biofilms in vivo is likely an important factor in 
skewing monocyte/macrophages toward a M2 anti-inflammatory phenotype that promotes 
bacterial persistence, and our studies confirmed that MDSCs recovered from the site of 
orthopedic biofilm infection express Arg-1 and IL-10. By further extension, we predicted that 
depletion of the suppressive MDSC population would allow infiltrating monocytes to act as true 
effector cells. This was confirmed by the finding that Ly6C
+
 monocytes recovered from MDSC-
depleted animals expressed more proinflammatory genes compared with monocytes recovered 
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from IgG-treated mice where the MDSC population remained intact. Additionally, MDSC depletion 
significantly decreased biofilm burdens, confirming the importance of this population in 
orchestrating the anti-inflammatory biofilm milieu to facilitate infection persistence. Besides 
MDSCs, regulatory T cells also possess anti-inflammatory attributes similar to MDSCs [185]. 
However, we did not detect any CD4
+
CD25
+
Foxp3
+ 
cells associated with S. aureus biofilm 
infections (data not shown), whereas another group has reported regulatory T cell involvement in 
biofilm clearance [28]. The reasons for these discrepancies are not clear but may arise from 
differences in experimental models and/or S. aureus strains tested. Based on our analysis, we 
propose that MDSCs represent the main immunosuppressive effector cell during S. aureus 
orthopedic biofilm infection. The signals controlling MDSC recruitment, activation, and 
suppressive activity during S. aureus biofilm infection remain ill-defined and are ongoing topics of 
investigation in our laboratory.  
 Our RB6-C85 depletion studies revealed significant increases in bacterial dissemination 
from the orthopedic infection site. As mentioned previously, RB6-C85 recognizes both Ly6G and 
Ly6C epitopes, effectively depleting MDSCs, neutrophils, monocytes, and by extension, 
macrophages. Therefore, although MDSC infiltrates were reduced, effector populations were also 
targeted, leaving fewer leukocytes either locally or systemically to prevent S. aureus 
dissemination to peripheral organs. By extension, we propose that the function of each leukocyte 
subset differs depending on the local microenvironment; namely, although the inhibitory actions of 
MDSCs were negated following RB6-C85 treatment, this coincided with a local reduction in 
inflammatory monocytes/macrophages, such that biofilm growth could not be held in check at the 
primary infection site (i.e., joint). When biofilm-associated bacteria seeded peripheral sites, the 
paucity of systemic neutrophils likely accounted for the failure to effectively clear the infection, 
which is essential because neutrophils are a main effector cell against planktonic S. aureus [83, 
97, 186, 187]. Dissemination was not observed with anti-Ly6G Ab treatment, which was attributed 
to the local monocyte/macrophage population that remained intact and exhibited heightened 
proinflammatory activity. MDSC infiltrates were also detected in a S. aureus catheter-associated 
biofilm infection model (Supplemental Fig. S3.3), and RB6-C85 treatment similarly increased 
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bacterial burdens and dissemination (Supplemental Fig. S3.4), providing independent 
confirmation that MDSCs are a hallmark of S. aureus biofilm infection. 
 One notable finding in the present study was the extensive extramedullary hematopoiesis 
observed in the spleens of RB6-C85-treated animals compared with isotype controls. 
Extramedullary hematopoiesis is frequently seen during chronic inflammatory diseases and 
cancer [161] and expansion of CD11b
+
Gr-1
+
 MDSCs has been reported in tumor and 
polymicrobial sepsis models [123, 188, 189]. During infection, the requirement for myeloid cells 
dramatically increases in response to an expanding infectious burden, which creates a need for 
emergency myelopoiesis and the mobilization of immature myeloid cells from the bone marrow 
and spleen [161]. The targeted reduction in Gr-1
+
 cells coincident with increasing biofilm burdens 
with RB6-C85 treatment likely explains the extensive extramedullary hematopoiesis observed in 
the spleens of these animals. Another unexpected finding was that Gr-1
+
 (Ly6G/Ly6C) infiltrates 
were increased at the site of orthopedic infection following RB6-C85 administration. However, this 
was likely a compensatory mechanism in response to elevated bacterial burdens both locally and 
systemically in Gr-1-depleted mice, because these newly recruited Ly6G
+
Ly6C
+
 cells were unable 
to suppress CD4
+
 T cell proliferation, which agrees with reports of polymicrobial sepsis [123]. 
Additionally, we also observed enhanced levels of G-CSF, IL-6 and VEGF in the serum of RB6-
C85-treated mice, all of which contribute to the expansion of immature myeloid populations [120, 
137]. Alternatively, the failure to deplete Ly6G
+
Ly6C
+
 infiltrates at later intervals could be 
explained by the induction of anti-rat IgG Abs that would be expected to impair the efficacy of 
RB6-C85 treatment (rat anti-mouse Gr-1). However, this appears less likely because RB6-C85 
was still capable of significantly reducing inflammatory monocyte and macrophage infiltrates into 
S. aureus-infected joints 2 wk after repeated Ab administration. 
 Live CT scans revealed significantly more osteolysis in the femurs of RB6-C85-treated 
animals compared with 1A8 and isotype control mice, which may be attributed to the increased 
bacterial burdens in the former. The exact mechanisms of osteolysis are still not completely 
understood, and they differ depending on pathologic conditions [190, 191]. However, several 
studies suggest that proinflammatory mediators, such as IL-1β, could play a role in the initiation 
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and progression of osteolysis [192-194], and numerous proinflammatory mediators were 
significantly elevated in the joint and surrounding soft tissue following RB6-C85 treatment, 
including IL-1β, that coincided with increased bone destruction. Additionally, S. aureus is not only 
capable of colonizing the bone matrix, but it can also invade osteoblasts, which could contribute 
to chronicity [195]. Interestingly, a recent study identified phenol-soluble modulins as a key 
inducer of osteoblast proliferation in and S. aureus osteomyelitis model [196]; however, effects on 
osteoclasts remain to be defined. 
 Our studies are just beginning to explore the role of MDSCs during S. aureus infection. 
By manipulating these cells with Ab depletion strategies, we demonstrated that their 
immunosuppressive function prevents monocytes/macrophages from eliminating biofilm-
associated bacteria by attenuating their proinflammatory properties. Our findings do not exclude 
the possibility that the biofilm matrix may also play a role in thwarting immune recognition in vivo; 
however, this remains an area of debate. Although it is clear that intact biofilms do afford some 
degree of protection against macrophage phagocytosis as previously shown by our laboratory 
and others [32, 100, 114, 197-199], it is clear that neutrophils are fully capable of invading and 
phagocytosing biofilm-associated bacteria [61, 100, 112, 200], yet there is no apparent impact on 
biofilm growth. The fact that staphylococcal biofilms polarize macrophages toward an alternatively 
activated M2 phenotype does suggest that macrophage surface receptors are triggered to elicit 
this programming event; however, the identity of these receptors remains unknown. Future 
studies examining a S. aureus biofilm-defective mutant would be valuable for determining 
whether signals from the biofilm itself are responsible for MDSC recruitment and 
immunosuppressive activities. Preventing the presumed immunosuppressive action of infiltrating 
MDSCs may offer a novel therapeutic strategy to thwart these devastating chronic infections.  
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Abstract 
Staphylococcus aureus is a leading cause of human prosthetic joint infections (PJIs) typified by 
biofilm formation. We recently identified a critical role for myeloid-derived suppressor cells 
(MDSCs) in S. aureus biofilm persistence. Proinflammatory signals induce MDSC recruitment and 
activation in tumor models; however, the mechanisms responsible for MDSC homing to sites of 
biofilm infection are unknown. In this study, we report that several cytokines (IL-12p40, IL-1β, 
TNF-α, and G-CSF) and chemokines (CXCL2, CCL5) were significantly elevated in a mouse 
model of S. aureus PJI. This coincided with significantly increased MDSC infiltrates concomitant 
with reduced monocyte, macrophage, and T cell influx compared with uninfected animals. Of the 
cytokines detected, IL-12 was of particular interest based on its ability to possess either pro- or 
anti-inflammatory effects mediated through p35-p40 heterdimers, respectively. MDSC recruitment 
was significantly reduced in both p40 and p35 knockout mice, which resulted in enhanced 
monocyte and neutrophil influx and bacterial clearance. Adoptive transfer of wild-type MDSCs 
into infected p40 knockout animals worsened disease outcome, as evidenced by the return of S. 
aureus burdens to level typical of wild-type mice. Tissues obtained from patients undergoing 
revision surgery for PJI revealed similar patterns of immune cell influx, with increased MDSC-like 
cells and significantly fewer T cells compared with aseptic revisions. These findings reveal a 
critical role for IL-12 in shaping the anti-inflammatory biofilm milieu by promoting MDSC 
recruitment. 
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Introduction 
 The number of patients undergoing primary total hip and knee arthroplasties has steadily 
increased over the past decade, with nearly 800,000 procedures being performed in the United 
States each year [49]. Prosthetic joint infection (PJI) is a serious complication following 
arthroplasty, with S. aureus being a common inciting pathogen [49]. A recent study using National 
Inpatient Sample data from 1990-2003 projected the infection incidence following total hip 
revision to increase from 3,400 in 3005 to 46,000 in 2030, and for total knee replacements from 
6,400 in 2003 to 175,500 in 2030 based on the increased volume of prosthetic joint replacement 
procedures with an aging population [201]. The majority of PJIs are thought to occur during 
surgery, likely originating from skin commensals. This has led to increased screening for S. 
aureus carriage to ensure that patients undergo decolonization regimens prior to their surgical 
procedure in an attempt to minimize infection risk [13, 202, 203]. Only a small number of bacteria 
are required to seed an implanted prosthesis; however, once adherent they can establish a 
biofilm, affording protection from conventional antimicrobial agents as well as the host immune 
system [1, 31, 61]. In addition to biofilm formation on prostheses, PJIs are often associated with 
chronic osteomyelitis, reflecting biofilm growth on a native surface [36, 204]. Due to the difficulty 
in treating PJIs, patients are often subjected to a staged protocol requiring two surgeries, the first 
being removal of the infected prosthetic joint and placement of a temporary spacer impregnated 
with high doses of antibiotics for several weeks, followed by a second surgery for prosthetic joint 
re-implantation [205-207]. However, patients experiencing a prior PJI are at increased risk for 
subsequent infections after the placement of a new prosthesis [36, 208]. The significant disease 
burden associated with PJIs and the increasing prevalence of antibiotic-resistant strains, such as 
methicillin-resistant and vancomycin intermediate S. aureus (MRSA and VISA, respectively), 
highlights the importance of investigating alternative treatment paradigms. Our approach has 
been to understand how the host innate immune response is altered during biofilm-associated 
PJI, with the goal of re-directing this response to facilitate bacterial clearance in combination with 
conventional antibiotic therapy. This would provide an opportunity for either nonsurgical or one-
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stage re-implantation, where removal of the infected prosthesis and reinsertion of the new implant 
occur simultaneously. 
 A number of animal models examining S. aureus osteomyelitis have shown an elevation 
of inflammatory cytokines that have been implicated in bone remodeling as well as pathology 
[209-212]. In contrast, the inflammatory events associated with S. aureus PJI remain to be fully 
elucidated. In particular, the presence of a foreign body may alter the kinetics and/or dynamics of 
the host immune response to inadvertently facilitate biofilm formation and persistence. Although a 
recent report described a key role for IL-1β in a mouse model of S. aureus post-arthroplasty 
infection [162], the cellular source of IL-1β and a detailed analysis of infiltrating leukocytes was 
not assessed. Other investigations using a mouse S. aureus tibial implant model have suggested 
the involvement of Th2 and Treg cells in bacterial clearance [167]; however, an in-depth analysis 
of innate immune mechanisms was not conducted. A detailed evaluation of the inflammatory 
events during S. aureus PJI is warranted to identify mechanisms whereby the organism is able to 
subvert host innate immunity to establish chronic disease.  
Our recent report documented an important role for myeloid-derived suppressor cells 
(MDSCs) in S. aureus persistence during PJI [60]. In particular, MDSC depletion facilitated biofilm 
clearance by augmenting the proinflammatory properties of infiltrating monocytes. The objective 
of the current report was to identify critical cytokines responsible for MDSC action during biofilm 
formation in vivo. One candidate was IL-12p40, which was markedly elevated during S. aureus 
biofilm formation. IL-12p40 pairs with the p35 or p19 polypeptides to form the heterodimeric 
cytokines IL-12 and IL-23, respectively [213, 214]. However, it is well known that IL-12p40 is 
produced in excess of the other IL-12 family subunits and can exert negative regulatory effects as 
a homodimer by competitively binding the IL-12 receptor [215-217]. A recent report demonstrated 
a role for IL-12p40 in S. aureus orthopedic implant infection after treatment with a neutralizing Ab 
[167]. However, the only readout reported was a reduction in the percentage of mice that 
remained infected after 21 days; no information pertaining to bacterial burdens, inflammatory 
infiltrates, or the cytokine’s mechanism of action was described. In the current study, we found 
that both p40 and p35 KO mice displayed significant reductions in MDSC infiltrates during S. 
105 
 
aureus PJI, which coincided with significantly increased monocyte and macrophage infiltrates and 
improved bacterial clearance. A direct role for MDSCs in this process was revealed by the ability 
of adoptively transferred wild type MDSCs to significantly increase S. aureus biofilm burdens in 
IL-12p40 KO mice, implicating a key role for IL-12 in shaping the local inflammatory milieu to 
favor MDSC accumulation and biofilm persistence. These effects were not observed in p19 KO 
mice, demonstrating that IL-23 does not play a role in shaping the biofilm inflammatory milieu. 
Examination of tissues obtained from patients undergoing revision surgery for PJI revealed 
increased MDSC-like infiltrates and a paucity of T cells compared with aseptic revisions, along 
with dramatic increases in a variety of pro-inflammatory mediators. These findings recapitulate 
what is observed in our mouse model of orthopedic implant infection, demonstrating its utility for 
deciphering mechanisms of biofilm evasion of host immunity during PJI and therapeutic 
interventions. 
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Results 
S. aureus orthopedic implant infections are typified by immune skewing and chronicity. 
One complication after joint replacement surgery is persistent biofilm-associated PJI, with S. 
aureus being a frequent etiological agent [36, 218, 219]. Here we utilized a mouse model of S. 
aureus post-arthroplasty joint infection that mimics PJI [220, 221]. Prior studies from our 
laboratory and others have demonstrated ultrastructural evidence of biofilm formation on infected 
implants in this mouse model by SEM [162, 213](Goriely et al 2008, Bernthal et al 2010). Biofilm 
formation is typified by bacterial persistence, which was demonstrated in the knee joint, 
surrounding soft tissue, and femur until day 28 postinfection (Fig. 4.1) with bacterial burdens still 
evident at 3 mo (data not shown). Fewer bacteria were associated with the implant (10-1000 
CFU; data not shown), despite the continued colonization of neighboring sites. This suggests that 
our model has features of chronic osteomyelitis, which is a common sequelae of PJI [36, 204]. 
However, the possibility remains that PJI-associated bacteria were dislodged from the implant 
upon removal from the medullary cavity because of the constricted space. Bacterial growth was 
never detected in animals receiving aseptic implants in any of the tissues examined (data not 
shown). 
 Histological evaluation revealed dramatic inflammation of the soft tissues surrounding 
infected joints at day 7, which was increased by day 28 (Supplemental Fig. S4.1B and D). Gram 
stains revealed bacterial localization along the implant-tissue interface in S. aureus-infected 
animals suggestive of biofilm formation (Supplemental Fig. S4.1E). CT analysis revealed 
substantial bone loss at the distal tip of infected implants near the patella, which was most 
discernable at later stages of infection (Supplemental Fig. 4.2). In contrast, animals receiving 
aseptic implants showed no evidence of bone destruction. Collectively, these features 
demonstrate good fidelity of the mouse model to pathology that occurs during PJIs in humans. 
 A better understanding of the inflammatory processes that ensue during persistent PJI is 
needed to develop more effective treatment paradigms. To this end, we first examined the 
production of inflammatory mediators in the knee joint, surrounding soft tissue, and femur in the 
mouse model. Several proinflammatory cytokines, including IL-12p40, IL-1β, TNF-α, and G-CSF, 
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were increased in all tissue regions from S. aureus-infected mice throughout the 28 d time course 
(Fig. 4.2). Likewise, numerous chemokines, such as CXCL2 and CCL5, were also markedly 
elevated in infected tissues (Fig. 4.2). Aseptic implants elicited transient inflammatory mediator 
production (Fig. 4.2), which most likely originated from the trauma generated during the surgical 
procedure. To evaluate whether enhanced chemokine production in S. aureus-infected joints 
translated to increased leukocyte infiltrates, FACS analysis was performed at weekly intervals for 
1 mo postinfeciton. Of the total CD45
+
 leukocyte infiltrate, the predominant cell type detected was 
Ly6G
high
Ly6C
+
, which we have recently identified as functional MDSCs (Fig 4.3A and B) [60]. 
Contrary to the significant influx of MDSCs into S. aureus-infected tissues, monocyte (Ly6G
-
Ly6C
+
), macrophage (F4/80
+
), and neutrophil (Ly6G
low
Ly6C
low
) infiltrates were significantly 
decreased compared with mice receiving aseptic implants (Fig 4.3C, D and F) despite the 
heightened expression of numerous chemokines that target these specific cell populations (Fig 
4.2). In addition to these innate leukocyte populations, CD3
+
 T cells were significantly decreased 
in infected tissues, whereas T cell infiltrates were elevated in animals receiving aseptic implants, 
particularly during the first two weeks post-surgery (Fig 4.3G). Collectively, these results 
demonstrate that S. aureus PJIs actively augment MDSC influx while suppressing the recruitment 
of numerous leukocyte subsets. 
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Figure 4.1 
 
 
S. aureus persistence during orthopedic implant infection. The femur, knee joint, and 
surrounding soft tissue associated with S. aureus-infected titanium implants were collected at the 
indicated intervals for quantitation of bacterial burdens. Animals receiving aseptic implants did not 
display any bacterial growth and are not shown. Results are expressed as CFU per gram of 
tissue to normalize for differences in sampling size and are presented from individual animals 
combined from three independent experiments (n = 12-24 mice/group). 
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Figure 4.2  
 
 
 
S. aureus orthopedic implant infection elicits sustained cytokine and chemokine 
production. Tissues surrounding the knee joint of mice with S. aureus-infected (n = 6) or aseptic 
(n = 8) implants were collected at the indicated time points, whereupon IL-12p40, IL-1β, TNF-α, 
G-CSF, CXCL2, and CCL5 production was measured by multi-analyte bead arrays. Results are 
normalized to the amount of total protein to correct for differences in tissue sampling size (*p < 
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; unpaired Student’s t test). ND, not detected 
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Figure 4.3  
 
 
S. aureus orthopedic implant infections are typified by a robust MDSC infiltrate. Soft 
tissues surrounding the knee joint of mice with S. aureus-infected (n = 6-8) or aseptic (n = 8) 
implants were analyzed by flow cytometry for leukocyte infiltrates at the indicated time days after 
infection. Results were calculated after gating on the CD45
+
 population. (A) Representative 
contour plots of Ly6G and Ly6C-stained cells and quantitation of (B) Ly6G
high
Ly6C
+
 MDSCs; (C) 
Ly6G
-
Ly6C
+
 monocytes; and (D) Ly6G
low
Ly6C
low
 neutrophils. (F) Representative contour plots of 
CD45 and F4/80-stained cells and quantification of (E) F4/80
+
 macrophages. (G) Quantification of 
CD3
+
 T cells. Results are representative of three independent experiments (*p < 0.05; ***p < 
0.001; ****p < 0.0001; unpaired Students t test).  
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Tissues from human PJIs display increased MDSC-like and reduced T cell infiltrates with 
elevated pro-inflammatory mediator expression. To determine whether the patterns of 
leukocyte infiltration and inflammatory mediator production observed in our mouse model 
translated to human infection, these parameters were assessed in tissue samples from patients 
undergoing revision surgeries for PJIs or aseptic loosening as a control (Fig 4.4A). Of the infected 
tissues analyzed in this study, three were confirmed group B streptococcus and two were S. 
epidermidis. Here we report findings with S. epidermidis, since it is most closely related to S. 
aureus, which was utilized throughout our mouse studies. Compared with mice, human MDSC 
markers are less well-defined, with some reports describing this population as CD33
+
HLA-DR
-
 
[129, 222]. Similar to our mouse model, a population of MDSC-like cells (CD33
+
HLA-DR
-
) was 
detected in tissues from a patient with confirmed S. epidermidis PJI, whereas few of these cells 
were observed in aseptic samples (Fig 4.4C). In contrast, T cell influx was minimal in infected 
specimens, whereas T cells were the most abundant infiltrate associated with tissues recovered 
from aseptic orthopedic revisions (Fig 4.4B). Additional CD45
+
 leukocyte populations were also 
detected in infected patient tissues, including CD33
-
HLA-DR
+
 (Fig 4.4C) as well as CD66
+
CD14
-
 
and CD66
-
CD14
+
 cells (Fig 4.4D). To better define these leukocyte populations and examine their 
activation status, subsets were purified from infected patient tissues by FACS, whereupon RNA 
was immediately isolated to examine gene expression by qRT-PCR. The CD33
+
HLA-DR
-
 
population recovered from the confirmed S. epidermidis infection expressed several genes 
characteristic of MDSCs, including Arg-1, iNOS, and IDO-1, further strengthening the 
classification of these cells as MDSC-like (Fig 4.4E) [139, 222]. Interestingly, none of the genes 
analyzed were detected in CD33
-
HLA-DR
-
CD66b
+
 neutrophil-like cells, whereas CD33
-
HLA-DR
+
 
monocyte/macrophage infiltrates expressed iNOS, IDO-1, and TNF-α (Fig 4.4E). Analysis of 
inflammatory mediator expression revealed elevated levels of G-CSF, IL-1β, IL-6, IL-8, and 
soluble CD40 ligand (sCD40L) in S. epidermidis-infected tissues compared to aseptic specimens 
(Fig. 4.4F). These results confirm that similar leukocyte infiltration patterns are observed between 
our mouse post-arthroplasty infection model and human PJI tissues; namely, increased MDSC-
like cells and a paucity of T cells. In addition, human PJI tissues were typified by elevated 
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inflammatory mediator expression as was seen in the mouse. These findings demonstrate the 
utility of the mouse model for deciphering mechanisms of biofilm evasion of host immunity during 
human PJI and therapeutic interventions. 
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Figure 4.4 
 
 
Tissues from human PJIs display increased MDSC-like and reduced T cell infiltrates. (A) 
Tissues surrounding aseptic and S. epidermidis-infected knee prostheses were collected for flow 
cytometric analysis, qRT-PCR, and inflammatory mediator production. Representative contour 
plots of (B) CD3
+
 T cells; (C) MDSC-like infiltrates (CD33
+
HLA-DR
-
); (D) CD66b
+
 granulocytes 
and CD14
+
 mononuclear cells gated on the CD45
+
 population. (E) qRT-PCR analysis of genes 
that were detected (+) versus absent (-) in each sorted cell population and (F) quantitation of G-
CSF, IL-1β, IL-6, IL-8 and sCD40L expression in tissues shown in (A). Results were normalized 
to the amount of total protein to correct for differences in tissue sampling size. ND, not detected. 
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IL-12 is critical for MDSC recruitment and attenuating innate immune cell influx during S. 
aureus orthopedic implant infection. The IL-12 family of cytokines possesses pro-inflammatory 
properties that regulate macrophage and T cell activation [223-225]. In addition, pro-inflammatory 
cytokines have been reported to recruit and activate MDSCs [121, 226], which are significantly 
elevated in our S. aureus orthopedic implant infection model (Fig 4.3) and inhibit T cell activation 
[60]. Based on the increases in IL-12p40 expression in human PJI tissues (data not shown) and 
our mouse model (Fig 4.2) and its ability to exert either pro- or anti-inflammatory activity mediated 
by p35-p40 heterodimers or p40 homodimers, respectively, we examined the importance of IL-12 
family members during early S. aureus orthopedic infection using IL-12p40 and p35 KO mice. 
 Examination of leukocyte recruitment in S. aureus-infected IL-12p40 and p35 KO animals 
revealed significant decreases in Ly6G
high
Ly6C
+
 MDSCs (Fig 4.5A and B). To determine whether 
these residual MDSC infiltrates retained suppressive activity, MDSCs from IL-12p40 and p35 KO 
mice were purified by FACS at days 7 and 14 after infection and examined for their ability to 
inhibit polyclonal T cell activation. MDSCs recovered from both IL-12p40 and p35 KO mice were 
capable of inhibiting T cell proliferation (Fig 4.5C and D, respectively). However, IL-12p40 KO 
mice do not display any evidence of defects in MDSC development, and analysis of MDSCs from 
the spleens of WT and IL-12p40 KO mice reveal similar percentages in both naïve animals and 
following S. aureus PJI (data not shown).This finding suggests that IL-12 promotes MDSC 
recruitment rather than functional activity. Our recent report demonstrated that MDSC depletion 
during S. aureus PJI enhanced monocyte recruitment and intrinsic pro-inflammatory activity 
(Heim et al 2014). Similarly, the nearly 70-80% reduction in MDSC infiltrates observed in IL-
12p40 and p35 KO mice translated into significant increases in Ly6G
-
Ly6C
+
 monocyte recruitment 
(Fig 4.6) and improved bacterial clearance in both IL-12p40 and p35 KO mice compared with WT 
animals (Fig 4.7). Coincident with reduced bacterial burdens, the production of numerous 
inflammatory mediators, including IL-1β, TNF-α, G-CSF, and CXCL2 was decreased in IL-12p40 
and p35 KO mice (Fig 4.8). Since IL-23p19 also shares the common p40 subunit [227], we 
examined S. aureus infection in p19 KO mice but found no differences in inflammatory indices in 
comparison with WT animals (data not shown). 
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 To further implicate MDSCs as the key cell type responsible for inhibiting innate immune 
cell influx and promoting S. aureus persistence during PJI, bone marrow-derived MDSCs from 
WT mice were adoptively transferred into IL-12p40 KO animals one day after infection, 
whereupon bacterial burdens were assessed 7 and 14 days later (Fig 4.9). MDSCs for these 
experiments were expanded from bone marrow in vitro and confirmed for their ability to inhibit T 
cell proliferation (Supplemental Fig S4.3). The adoptive transfer of WT MDSCs into IL-12p40 KO 
animals restored bacterial burdens to those typically observed in WT mice and reduced monocyte 
and neutrophil infiltrates (Fig. 4.9). These effects are likely the result of MDSC activity and not IL-
12 release per se, since MDSCs are not a major source of IL-12. This experiment was not 
performed in p35 KO animals, since all of our prior studies demonstrated a concordance in 
phenotypes between p40 and p35 KO mice (Figs 4.5-8). Collectively, these findings demonstrate 
that IL-12 plays a key role in MDSC recruitment during S. aureus PJI to actively suppress 
monocyte and neutrophil influx and promote bacterial persistence. 
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Figure 4.5 
 
Recruitment of T cell-suppressive MDSCs during S. aureus orthopedic infection is 
regulated by IL-12. LyG
high
Ly6C
+
 MDSCs associated with knee joint of S. aureus-infected wild-
type (WT) and (A) IL-12p40 or (B) IL-12p35 knockout (KO) mice (n = 8/group) were quantified by 
flow cytometry at the indicated times after infection. Results were calculated after gating on the 
CD45
+
 population and represent the mean ± SEM of three independent experiments. MDSCs 
were purified from infected knee tissues of WT and (C) IL-12p40 or (D) IL-12p35 KO mice at days 
7 and 14 post-infection for T cell proliferation assays. Results are expressed as the % 
proliferation with T cells alone (-) and CD3/CD38-stimulated T cells (+) as controls. Results 
represent two independent experiments. (*p < 0.05; **p < 0.01; ***p < 0.001; unpaired Student’s t 
test). 
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Figure 4.6 
 
IL-12 deficiency increases monocyte influx during S. aureus orthopedic implant infection. 
Ly6G
-
Ly6C
+
 monocytes associated with the knee joint of S. aureus-infected WT and (A) IL-12p40 
or (B) IL-12p35 KO mice (n = 8/group) were quantified by flow cytometry at the indicated times 
after infection. Results were calculated after gating on the CD45
+
 population and are 
representative of three independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001; unpaired 
Student’s t test). 
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Figure 4.7 
 
 
IL-12 is critical for the establishment of S. aureus implant-associated infection. A titanium 
implant was place in the femur of WT and IL-12p40 or IL-12p35 KO mice (n = 8/group) followed 
by inoculation with 10
3
 CFU S. aureus. The femur, knee joint, and surrounding soft tissue were 
collected at the indicated intervals after infection for quantitation of bacterial burdens. Results are 
expressed as CFU per gram of tissue to normalize for differences in sampling size and are 
combined from the three independent experiments (*p < 0.05; **p <0.01; ***p < 0.001; Wilcoxon 
rank sum test).  
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Figure 4.8  
 
 
IL-12 regulates inflammatory mediator production during S. aureus orthopedic implant 
infection. Tissues surrounding the knee joint of S. aureus-infected WT (n = 8) and IL-12p40 (n = 
8) or IL-12p35 KO (n = 8) mice were collected at days 7 and 14 post-infection, whereupon IL-1β, 
TNF-α, G-CSF and CXCL2 production was measured using multi-analyte bead arrays. Results 
are representative of two independent experiments and are normalized to the amount of total 
protein to correct for differences in tissue sampling size (*p < 0.05; **p < 0.01; ***p < 0.001; 
unpaired Student’s t test). ND, not detected. 
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Figure 4.9 
 
 
MDSCs are responsible for S. aureus persistence and inhibition of immune cell influx 
during orthopedic implant infection. WT and IL-12p40 KO mice (n = 10/group) were infected 
with S. aureus, whereupon IL-12p40 KO animals received an adoptive transfer of 2.5 x 10
6
 
purified WT MDSCs s.c. at the implant site one day post-infection, whereas WT and a separate 
group of IL-12p40 KO animals received s.c. injections of PBS. (Left) The femur, knee joint and 
surrounding soft tissue were collected at day 7 after infection for quantitation of bacterial burdens. 
(Right) Quantitation of Ly6G
high
Ly6C
+
 MDSCs, Ly6G
-
Ly6C
+
 monocytes, and Ly6G
low
Ly6C
low
 
neutrophils. Results were calculated after gating on the CD45
+
 population and represent two 
independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001; unpaired Student’s t test). 
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Supplemental Figure S4.1 
 
 
S. aureus orthopedic implant infections are typified by robust and persistent inflammation. 
H&E-stained sections of tissues surrounding the knee joint of animals receiving aseptic (A and C) 
or S. aureus-infected (B and D) implants at days 7 (A and B) and 28 (C and D) after 
placement/infection (10x magnification). (E) Gram stain of S. aureus-infected knee tissue 7 days 
after infection (40x magnification; arrows indicate S. aureus at the implant-tissue interface). 
Representative images are presented from mice receiving aseptic (n = 2) and S. aureus-infected 
(n = 6) implants.
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Supplemental Figure S4.2 
 
 
Chronic S. aureus orthopedic implant infection results in marked bone loss. Comparison of 
bone integrity in mice with aseptic or S. aureus-infected orthopedic implants 28 days after 
placement/infection using live CT imaging (ventral view). Color intensity is indicative of bone 
density, where white = most dense and dark orange = least dense. Arrows indicate the implant 
protruding into the joint space. Representative images are presented from mice receiving aseptic 
(n = 2) and S. aureus-infected (n = 4) implants.  
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Supplemental Figure S4.3 
 
 
In vitro generated MDSCs inhibit polyclonal CD4
+
 T cell proliferation. Bone marrow-derived 
Ly6G
+
Ly6C
+
 MDSCs were purified by FACS and cultured with efluor670-labeled CD4
+
 T cells at 
either a 1:1 or 5:1 ratio for proliferation assays. (A) Representative contour plot depicting Ly6G 
and Ly6C expression in the expanded population. (B) Representative histograms of fluorescence 
intensity and (C) % proliferation compared with T cells alone (-) or CD3/CD28-stimulated T cells 
(+). Each treatment was performed in triplicate and results represent two independent 
experiments (*p < 0.05; unpaired Student’s t test).  
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Discussion 
 Despite extensive antiseptic precautions, most PJIs are thought to occur by hardware 
contamination from skin microflora during surgical insertion [36, 228]. As such, PJIs often take 
several months to years to manifest and most are attributed to S. aureus and S. epidermidis [27, 
229, 230]. The paramount obstacle for effective treatment of PJIs is their recalcitrance to 
antibiotic therapy coupled with the ability to skew the immune response towards an anti-
inflammatory, pro-fibrotic state [31, 61]. Therefore, the current standard-of-care to treat chronic 
PJIs requires removal of all foreign material, intravenous antibiotics for four to six weeks, and re-
implantation of the prosthetic joint. This treatment does carry a high success rate of 80-90%; 
however, the morbidity and mortality associated with the patient’s infection and its treatment is 
one of the most catastrophic complications in orthopedics [220, 231, 232]. Another important 
point is that the majority of prosthetic joint replacement surgeries are performed in the elderly, a 
population known to have waning immunity compared with younger patients [233, 234]. 
Therefore, with the expanding aging population, the frequency of PJIs is projected to increase. 
Collectively, these facts highlight the need for a better understanding of the underlying 
mechanisms involved in immune deviation during PJIs, which facilitate the development of novel 
therapeutics. 
 Importantly, our mouse model of PJI utilizes a very low infectious inoculum (i.e. 1,000 
bacteria), which represents a realistic level of bacterial exposure that might occur following the 
inadvertent transfer of organisms during prosthesis insertion in patients. The ability of the mouse 
model to recapitulate features of human PJI was substantiated by our analysis of tissues 
collected from patients undergoing revision surgeries for the treatment of PJI. Namely, cells with 
markers and gene expression profiles indicative of MDSCs (i.e. CD33
+
HLA-DR
-
) were evident 
with few/no T cell infiltrates detected. Both infected human and mouse tissues were typified by 
heightened inflammatory mediator expression compared with aseptic specimens; however, this 
was not sufficient to program infiltrating phagocytes for anti-biofilm activity, since infections 
persisted. We show that this results from MDSC action, which actively inhibits phagocyte 
microbicidal activity. Of the tissues collected from patients undergoing revision surgeries for PJI in 
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this study, three were confirmed group B streptococcus and two were S. epidermidis. In general, 
immune profiles were similar among these patient samples, suggesting that common immune 
responses are elicited during chronic PJI regardless of the inciting pathogen. This is important, 
since it implies that identifying methods to augment anti-biofilm immunity for the treatment of PJI 
might be efficacious against numerous bacterial species. 
 In these studies, IL-12 was critical for organizing the local inflammatory milieu as 
revealed by the significant reduction in MDSC infiltrates at the site of PJI in both p40 and -35 KO 
mice. Impaired MDSC recruitment coincided with increased phagocyte influx, including 
monocytes and neutrophils, which resulted in enhanced biofilm clearance. A direct role for 
MDSCs in this process was confirmed by the ability of adoptively transferred WT MDSCs to 
worsen disease outcome in IL-12p40 KO animals, as evidenced by the return of S. aureus 
burdens to levels of WT mice concomitant with significant reductions in monocyte and neutrophil 
recruitment. Previously, we have reported that IL-12p40 expression is dramatically reduced in 
MDSCs isolated from PJIs (Heim et al 2014); however, in the current report, we failed to detect 
IL-12p40 expression in MDSCs recovered from PJIs of WT mice by qRT-PCR (data not shown), 
indicating that MDSCs are not a major source for IL-12 production. The finding that immune 
phenotypes were similar in p40 and p35 KO mice and not evident in p19 KO animals suggests 
that IL-12p70 is important for organizing the immune permissive biofilm response. However, we 
cannot rule out the potential contribution of inhibitory p40 homodimers, since p40 is secreted in 
large excess of p40-p35 heterodimers and has recently been shown to bind to other polypeptides 
distinct from the IL-12 family that may also impact the local biofilm inflammatory milieu. The 
requirement for IL-12 was unexpected given its prominent role in Th1 polarization, since few T 
cell infiltrates were detected at the site of infection in both the mouse model and human PJI 
tissues. Instead, our findings suggest that IL-12 induces MDSC recruitment, as revealed by the 
70-80% reduction in MDSC influx into S. aureus-infected IL-12p40 and p35 KO properties argues 
against a role for IL-12 in MDSC activation. Although seemingly counterintuitive based on the 
suppressive properties of MDSCs, proinflammatory signals have been reported to induce MDSC 
recruitment and activation in the two-step model proposed by Gabrilovich [121, 226, 235]. 
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Impaired MDSC recruitment and activation in IL-12p35 and p40 KO mice likely accounted for 
improved bacterial clearance due to the removal of this suppressive population in conjunction 
with elevated granulocytic and monocytic infiltrates, which was confirmed by our adoptive transfer 
studies. Similar to our findings, a recent report demonstrated a role for IL-12p40 in S. aureus 
orthopedic implant infection after treatment with a neutralizing Ab [28]; however, the only readout 
described in this study was a reduction in the percentage of mice that remained infected after 21 
days; no information pertaining to bacterial burdens, inflammatory infiltrates, or the effect on other 
cytokines/chemokines at the infection site was reported. Therefore, our studies provide important 
mechanistic information regarding the role of IL-12 in the establishment of a local inflammatory 
microenvironment that is favorable for bacterial persistence. In addition, the proposed mechanism 
of IL-12 action between this earlier study and our report is strikingly different. Namely, 
Prabhakara et al. suggested that IL-12p40 promotes Th1/Th17 action to favor infection 
persistence; however, this is likely not the case in our model, since few T cell infiltrates were 
observed. Instead, we propose that IL-12 induces MDSC recruitment, leading to the diminished 
influx of professional phagocytes and impaired bacterial clearance. In addition, a few differences 
in the models utilized in these studies may account for these distinct findings. For example, 
Prabhakara et al. inserted implants that were precoated with S. aureus [28], whereas our devices 
were infected after surgical placement and the location of implants was distinct (femur versus 
tibia).  
 One question that remains is how does IL-12 promote MDSC recruitment to sites of S. 
aureus PJI? The most plausible explanation is that IL-12 acts indirectly by inducing the 
expression of a chemokine(s) with actions on MDSCs. Potential candidates include CXCL2 and 
CCL2 that are elevated at the site of S. aureus PJI and MDSCs have been reported to express 
the associated chemokine receptors CXCR2 and CCR2, respectively [236-240]. Of note, both 
CXCL2 and CCL2 expression were significantly reduced in S. aureus-infected IL-12p40 and p35 
KO mice in agreement with the minimal MDSC infiltrates observed in these animals. Alternatively, 
it is possible that IL-12 plays a non-canonical role in eliciting MDSC recruitment during the course 
of S. aureus post-arthroplasty infection such as augmenting PGE2 expression, which has also 
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been shown to be a potent MDSC attractant [148, 241-243]. These possibilities remain 
speculative at the present time and warrant investigation in future studies. 
 Another intriguing finding in this study was the apparent disconnect between the 
prolonged elevation of monocyte/macrophage chemokines and cell recruitment in S. aureus-
infected animals. Specifically, CCL2, CCL3, and CCL5 were chronically elevated during S. aureus 
PJI (Fig. 4.2 and data not shown), yet monocyte/macrophage influx was significantly reduced 
compared with animals receiving aseptic implants. This could be explained by differential MDSC 
fates based on the local environment. For example, it is known that MDSCs are recruited to sites 
of injury where they differentiate into macrophages and neutrophils to protect against potential 
infection during the wound healing process [150, 161]. However, in the case of tumors or S. 
aureus infection as we recently showed, MDSCs remain arrested in their immature state and 
exert potent immunosuppressive activity [60, 137]. In the current report, it is challenging to 
definitively assign this suppressive activity to either MDSC subset, based on the inability to 
accurately identify each population for downstream analysis. However, our findings to date 
suggest that G-MDSCs may represent the main effector, based on the propensity of infiltrating 
MDSCs to express higher levels of the granulocytic marker Ly6G compared with the monocytic 
marker Ly6C. Our results here suggest that S. aureus biofilms play an active role in arresting 
MDSCs in their suppressive state to foster infection persistence. Indeed, MDSCs can thwart 
monocyte/macrophage proinflammatory activity [148, 163], which may negatively affect their 
numbers at the infection site as we observed. Similarly, although neutrophil chemokines were 
significantly increased throughout the course of infection, little evidence of neutrophil influx (i.e. 
Ly6G
+
Ly6C
-
) was detected. Instead, lesions were dominated by MDSCs, which are responsive to 
similar chemokines [137]. 
 In conclusion, we have identified that IL-12 is critical for MDSC recruitment to the site of 
S. aureus PJI, where they impair phagocyte influx and biofilm clearance. Analysis of tissues from 
patients undergoing revision surgeries for PJIs revealed similar immune profiles as our mouse 
model, reflecting the utility of the mouse system to evaluate the efficacy of anti-biofilm 
therapeutics. Elucidating the mechanisms whereby bacterial biofilms thwart protective immunity 
128 
 
may lead to the development of novel immune-mediated approaches to facilitate PJI clearance in 
combination with conventional antibiotics. 
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Abstract 
 Staphylococcus aureus (S. aureus) is known to establish biofilms on medical devices. We 
recently demonstrated that Ly6G
high
Ly6C
+
 MDSCs are critical for allowing S. aureus biofilms to 
subvert immune-mediated clearance; however, the mechanisms whereby MDSCs promote 
biofilm persistence remain unknown. IL-10 expression was significantly increased in a mouse 
model of S. aureus orthopedic implant biofilm infection with kinetics that mirrored MDSC 
recruitment. Since MDSCs produce IL-10, we explored whether it was involved in orchestrating 
the non-productive immune response that facilitates biofilm formation. Analysis of IL-10-GFP 
reporter mice revealed that Ly6G
high
Ly6C
+
 MDSCs were the main source of IL-10 during the first 
two weeks of biofilm infection, whereas monocytes had negligible IL-10 expression until day 14. 
MDSC influx into implant-associated tissues was significantly reduced in IL-10 KO mice at day 14 
post-infection, concomitant with increased monocyte and macrophage infiltrates that displayed 
enhanced proinflammatory gene expression. Reduced MDSC recruitment facilitated bacterial 
clearance as revealed by significant decreases in S. aureus burdens in the knee joint, 
surrounding soft tissue, and femur of IL-10 KO mice. Adoptive transfer of IL-10 WT MDSCs into 
S. aureus infected IL-10 KO mice restored the local biofilm-permissive environment, as evidenced 
by increased bacterial burdens and inhibition of monocyte proinflammatory activity. These effects 
were both IL-10-dependent and –independent, as MDSC-derived IL-10 was required for 
promoting biofilm growth and anti-inflammatory gene expression in monocytes, but was not 
involved in monocyte recruitment to biofilm-infected tissues. These results demonstrate that IL-10 
production by MDSCs contributes to the persistence of S. aureus orthopedic biofilm infections. 
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Introduction 
 Staphylococcus aureus (S. aureus) is a major cause of healthcare- and community-
associated infections and due to the increased prevalence of methicillin-resistant S. aureus 
(MRSA) strains, this pathogen has become an even greater therapeutic challenge [4, 16, 244, 
245]. The risk of infection increases in the presence of a foreign body, and S. aureus is known for 
its ability to colonize and form biofilms on medical devices, such as indwelling catheters and 
orthopedic implants [34, 36, 49, 246]. Biofilm-associated bacteria exhibit distinct properties 
compared to planktonic growth phases of the same species, and it is becoming clear that the 
composition and kinetics of the host immune response to S. aureus biofilms inadvertently 
facilitates biofilm persistence, whereas planktonic infections, such as abscesses, are often 
resolved [187, 247]. Our laboratory was the first to identify myeloid-derived suppressor cells 
(MDSCs) during S. aureus biofilm infection, which represents a key immunosuppressive 
mechanism that supports chronic infection [60]. 
 MDSCs are a heterogeneous population of immature monocytes and granulocytes that 
are intermediates of normal myeloid development and differentiation [130]. Under typical 
conditions, MDSCs differentiate at the site of inflammation or injury to generate mature myeloid 
populations, including neutrophils, macrophages (MΦs) and dendritic cells [130, 135, 137]. 
However, in pathological situations, such as tumors, chronic inflammation, and bacterial biofilm 
infection, MDSCs become arrested in an immature state where they negatively regulate 
inflammatory mechanisms through their suppressive actions [248, 163]. In cancer, MDSC 
expansion can be induced by various cytokines and growth factors, such as IL-6, G-CSF, GM-
CSF, and VEGF; however, it is currently unknown what host or bacterial products promote MDSC 
propagation during S. aureus biofilm infection or their arrest in the immature state. Following 
MDSC expansion, inflammatory stimuli provide activation signals and induce the acquisition of 
immunosuppressive properties [121]. Our recent report demonstrated that IL-12 facilitates MDSC 
accumulation at the site of S. aureus biofilm infection, which is likely an indirect effect, since the 
cytokine is not a chemoattractant [59]. However, IL-12 is not required for MDSC activation during 
S. aureus biofilm infection, as MDSCs from both IL-12p40 and p35 KO mice still inhibited CD4+ T 
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cell proliferation. Therefore, other inflammatory factors must be involved in inducing the 
expression Arg-1, IL-10, and other anti-inflammatory mediators expressed by MDSCs that 
contribute to their immunosuppressive functions during S. aureus biofilm infection. 
 IL-10 is an anti-inflammatory cytokine known for its role in controlling inflammatory 
responses [249, 250], including inhibiting T cell activation and polarization, and IL-10 secretion by 
MDSCs has been implicated in programming MΦs toward an anti-inflammatory phenotype [145, 
251-254]. Previously, we have shown that IL-10 expression is increased in FACS-purified MDSCs 
recovered from S. aureus biofilms in a mouse orthopedic infection model [60]. Here we sought to 
identify the role of IL-10 in MDSC-mediated immune suppression during biofilm infection and 
determine whether its actions contribute to bacterial persistence. The use of IL-10-GFP reporter 
mice revealed that Ly6GhighLy6C+ MDSCs were the main source of IL-10 during S. aureus 
biofilm infection. To demonstrate the functional importance of IL-10 in shaping the inflammatory 
milieu typical of biofilm infection, we performed studies in IL-10 knockout (KO) mice. Fewer 
MDSCs infiltrated implant-associated tissues of IL-10 KO mice at day 14 post-infection 
concomitant with enhanced monocyte and MΦ infiltrates. The reduction in MDSCs translated into 
bacterial clearance, as revealed by significant decreases in S. aureus burdens in the knee joint, 
surrounding soft tissue, and femur of IL-10 KO mice, which coincided with increased monocyte 
proinflammatory gene expression. The adoptive transfer of IL-10 WT MDSCs into IL-10 KO mice 
during S. aureus infection resulted in fewer monocyte infiltrates and attenuated proinflammatory 
gene expression, which consequently restored bacterial burdens to levels reminiscent of WT 
animals. In contrast, the adoptive transfer of IL-10 KO MDSCs into IL-10 KO mice did not 
augment bacterial biofilm growth, indicating that MDSC-derived IL-10 is important for promoting 
biofilm persistence. Collectively, these data demonstrate that IL-10 production by MDSCs is one 
mechanism to promote S. aureus orthopedic biofilm formation by limiting monocyte/MΦ 
recruitment and proinflammatory activity. 
  
133 
 
Results 
MDSCs are the main source of IL-10 during S. aureus orthopedic implant biofilm infection.  
IL-10 has been shown to inhibit T cell activation and polarize MΦs toward an anti-inflammatory 
phenotype (Perrin, Taga, Letterio, Sinha). We recently reported that FACS-purified Ly6G
high
Ly6C
+
 
MDSCs recovered from S. aureus biofilm infections had increased IL-10 gene expression 
compared to Ly6G
-
Ly6C
+
 monocytes from the same region [60]. However, it remained unclear 
how much IL-10 was present at the infection site and whether MDSCs or other leukocytes were 
responsible for its production. In the present study, we used a mouse model of S. aureus 
orthopedic implant biofilm infection [59, 60, 62] to determine the contribution of MDSC-derived IL-
10 in shaping the anti-inflammatory biofilm milieu. We first evaluated the kinetics of IL-10 
production associated with sterile and S. aureus-infected implants (Fig 1). IL-10 levels were 
similar at day 3, the earliest time point examined; however, by day 5, IL-10 expression was 
significantly increased in biofilm-infected tissues and remained elevated at day 14 (Fig 1). 
 To determine which cell types were producing IL-10 in infected tissues, IL-10-GFP 
reporter mice were utilized, since our previous study only compared IL-10 mRNA expression in 
sorted MDSCs and monocytes and the FACS panels here were designed to also monitor 
neutrophils, MΦs, and T cells in addition to MDSCs and monocytes. FACS analysis revealed that 
Ly6G
high
Ly6C
+
 MDSCs were the main source of IL-10, since nearly 70% were GFP
+
 at day 5 
post-infection (Fig 2C). The frequency of IL-10-GFP
+ 
MDSCs progressively decreased to 
approximately 55% and 20% by days 7 and 14 post-infection, respectively (Fig 2C). Previous 
studies from our laboratory have shown that MDSC infiltrates progressively increase in S. aureus 
infected tissues from days 3 to 14 and remain relatively stable as the infection persists [59]. 
Interestingly, GFP levels in the Ly6G
-
Ly6C
+
 monocyte population were low throughout the first 
week of S. aureus infection (Fig 2D); however, as the percentage of IL-10-GFP
+
 MDSCs 
decreased there was a significant increase in IL-10-GFP
+
 monocytes at day 14 post-infection (Fig 
2D). These results establish MDSCs as the main source of IL-10 during early S. aureus 
orthopedic implant biofilm infection.  
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Figure 5.1 
                   
 
 
IL-10 production is increased during S. aureus orthopedic biofilm infection. Implant-
associated tissues from sterile and S. aureus infected mice (n = 4-5/group) were collected at the 
indicated time points, whereupon IL-10 expression was quantitated by ELISA. Results were 
normalized to the amount of total protein recovered to correct for variances in tissue sampling 
size and are representative of five mice per group. Statistical differences are denoted by asterisks 
(*, p < 0.05; unpaired two-tailed Students t-test). 
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Figure 5.2 
 
 
Figure 2. Ly6G
high
Ly6C
+
 MDSCs are the main source of IL-10 during S. aureus orthopedic 
implant biofilm infection. Implant-associated tissues were collected from IL-10-GFP reporter 
mice at the indicated intervals following infection and processed for flow cytometry. The 
CD45
+
GFP
+
 leukocyte population from S. aureus biofilm infected tissues (A) was gated to identify 
IL-10-GFP expressing Ly6C
+
 and Ly6G
+
 cells (B). The percentage of CD45
+
GFP
+
Ly6G
high
Ly6C
+
 
MDSCs (C) and CD45
+
GFP
+
 Ly6G
-
Ly6C
+
 monocytes (D) is shown. Results are representative of 
two independent experiments (n = 10 mice/time point). Statistical differences are denoted by 
asterisks (*, p < 0.05; **, p < 0.01; unpaired two-tailed Student’s t-test). 
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IL-10 is critical for organizing the anti-inflammatory biofilm milieu and maintaining S. 
aureus orthopedic implant infection. Since MDSCs are the primary cell type responsible for IL-
10 production, we next determined the importance of this cytokine to the immunosuppressive 
function of MDSCs and its role in regulating the anti-inflammatory milieu that allows for biofilm 
persistence. Examination of leukocyte recruitment in S. aureus-infected IL-10 KO animals 
revealed a significant decrease in Ly6G
high
Ly6C
+
MDSCs at day 14 post-infection compared to WT 
(Fig 3A) concomitant with increased Ly6G
-
Ly6C
+
 monocytes (Fig 3B) and F4/80
+
 MΦs (Fig 3C). 
No differences in neutrophil or T cell infiltrates were observed in the absence of IL-10 and both 
leukocyte populations represented a minor fraction of the CD45
+
 infiltrate (i.e. < 5%; data not 
shown). Biofilm-associated MDSCs from IL-10 KO mice maintained their ability to inhibit CD4
+
 T 
cell proliferation (Fig 4), demonstrating that MDSC-mediated T cell suppression during S. aureus 
orthopedic infection is IL-10-independent. 
Our recent report demonstrated that MDSC depletion with the Ly6G Ab 1A8 led to 
significant increases in Ly6C
+ 
monocyte infiltrates with heightened pro-inflammatory activity [60]. 
By extension, we predicted that the reduced MDSC population in IL-10 KO mice at day 14 post-
infection would also promote monocyte proinflammatory attributes. This possibility was assessed 
by monitoring gene expression profiles of FACS-purified IL-10 KO and WT monocytes 
immediately ex vivo by qRT-PCR. Ly6G
-
Ly6C
+
 cells recovered from IL-10 KO tissues at day 14 
post-infection displayed increased expression of iNOS, IL-1β, IL-12p40 and TNF-α and 
decreased Arg-1 compared with Ly6G
-
Ly6C
+
 monocytes from WT tissues (Fig 5). Since MDSCs 
are a main source of IL-10 at day 14 post-infection when monocyte proinflammatory attributes 
were heightened, this finding suggests that both the presence of MDSCs as well as their 
expression of IL-10 polarizes infiltrating monocytes towards an anti-inflammatory phenotype 
during S. aureus biofilm formation. 
The ability of IL-10 to promote biofilm persistence was confirmed by significant reductions 
in S. aureus burdens in the tissue, knee joint, and femur of IL-10 KO animals by days 7 to 14 
post-infection depending on the site (Fig 6).  In addition, IL-10 KO mice displayed altered 
cytokine/chemokine expression patterns during S. aureus biofilm infection. For example, G-CSF 
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levels in IL-10 KO animals were significantly decreased at day 14 (Fig 7A). G-CSF has been 
implicated in initiating granulocytic MDSC accumulation [255] and the decrease in G-CSF in IL-10 
KO tissues at day 14 was concomitant with reduced MDSC infiltrates (Fig 3A), indicating that G-
CSF may play a critical role in the expansion and accumulation of this population. In addition, IL-
1β and CCL3 levels were significantly decreased at day 14 post-infection (Fig 7C and F), 
whereas IL-1α and CCL2 levels were significantly increased in IL-10 KO tissues at day 3 (Fig 7B 
and E). Interestingly, IL-9 levels were significantly increased in IL-10 KO mice at day 14 post-
infection (Fig 7D) even though there is a paucity of T cell infiltrates in this model as determined by 
CD3
+
CD4
+
 or CD3
+
CD8
+ 
staining (data not shown) [32, 59, 60]. 
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Figure 5.3 
 
IL-10 loss augments monocyte/macrophage recruitment during S. aureus orthopedic 
biofilm infection. Implant-associated tissues from IL-10 KO and WT mice (n = 10/group) were 
collected at the indicated time points after infection and analyzed by flow cytometry. (A) 
Quantitation of Ly6G
high
Ly6C
+
 MDSCs, (B) Ly6G
-
Ly6C
+
 monocytes, and (C) F4/80
+
 macrophages 
from the total CD45
+
 leukocyte infiltrate. Results are presented from two independent 
experiments where significant differences between WT and IL-10 KO animals are denoted with 
asterisks (***, p < 0.001; unpaired two-tailed Student’s t-test).  
 
  
139 
 
Figure 5.4 
 
S. aureus biofilm-associated MDSCs inhibit T cell activation in and IL-10-independent 
manner. MDSCs were purified by FACS from infected WT and IL-10 KO mice at day 14 post-
infection for T cell proliferation assays at a 1:1 or 5:1 ratio (T cell:MDSC). Results are expressed 
as the % proliferation with T cells alone (-) and CD3/CD28-stimulated T cells (+) as controls. 
Results represent two independent experiments with significant differences denoted by asterisks 
(***, p < 0.001; ****, p < 0.0001; unpaired Student’s t –test).  
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Figure 5.5 
 
 
Loss of IL-10 augments proinflammatory gene expression in Ly6C
+
 monocytes during S. 
aureus biofilm infection. Ly6G
-
Ly6C
+
 monocytes were purified from tissues surrounding the 
infected joints of IL-10 WT and KO mice (n = 10/group) at days 3, 7 and 14 post-infection by 
FACS, whereupon RNA was immediately isolated for qRT-PCR analysis. Gene expression levels 
in IL-10 KO monocytes were calculated after normalizing signals against GAPDH and are 
presented as the fold-change relative to WT monocytes. 
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Figure 5.6 
 
 
IL-10 is critical for S. aureus persistence during orthopedic biofilm infection. Bacterial 
burdens associated with the implant-associated tissue, femur, and knee joint of WT and IL-10 KO 
mice (n = 10/group) were determined at days 3.7 and 14 post-infection. Results are expressed as 
the number of CFU per gram tissue to correct for alteration in tissue sampling sizes. Significant 
differences in bacterial burdens between WT and IL-10 KO mice are denoted by asterisks (*, p < 
0.05; **, p < 0.01; ***, p < 0.001; unpaired two-tailed Student’s t-test) and are from two 
independent experiments.  
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Figure 5.7 
 
 
IL-10 KO mice have altered cytokine and chemokine expression patterns. Tissues 
surrounding the knee joint of WT or IL-10 KO mice (n = 10/group) with S. aureus-infected 
implants were collected at the indicated time points, whereupon (A) G-CSF, (B) IL-1α, (C) IL-1β, 
(D) IL-9, (E) CCL2, and (F) CCL3 production was measured by multi-analyte bead arrays. Results 
are normalized to the amount of total protein to correct for differences in tissue sampling size and 
are representative of two independent experiments. Significant differences are denoted by 
asterisks (*, p < 0.05; **, p < 0.01; unpaired two-tailed Student’s t-test). 
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MDSCs influence bacterial burdens and monocyte infiltrates during S. aureus orthopedic 
implant biofilm infection via both IL-10-dependent and –independent mechanisms. To 
directly assess the contribution of MDSC-derived IL-10 in inhibiting innate immune cell function 
and promoting S. aureus persistence during orthopedic implant biofilm infection, bone marrow-
derived MDSCs from either WT or IL-10 KO mice were adoptively transferred into IL-10 KO 
animals 7 days after infection, whereupon bacterial burdens were assessed at day 14. This timing 
strategy was selected since most differences in IL-10 KO mice were observed at day 14. In vitro-
derived MDSCs have been previously used in our laboratory and were confirmed to inhibit T cell 
proliferation [59].  The adoptive transfer of WT MDSCs into WT mice failed to significantly alter 
bacterial burdens or immune cell infiltrates at the site of S. aureus biofilm infection (data not 
shown), which eliminated this approach as a control. This is likely because MDSCs already 
represent approximately 50% of the total CD45
+
 population at day 7 [59], and the adoptive 
transfer of additional MDSCs does not exacerbate S. aureus infection. Instead, the reduced 
numbers of MDSCs in IL-10 KO mice at day 14 post-infection allowed us to detect the impact of 
adoptively transferred MDSCs in these animals. Therefore, WT MDSCs represented the control 
cell population, whereas IL-10 KO MDSCs were the experimental group, with both populations 
being transferred to IL-10 KO mice to monitor effects on bacterial burdens and leukocyte 
infiltrates. Indeed, the utility of WT MDSCs as a control was demonstrated by the finding that 
bacterial burdens were restored to levels typically observed in WT mice following the adoptive 
transfer of WT MDSCs into IL-10 KO animals (Fig 8A), which coincided with an increase in 
Ly6G
high
Ly6C
+
 MDSCs (Fig 8B) and reduced Ly6G
-
Ly6C
+
 monocytes compared to IL-10 KO mice 
that did not receive MDSCs (Fig 8C). 
To determine whether IL-10 produced by MDSCs is solely responsible for promoting 
biofilm growth and inhibiting monocyte recruitment, we also performed adoptive transfers of IL-10 
KO MDSCs into S. aureus infected tissues of IL-10 KO mice at day 7 post-infection. The results 
demonstrated the complex involvement of both IL-10-dependent and –independent mechanisms. 
With regard to the former, MDSC-derived IL-10 was required for promoting bacterial biofilm 
growth in the tissue, joint, and femur, since the transfer of IL-10 KO MDSCs had no impact on 
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these measures compared to IL-10 KO animals that did not receive MDSCs (Fig 8A). However, 
the effect of MDSCs on monocyte recruitment was found to be IL-10-independent, since the 
adoptive transfer of both WT and IL-10 KO MDSCs into IL-10 KO mice resulted in similar 
changes in monocyte infiltrates (Fig 8C). 
Monocytes recovered from infected tissues of IL-10 KO animals have increased pro-inflammatory 
gene expression (Fig 5), which is likely not only due to the absence of IL-10 but also decreased 
MDSCs. To further validate these findings, gene expression profiles of FACS-purified Ly6G
-
Ly6C
+
 
monocytes following adoptive transfer were performed. The adoptive transfer of WT MDSCs into 
IL-10 KO mice decreased monocyte proinflammatory gene expression, with reductions in iNOS, 
IL-1β, IL-12p40, and TNF-α, demonstrating a direct effect of MDSCs on monocyte activation state 
(Fig 9). 
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Figure 5.8 
 
 
MDSCs influence bacterial burdens and monocyte infiltrates during S. aureus orthopedic 
implant biofilm infection via both IL-10-dependent and –independent mechanisms. S. 
aureus orthopedic implant infection was established in IL-10 KO and WT mice, whereupon IL-10 
KO animals received an adoptive transfer of 2.5 x 10
6
 purified IL-10 WT or IL-10 KO MDSCs s.c. 
at the implant site at day 7 post-infection, whereas WT and a separate group of IL-10 KO animals 
received s.c. injections of PBS (n = 10/group). (A) Implant-associated tissue, knee joint, and 
femur were collected at day 7 following MDSC transfer (day 14 after infection) for quantitation of 
bacterial burdens. (B) Quantitation of Ly6G
high
Ly6C
+
 MDSCs and (C) Ly6G
-
Ly6C
+
 monocytes at 
day 7 following MDSC adoptive transfer (day 14 post-infection). Results were calculated after 
gating on the CD45
+
 population and represent two independent experiments. Significant 
differences are denoted by asterisks (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; 
unpaired two-tailed Student’s t-test). 
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Figure 5.9 
           
 
 
Monocyte proinflammatory gene expression is reduced following adoptive transfer of WT 
MDSCs. Ly6G
-
Ly6C
+
 monocytes were purified from infected tissues of WT and IL-10 KO mice ± 
MDSC adoptive transfer at day 14 post-infection by FACS (n = 10/group), whereupon RNA was 
immediately isolated for qRT-PCR analysis. Gene expression levels in monocytes from IL-10 KO 
animals or IL-10 KO mice receiving WT MDSCs were calculated after normalizing signals against 
GAPDH and are presented as the fold-change relative to monocytes recovered from IL-10 WT 
animals. 
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Figure 5.10 
 
Temporal relationship between IL-10 and IL-12 actions during S. aureus orthopedic 
implant biofilm infection. IL-12 plays a key role in MDSC recruitment during biofilm infection via 
a chemoattractant that remains to be identified. IL-10 is produced by infiltrating MDSCs at the site 
of S. aureus biofilm infection, whereupon it plays a critical role in polarizing monocytes towards 
an anti-inflammatory phenotype, thereby promoting bacterial persistence. Loss of either IL-12 or 
IL-10 during the early MDSC recruitment or effector phases, respectively, promotes biofilm 
clearance, implicating key roles for each cytokine at distinct stages of infection. 
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DISCUSSION 
MDSCs are emerging as a critical player in the anti-inflammatory response to S. aureus 
and promote chronic infection [59, 60, 149, 257]. Biofilm infections are known to skew the host 
innate immune response towards an anti-inflammatory phenotype [32, 100, 167]. In this setting, 
IL-10 could facilitate the establishment of persistent infection and allow organisms to subvert 
traditional mechanisms of bacterial clearance. Although IL-10 production has been implicated as 
an immunosuppressive mechanism by MDSCs [145, 258], to date there are no reports examining 
whether MDSC function is dependent on IL-10 during biofilm infection. This study is the first to 
demonstrate that MDSCs express significant amounts of IL-10 in response to biofilm-associated 
bacteria, which limits monocyte proinflammatory gene expression and directly contributes to S. 
aureus biofilm persistence during later stages of infection. Of note, the consequences of IL-10 
action are likely context-dependent, since several studies have reported a beneficial role for IL-10 
during S. aureus sepsis by controlling damaging inflammation and minimizing pathology [209, 
250, 251, 259-262]. In contrast, our study suggests a deleterious role for IL-10 in preventing the 
genesis of an effective microbicidal response to facilitate biofilm clearance. 
 In terms of kinetics, IL-10 levels in S. aureus biofilm tissues were not significantly 
increased compared to animals receiving sterile orthopedic implants until day 5. This delay in IL-
10 elevation implies that the biofilm is directing cytokine production and our results indicate that 
MDSCs are responsible for IL-10 synthesis. Here we demonstrate that nearly 70% of the MDSCs 
recruited to the site of S. aureus biofilm infection at day 5 expressed IL-10, whereas monocytes 
represented a minor fraction in comparison. Our recent publication reported a progressive 
increase in the percentages of Ly6G
high
Ly6C
+
 MDSCs until day 21 post-infection that was 
significantly more pronounced compared to mice receiving sterile implants [59]. It is important to 
note that in addition to the percentages of MDSC infiltrates, their activation status is also 
influenced by biofilm infection. Indeed, we previously reported that only MDSCs recovered from 
S. aureus biofilm infected animals, but not those receiving sterile implants, were capable of 
attenuating T cell proliferation, reflecting the inhibitory nature of MDSCs specifically recruited to 
the biofilm infection site. Therefore, MDSC levels are only one aspect of the equation, with their 
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inhibitory capacity and gene expression profiles representing other important attributes, both of 
which were studied in the current report. MDSC-derived IL-10 began to decline by day 7 post-
infection, which coincided with the decrease in total IL-10 measured in infected tissues by ELISA. 
However, tissue IL-10 levels exhibited a bi-phasic increase at day 14, which may reflect cytokine 
production by both MDSCs and monocytes, the latter which exhibited a late rise in IL-10 
expression. It is currently unclear what causes MDSC-derived IL-10 to decrease after day 5 post-
infection while the percentage of MDSCs remains constant (data not shown). Although we 
currently have no evidence of regulatory T cells at the site of S. aureus biofilm infection as 
determined by CD4 and FoxP3 staining (data not shown), IL-10 production by MDSCs has been 
shown to induce Tregs that can produce IL-10 [258], which could perpetuate the anti-
inflammatory circuit. It remains possible that the number of Tregs associated with S. aureus 
biofilms in our orthopedic model remain below the limit of detection by FACS. Alternatively, 
synovial cells could contribute to sustained IL-10 levels during S. aureus biofilm infection when IL-
10 producing MDSCs have begun to decline (i.e. day 14 post-infection). It has been shown that 
cultured fibroblast-like synoviocytes constitutively express IL-10 along with functional IL-10 
receptors and could modulate cellular responses in the joint. However, these and other tissue 
resident populations would need to be analyzed during S. aureus biofilm infection to determine if 
they contribute to IL-10 production and potentially assist in bacterial persistence. 
A direct role for MDSC-derived IL-10 in setting the stage for S. aureus biofilm persistence 
at later time points was supported by our observations in IL-10 KO mice. In general, in the 
absence of IL-10, infiltrating monocytes acquired a proinflammatory gene expression profile that 
translated into improved biofilm clearance at days 7 and 14 post-infection. These changes 
coincided with significant decreases in MDSC infiltrates and the adoptive transfer of MDSCs from 
WT but not IL-10 KO mice were capable of reversing these changes. In terms of mechanism, S. 
aureus could be co-opting MDSCs to promote their immunosuppressive activity during acute 
infection, which occurs via an IL-10-independent manner. When IL-10 expression peaks in 
MDSCs (i.e. day 5) we begin to see a reduction in biofilm burdens in IL-10 KO mice at day 7 and 
an inability to effectively skew monocytes toward an anti-inflammatory phenotype, which 
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altogether demonstrate that MDSC-derived IL-10 is critical for the chronicity of S. aureus biofilm 
infection.  
 Currently, the signals responsible for eliciting IL-10 production by MDSCs during biofilm 
infection have yet to be identified. It is known that IL-10 can be induced by Toll-like receptor 
(TLR) stimulation [263-265], that MDSCs express TLRs [163, 266], and TLR ligands can induce 
MDSC accumulation in tumor-bearing and septic mice [123, 124, 267]. However, this possibility 
appears less plausible in the context of biofilm infection, since we and others have reported that 
S. aureus biofilms circumvent recognition by TLR2 [187, 32, 62], although MDSCs were not 
examined in these studies. Regardless of the inciting signal that triggers IL-10 production, the 
cytokine can then signal through the IL-10R to activate signal transducer and activator of 
transcription 3 (STAT3), a critical factor for driving MDSC development as well as polarizing 
monocytes/MΦs toward an anti-inflammatory phenotype [125, 268-270]. In addition, STAT3 
activation can augment IL-10 production [271]. The role of IL-10 in inducing STAT3 activation 
during S. aureus biofilm infection and its subsequent contribution to the anti-inflammatory biofilm 
milieu are current topics of investigation in our laboratory. 
 G-CSF preferentially signals through STAT3, where it induces MDSC expansion and 
accelerates the proliferation and release of granulocytic precursors in tumor-bearing mice in 
addition to its well-known ability to direct neutrophilic granulocyte differentiation [255, 272]. We 
have previously reported that G-CSF is significantly increased in S. aureus-infected tissues 
during the time when MDSCs represent the main cellular infiltrate in implant-associated tissue 
[59]. Interestingly, in the current study, G-CSF levels were reduced in IL-10 KO mice at day 14 
post-infection, concomitant with reduced MDSC infiltrates. By extension, it is possible that G-CSF 
contributes to MDSC expansion and accumulation during S. aureus biofilm infection and that IL-
10 loss may limit STAT3 activation and subsequent G-CSF production. However, this possibility 
remains speculative. 
 Both IL-10 and STAT3 are known to inhibit IL-12 production, and MDSCs are traditionally 
thought to secrete IL-10 to down-regulate IL-12 release from monocytes/MΦs. This relationship 
appears to be operative during S. aureus biofilm infection; however, unlike planktonic infections, 
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MDSCs persist and maintain the biofilm milieu in an anti-inflammatory state. For example, our 
recent report showed that IL-12 was increased in S. aureus infected tissues over a one month 
period and IL-12p40 and p35 KO animals had significantly fewer MDSC infiltrates concomitant 
with reduced bacterial burdens as early as day 7 post-infection [59]. In the current study, because 
IL-10 is not elevated in infected tissues until day 5 and MDSC infiltrates are not significantly 
reduced in IL-10 KO animals until day 14, this indicates that IL-10 operates downstream of MDSC 
recruitment and IL-12 action (Fig 10). Indeed, IL-12p40 gene expression was increased in 
monocytes from IL-10 KO mice beginning at day 7 post-infection, revealing a negative effect of 
MDSC-derived IL-10 on monocyte IL-12 expression. This was also directly demonstrated by the 
ability of adoptively transferred WT MDSCs to inhibit IL-12 in monocytes from IL-10 KO animals. 
Despite these cell type-specific changes, IL-12p40 levels in tissue homogenates of both IL-10 KO 
and WT animals were similar at days 3, 7 and 14 post-infection (data not shown) and since 
MDSC recruitment was unaffected during the first week of S. aureus orthopedic biofilm infection, 
this suggests the delayed action of an alternative chemoattractant that is IL-12-independent. 
Taken together, it appears that IL-12 produced during early S. aureus biofilm infection is key for 
MDSC recruitment, which is likely an indirect effect mediated by chemoattractants that remain to 
be defined, whereupon MDSCs produce IL-10 that dampens the proinflammatory immune 
response of monocytes/macrophages and contributes to biofilm persistence (Fig 10). These 
studies assessing the role of IL-10 in regulating innate immune responses have focused on 
monocytes, as they represent the most numerous population after MDSCs in our S. aureus 
orthopedic biofilm infection model. It remains possible that MDSCs could be influencing neutrophil 
responses; however, neutrophils represent a very minor infiltrate and no significant differences 
were observed between IL-10 KO and WT animals. Therefore, we did not explore the possible 
effects of MDSCs and IL-10 on neutrophil function. 
 Recently, we and others have shown that the adoptive transfer of MDSCs significantly 
exacerbates S. aureus infection [59, 149]; however, the mediators released by MDSCs that are 
responsible for this effect remain to be defined. Here we show that IL-10 is one factor, since the 
adoptive transfer of MDSCs from IL-10 KO mice did not exacerbate biofilm growth, whereas WT 
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MDSCs significantly increased biofilm burdens in the joint, surrounding soft tissue, and femur. 
However, it is apparent that IL-10 is not the only immunosuppressive mechanism of MDSCs 
during S. aureus biofilm infection, since IL-10 KO MDSCs still impacted monocyte recruitment 
during biofilm infection, reflecting an IL-10-independent mechanism of action. Originally, IL-10 
was defined by its ability to inhibit Th1 activation and cytokine production; however, it is now 
recognized that the biological effects of IL-10 are also directed at monocytes/MΦs [273]. Indeed, 
we found that MDSC inhibition of CD4
+
 T cell proliferation was IL-10-independent, in agreement 
with another recent report [149], again indicating the existence of additional inhibitory effector 
mechanisms for MDSCs. A potential candidate is Arg-1, which we have previously shown is 
elevated in MDSCs recovered from the site of S. aureus orthopedic biofilm infection in both our 
mouse model and in tissue specimens from humans with prosthetic joint infections [32, 59, 60]. A 
role for Arg-1 in the anti-inflammatory response to S. aureus biofilms is a topic of ongoing 
investigation in our laboratory. 
Inflammatory mediator analysis in infected IL-10 KO mice revealed some interesting 
disparities, particularly with respect to the timing of when differences were apparent. For 
example, both IL-1α and CCL2 were significantly increased in IL-10 KO animals at day 3 post-
infection but not at later time points. In contrast, more differences were evident at day 14, which 
coincided with the significant decrease in biofilm burdens in IL-10 KO mice, namely reductions in 
G-CSF, IL-1β, and CCL3. However, not all mediators were reduced, since IL-9 production was 
significantly elevated in IL-10 KO animals at this later interval. The fact that IL-9 was detected is 
intriguing, since this cytokine is only produced by select T cell subsets; however, minimal T cell 
infiltrates (CD3
+
CD4
+
 or CD3
+
CD8
+
) were observed in either IL-10 KO or WT mice in this and our 
prior reports, making it difficult to predict the source of IL-9 production. Another interesting finding 
is that IL-9 has been reported to promote Treg expansion, yet we have not been able to detect 
CD4
+
FoxP3
+ 
cells in any of our S. aureus biofilm infection models (data not shown) [32, 59, 60]. 
However, IL-9 is known to stimulate mast cell expansion from the bone marrow [274-276] and 
mast cells have been shown to release several cytokines and nitric oxide into the knee joint 
during osteoarthritis [277] and drive tissue metaplasia and heterotrophic ossification in patients 
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following total knee arthroplasty [278]. It is possible that the absence of IL-10 at later time points 
allows the proinflammatory activities of IL-9 to be heightened, although the presence of mast cells 
and their role during S. aureus orthopedic biofilm infection have not yet been examined. 
 The role of MDSCs during S. aureus biofilm infection and the mechanisms involved in 
their expansion, accumulation, and effector functions are only beginning to be explored. By 
manipulating the ability of these cells to exert their immunosuppressive pressure, we have 
demonstrated that they directly attenuate monocyte proinflammatory properties. However, there 
are still many areas of MDSC-biofilm interaction that remain to be examined. For instance, we 
know that IL-12 is involved in MDSC recruitment to biofilm infections, but it is unclear whether 
biofilm-derived products directly contribute to MDSC accumulation by interfering with myeloid 
precursor differentiation. In addition, whether MDSCs can recognize S. aureus PAMPs through 
TLRs or other PRRs to activate genes essential for their effector functions could contribute to our 
understanding of their role during infection. Our findings to date do not exclude the possibility that 
S. aureus biofilms cooperate with MDSCs to directly inhibit monocyte/MΦ effector functions and 
studies are ongoing in our laboratory to address these interactions. However, preventing the 
immunosuppressive action of infiltrating MDSCs may offer a novel therapeutic strategy to treat 
chronic biofilm infections. 
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Abstract 
 Biofilm infections often lead to significant morbidity due to their chronicity and 
recalcitrance to antibiotics. We have demonstrated that methicillin-resistant Staphylococcus 
aureus (MRSA) biofilms can evade macrophage (MΦ) antibacterial effector mechanisms by 
skewing MΦ toward an alternatively activated M2 phenotype. To overcome this immune evasion, 
we have used two complimentary approaches. In the first, a proinflammatory milieu was elicited 
by local administration of classically activated M1 MΦs and in the second by treatment with the 
C5a receptor (CD88) agonist EP67, which invokes MΦ proinflammatory activity. Early 
administration of M1-activated MΦ or EP67 significantly attenuated biofilm formation in a mouse 
model of MRSA catheter-associated infection. Several proinflammatory mediators were 
significantly elevated in biofilm-infected tissues from MΦ- and EP67-treated animals, revealing 
effective reprogramming of the biofilm environment to a proinflammatory milieu. A requirement for 
MΦ proinflammatory activity was demonstrated by the fact that transfer of MyD88-deficient MΦ 
had minimal impact on biofilm growth. Likewise, neutrophil administration had no effect on biofilm 
formation. Treatment of established biofilm infections with M1-activated MΦ also significantly 
reduced catheter-associated biofilm burdens compared with antibiotic treatment. Collectively, 
these results demonstrate that targeting MΦ proinflammatory activity can overcome the local 
immune inhibitory environment created during biofilm infections and represents a novel 
therapeutic strategy. 
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Introduction 
 Biofilms are heterogeneous bacterial communities that can form on both natural body 
surfaces as well as foreign devices, such as indwelling catheters and orthopedic implants [27, 
33]. The presence of a foreign body increases the likelihood of infection and drastically lowers the 
threshold for device colonization [279]. Methicillin-resistant Staphylococcus aureus (MRSA) is a 
common etiologic agent of biofilms and often causes chronic and recurrent infections when 
associated with indwelling medical devices [1, 246]. The current therapeutic option for managing 
device-associated biofilm infections is a staged-replacement of the hardware, either as a single 
step exchange, whereby the entire implant is replaced in a single procedure, or, more commonly, 
as a two-stage exchange [49]. In the latter case, patients receive extended antibiotic regimens in 
addition to surgical management, which generally consists of device removal and replacement 
with an antibiotic-impregnated temporary spacer, followed by insertion of a new prosthesis after a 
2 to 8 week period. This long and debilitating process is associated with significant morbidity and 
economic impact for patients. Further complicating available treatment strategies is that 
antibiotics alone are generally ineffective for biofilm eradication [36, 280], which is thought to 
result from altered metabolism during biofilm growth [281, 282]. The difficulties of biofilm 
treatment are further underscored in the context of more permanent implants such as artificial 
hips and knees, procedures that are particularly common in the elderly, who grow increasingly 
less immune responsive over time [283].  
 Based on these challenges, an urgent need exists for developing novel paradigms to 
prevent and/or facilitate biofilm eradication without the need for radical surgical interventions. One 
promising approach involves the exploitation of natural host immune mechanisms for therapeutic 
benefit. Targeting the host response rather than the pathogen itself offers certain advantages by 
largely avoiding selective pressures for the evolution of microbial resistance. Indeed, stimulating 
adaptive immunity through vaccination has remained resilient to microbial resistance over 
decades of clinical use, although not all pathogens have been amenable to vaccination 
strategies, most notable Staphylococcus aureus (S. aureus) [284, 285]. Furthermore, the fact that 
innate immune defenses are geared to rapidly recognize an infinite pathogen repertoire, suggests 
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that their modulation will afford broad-spectrum protection against a range of microbial 
pathogens, including S. aureus, and enable prophylactic use in high-risk groups or provide early 
treatment options prior to the identification of the causative infectious agent(s). 
 Earlier views regarding the host immune response to biofilm infections suggested that 
biofilms evaded immune recognition altogether [197, 286]. Recent reports by our group and 
others have proposed an alternative possibility, namely that biofilms can skew the immune 
response to favor anti-inflammatory and pro-fibrotic pathways, which contribute to biofilm 
persistence [32, 162]. Specifically, although macrophages (MΦs) are a prominent infiltrate in S. 
aureus biofilm infections, their penetration into the biofilm itself is impeded by a robust fibrotic 
response surrounding the infection. In addition, biofilm-associated MΦ are polarized towards an 
alternatively activated M2 phenotype that possess anti-inflammatory and pro-fibrotic properties 
that limit bacterial clearance [32]. By extension, the programming of MΦs towards a microbicidal 
M1 response is diverted, which led us to examine whether the exogenous administration of M1-
activated MΦs directly into sites of biofilm infection would overcome the local immune inhibitory 
environment and fibrotic barrier associated with biofilms. As a complementary approach to 
augment MΦ proinflammatory activity, we administered the MΦ activating peptide EP67, to 
facilitate bacterial clearance by inducing a proinflammatory milieu. EP67 (Tyr-Ser-Phe-Lys-Asp-
Met-Pro-(N-methylLeu)-D-Ala-Arg, or YSFKDMP(MeL)aR) is a response-selective agonist of the 
human C5a receptor (C5aR/CD88) that preferentially elicits proinflammatory mediator production 
from CD88
+
 MΦ without any effects on CD88
+
 neutrophils [287, 288]. Here we demonstrate that 
targeting MΦ activity with EP67 or the introduction of exogenous M1-activated MΦ inhibits S. 
aureus biofilm formation and provides a novel therapeutic treatment for these persistent 
infections. This therapeutic approach is not afforded by neutrophils, which agrees with our 
findings that neutrophils are not a prominent infiltrate in this model of S. aureus biofilm infection 
[31]. Collectively, these finding suggest that immune cell-based therapy using M1-acitvated MΦ 
may overcome the current confounds associated with biofilm treatment and control. 
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Results 
Activated MΦs exhibit S. aureus biofilm bactericidal activity in vitro. We have previously 
demonstrated that MRSA biofilms are capable of attenuating traditional proinflammatory 
responses explaining, in part, why these infections persist in an immunocompetent host [32]. To 
determine whether MΦs that were preprogrammed towards a proinflammatory M1 phenotype 
were capable of overcoming the immune inhibitory aspects of biofilms, MΦs were stimulated with 
IFN-γ or TNF-α and S. aureus-derived peptidoglycan (PGN) for 6 h prior to their addition to S. 
aureus-GFP biofilms or planktonic cultures. Several attributes characteristic of M1-activated MΦs 
were detected using this treatment paradigm, including significant increases in CD86 and reactive 
oxygen species production (Supplemental Fig. S6.1). All MΦ populations were capable of 
phagocytosing planktonic bacteria regardless of their activation state (Fig. 6.1A, left column, 
“Planktonic”), whereas only M1-acitvated MΦs stimulated with either IFN-γ or TNF-α + PGN were 
capable of phagocytosing biofilm-associated organisms (Fig. 6.1A, right column, “Biofilm”), which 
resulted in significant reductions in bacterial burdens following a 24 h co-culture period (Fig. 
6.1B). In contrast, non-activated MΦs displayed no indication of intracellular bacteria when 
incubated with biofilms, confirming our earlier report [32], but were still able to decrease biofilm 
bacterial burdens (Fig. 6.1B). The ability of non-activated MΦs to reduce biofilm burdens without 
any evidence of phagocytic activity, suggests that antimicrobial mediator(s) are secreted upon 
contact with either organisms dispersed from the biofilm and/or bacterial components shed during 
biofilm growth. The ability of M1-activated MΦs to reduce biofilm burdens required MyD88-
dependent signals, since MyD88 KO MΦs treated with IFN-γ and PGN had no impact on biofilm 
growth (Fig. 6.1B). 
 To compare the efficacy of MΦ versus neutrophils in regulating MRSA biofilm growth, 
neutrophils were isolated from murine bone marrow and co-cultured with biofilms. Unlike MΦs, 
neutrophils were not activated prior to biofilm addition, wince this would lead to rapid 
degranulation and reduced cell viability. Interestingly, neutrophils were able to phagocytose 
MRSA biofilms, yet this did not translate into reduced bacterial numbers (Supplemental Fig. 
S6.2), revealing disconnect between the two processes. This may result from additional virulence 
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determinants released by S. aureus during biofilm growth, since the organism is known to 
produce numerous factors that interfere with neutrophil function [200, 289, 290]. Alternatively, S. 
aureus can survive inside neutrophils, which could explain why phagocytosis was observed 
without concomitant reductions in bacterial burdens [291]. On a comparative basis, biofilm 
formation did afford some protection against phagocytic uptake compared to planktonic growth 
conditions, since both MΦs and neutrophils actively phagocytosed planktonic S. aureus but were 
less capable of internalizing biofilm-associated bacteria (Fig. 6.1A and Supplemental Fig. S6.2). 
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Figure 6.1  
 
 
M1 macrophage polarization enhances phagocytosis and killing of S. aureus biofilms. (A) 
Non-activated macrophages (MΦs) and M1-activated MΦs (10 ng/ml IFN-γ or 100 ng/ml TNF-α + 
10 μg/ml PGN) from C57BL/6 mice, as well as MyD88 knockout (KO) MΦs were labeled with 
CellTracker Blue (blue) and co-cultured with S. aureus-GFP (green) during biofilm or planktonic 
growth for 2 h and imaged to observe their phagocytic ability. (B) After 24 h, biofilms were 
sonicated to quantitate bacterial burdens to evaluate the ability of the various MΦ populations to 
attenuate biofilm growth. Biofilms without MΦs were used as untreated controls. White arrows 
indicated phagocytic cells and significant difference are denoted by asterisks (**p < 0.01; ***p < 
0.001). Results are representative of at least three independent experiments. 
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M1-activated MΦs limit MRSA biofilm formation in vivo. Based on our in vitro studies 
demonstrating the ability of M1-polarized MΦs to phagocytose biofilm-associated S. aureus and 
reduce bacterial burdens, we next examined whether this could translate in vivo. These 
experiments utilized a mouse model of MRSA catheter-associated biofilm infection that we have 
previously shown limits MΦ invasion into biofilms and skews these cells toward an alternatively 
activated M2 phenotype [32]. We first employed an approach where M1-activated MΦs were 
administered beginning at 12 h following MRSA infection, with repeat injections occurring at 24 
and 48 h after bacterial exposure. The introduction of M1-activated MΦs directly into the biofilm 
infection site significantly reduced bacterial burdens on both infected catheters and in surrounding 
tissues at day 3 post-infection (Fig. 6.2A and 2B). More importantly this early intervention with 
M1-activated MΦs led to long-term effectiveness against biofilm formation, since catheters 
showed minimal evidence of biofilm growth at day 14 without any additional MΦ treatment and 
although some bacteria were observed in the surrounding tissues, this was significantly reduced 
compared to vehicle treatment (Fig. 6.3A and 3B). Interestingly, the introduction of non-activated 
MΦs also reduced biofilm burdens, although significant differences were only observed at day 14 
post-infection (Figs. 6.2 and 6.3). To better illustrate the superior efficacy of M1-activated 
compared to non-activated MΦs, a dose-response experiment was performed where animals 
were treated with increasing numbers (10
4
, 10
5
, or 10
6
) of either non-activated or M1-activated 
MΦs. Results from this experiment indicated that 10
5
 or 10
6
 M1-activated MΦs were capable of 
significantly reducing biofilm burdens compared to vehicle controls, whereas non-activated MΦs 
were not statistically effective at any dose (Fig. 6.4). Similar to the in vitro studies, MyD88-
dependent mechanisms were critical, since MΦs from MyD88 KO mice did not demonstrate any 
efficacy in controlling biofilm burdens on either infected catheters or surrounding tissues in vivo 
(Fig. 6.5). In addition, neutrophils had no impact on biofilm formation, even when the number of 
cells was increased to 10
7
 per injection (Fig. 6.2, and data not shown), which confirmed our in 
vitro findings and the fact that neutrophils are not a significant infiltrate in the MRSA catheter-
associated biofilm model utilized here (Supplemental Fig. S6.3). 
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 Previous work from our laboratory demonstrated that MRSA biofilms attenuated the 
expression of numerous proinflammatory mediators compared to a sterile foreign body [32]. The 
introduction of M1-activated, but not non-activated MΦs significantly increased CXCL9, CCL5, 
and IFN-γ expression within biofilm-infected tissues (Fig. 6.6) revealing the successful re-
direction towards a proinflammatory milieu. CXCL9 is an IFN-γ-induced T cell chemoattractant, 
whereas CCL5 recruits a broader array of leukocytes, including T cells, eosinophils, and 
basophils, although the influx of these target populations was not further examined in these 
studies following M1 MΦ treatment. The proinflammatory activity of M1-activated MΦs is likely a 
key mechanism responsible for limiting biofilm growth. Interestingly, no significant changes in IL-
10 were detected following M1 MΦ transfer (Fig. 6.6D), which suggests that the broader balance 
of pro- versus anti-inflammatory factors may be a better predictor of inflammatory outcome 
compared to individual mediators. 
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Figure 6.2 
 
 
Activated macrophages, but not neutrophils, impair MRSA biofilm formation in vivo. 
C57BL/6 mice were infected with 10
3
 colony forming units (cfu) of USA300 LAC in the lumen of 
surgically implanted catheters to establish biofilm infection. Animals were treated with vehicle, 10
6
 
neutrophils (PMN), 10
6
 non-activated macrophages (MΦs), or 10
6
 M1-activated MΦs at 12, 24, 
and 48 h post-infection, whereupon catheters (A) and surrounding tissues (B) were collected at 
72 h to quantitate bacterial burdens. Results are expressed as the number of cfu per ml for 
catheters or cfu per mg tissue, to correct for differences in tissue sampling size. Significant 
differences are denoted by asterisks (*p < 0.05). Results are presented from individual animals 
combined from at least two independent experiments. 
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Figure 6.3  
 
 
Activated macrophages provide long-lasting defense from MRSA biofilm infections in vivo. 
C57BL/6 mice were infected with 10
3 
colony forming units (cfu) of USA300 LAC in the lumen of 
surgically implanted catheters to establish biofilm infection. Animals were treated with vehicle, 10
6
 
non-activated or 10
6
 M1-activated macrophages (MΦs) at 12, 24, and 48 h post-infection, 
whereupon catheters (A) and surrounding tissues (B) were recovered at day 14 to quantitate 
bacterial burdens. Results are expressed as the number of cfu per ml for catheters or cfu per mg 
tissue, to correct for differences in tissue sampling size. Significant differences in bacterial 
burdens between vehicle and MΦ-treated mice are denoted by asterisks (*p < 0.05).  
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Figure 6.4  
 
 
M1-polarized macrophages display superior efficacy at impairing MRSA biofilm formation. 
C57BL/6 mice were infected with 10
3
 colony forming units (cfu) of USA300 LAC in the lumen of 
surgically implanted catheters to establish biofilm infection. Animals were treated with either 
vehicle or increasing numbers of non-activated or M1-activated macrophages (MΦs) at 12, 24, 
and 48 h post-infection, whereupon catheters (A) and surrounding tissues (B) were recovered at 
day 3 to quantitate bacterial burdens. Results are expressed as the number of cfu per ml for 
catheters of cfu per mg tissue, to correct for differences in tissue sampling size. Significant 
differences in bacterial burdens between vehicle and MΦ-treated mice are denoted by asterisks 
(*p < 0.05). 
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Figure 6.5 
 
 
The ability of M1-polarized macrophages to impair MRSA biofilm development is mediated 
by MyD88-dependent signals. C57BL/6 mice were infected with 10
3
 colony forming units (cfu) 
of USA300 LAC in the lumen of surgically implanted catheters to establish biofilm infection. 
Animals were treated with vehicle or 10
6
 M1-activated macrophages (MΦs) derived from wild type 
(WT) or MyD88 knockout (KO) mice at 12, 24, and 48 h post-infection, whereupon catheters (A) 
and surrounding tissues (B) were recovered at day 3 to quantitate bacterial burdens. Results are 
expressed as the number of cfu per ml for catheters or cfu per mg tissue, to correct for 
differences in tissue sampling size. Results are presented from individual animals combined from 
at least two independent experiments. Significant differences are denoted by asterisks (*p < 
0.05). 
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Figure 6.6 
 
 
M1-activated macrophage therapy augments the local proinflammatory milieu during 
MRSA biofilm infection. Tissues surrounding S. aureus biofilms of vehicle, non-activated 
macrophage (NA MΦ), and M1-activated MΦ (A MΦ) treated mice were collected at day 3 (early 
treatment) or day 10 (established biofilm treatment) post-infection and homogenized to quantitate 
CXCL9 (A and E), CCL5, (B), IFN-γ (C), IL-10 (D), IL-17 (F), CXCL2 (G) and IL-6 (H) expression 
by Milliplex analysis. Results were normalized to the amount of total protein recovered to correct 
for differences in tissue sampling size. Significant differences are denoted by asterisks (*p < 0.05) 
and are representative of 5-8 mice/group (N.D. = not detected). 
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Introduction of M1-activated MΦs for the treatment of established MRSA biofilm infections. 
Based on the efficacy of our M1 MΦ early treatment paradigm, we next examined whether this 
would extend to attenuate bacterial growth in established MRSA biofilm infections. We employed 
a similar strategy to the early treatment regimen for MΦ administration except that M1 MΦs were 
initially given at day 7 following S. aureus infection, a point where robust biofilm has formed [32], 
with a repeat injection occurring at day 9. Similar to the early treatment paradigm, the introduction 
of M1-activated MΦs directly into the biofilm infection site led to significant reductions in bacterial 
burdens on infected catheters at day 10 post-infection, although no effect was seen in 
surrounding tissues (Fig. 6.7A and B, respectively). In contrast to M1 MΦ delivery, antibiotic 
treatment had no effect on biofilm formation (Fig. 6.7). As expected, Iba-1 immunofluorescence 
was significantly increased following the administration of both non-activated and M1-activated 
MΦs compared to the endogenous MΦ population in vehicle-treated mice (Fig. 6.8H). 
Importantly, arginase-1 expression surrounding biofilms was significantly decreased only 
following M1 MΦ treatment, whereas non-activated MΦs had no effect (Fig. 6.8G). In addition, 
the introduction of M1-activated MΦs into established biofilms augmented CXCL9, CXCL2, IL-7 
and IL-6 expression (Fig. 6.6E-H), although only IL-17 reached statistical significance. 
Collectively, these results demonstrate the successful re-direction towards a proinflammatory 
milieu following M1 MΦ transfer. 
 To investigate the longevity of M1-activated MΦs after introduction into biofilm infection 
sites, MΦs were labeled with near-infrared Quantum Dots (Qtracker® 800) and injected either at 
the time of infection or on day 7, representing early and established treatment paradigms, 
respectively. Animals were subjected to IVIS imaging immediately following MΦ transfer and 
every 24 h thereafter. Qdot-labeled M1 MΦs were still visible at 4 days post-injection (Fig. 6.9), 
which likely accounts for their ability to significantly limit MRSA biofilm formation. Although it is 
well established that Qdots are retained in intact cells, it remains possible that they could be 
internalized by neighboring phagocytic cells if donor macrophages are dying in situ. 
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Figure 6.7 
 
 
M1-activated macrophages attenuate established MRSA biofilm infection. C57BL/6 mice 
were infected with 10
3
 colony forming units (cfu) of USA300 LAC in the lumen of surgically 
implanted catheters to establish infection. On days 7 and 9 post-infection, animals received 
injections of vehicle, antibiotic (rifampicin + daptomycin), 10
6
 non-activated macrophages (MΦs), 
or 10
6
 M1-activated MΦs, whereupon catheters (A) and surrounding tissues (B) were recovered 
at day 10 to quantitate bacterial burdens. Significant differences between groups are denoted by 
asterisks (*p < 0.05) and represent animals from two independent experiments. 
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Figure 6.8 
 
 
Administration of M1-activated macrophages attenuates arginase-1 expression in 
established biofilms. Mice received injections of vehicle (A & D), 10
6
 non-activated 
macrophages (B & E) or 10
6
 M1-activated macrophages (C & F) beginning at days 7 and 9 post-
infection, whereupon tissues surrounding infected catheters were collected at day 10 and 
subjected to immunofluorescence staining with Iba-1 to identify MΦs (red), arginase-1 (green), 
and nuclear staining with DAPI (blue). Asterisks represent the original location of the catheter, 
which is non-adherent to glass slides. (G & H). Quantitation of arginase-1 and Iba-1 
immunofluorescence staining associated with S. aureus biofilms of vehicle-, non-activated- or M1 
MΦ-treated animals. Significant differences are indicated with asterisks (*p < 0.05; **p < 0.01; 
***p < 0.001) and are representative of two independent experiments with 8 mice per group. 
171 
 
Figure 6.9 
 
 
M1-activated macrophages remain localized at the site of biofilm infection and maintain a 
M1 phenotype. Mice received one dose of 10
7
 Quantum Dot-labeled M1-activated macrophages 
(MΦs; red) either at the time of S. aureus challenge (A) or at day 7 following infection (B), 
representing early and established therapies, respectively. The same cohort of animals was 
subjected to daily IVIS imaging to visualize MΦ persistence. Results are representative of 10 
individual animals per group. 
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EP67 attenuates MRSA biofilm formation in vivo and stimulates local proinflammatory 
responses. As a complimentary approach to the introduction of exogenous M1-activated MΦs, 
we next examined whether the CD88 agonist EP67 would re-program the endogenous MΦ 
infiltrates associated with MRSA biofilms in vivo from an anti-inflammatory M2 to a 
proinflammatory M1 phenotype to facilitate bacterial clearance. Animals were initially treated with 
EP67 at the time of infection with additional injections occurring at 24 and 48 h. Bacterial burdens 
associated with biofilm-infected catheters as well as surrounding tissues were significantly 
decreased following EP67 treatment compared to animals receiving an inactive scrambled 
sequence of EP67 (sEP67) or vehicle control (Fig. 6.10). Importantly, early EP67 treatment was 
key to restricting MRSA biofilm establishment, since minimal bacterial growth was detected at day 
14 following infection, even though the last dosing interval of EP67 occurred at 48 h (Fig. 6.10C 
and 10D).  
 To determine whether EP67 could skew the biofilm environment to a proinflammatory 
state, we evaluated cytokine and chemokine expression in biofilm-infected tissues. Several 
inflammatory mediators predominantly expressed by activated MΦs, such as IL-12p40 and 
RANTES, were significantly increased in EP67- compared to vehicle-treated animals (Fig. 6.11A 
and 11B). To further investigate mechanisms of EP67 action during biofilm infections, we 
compared the degree of MΦ influx into tissues surrounding MRSA biofilms using two 
complementary approaches. Immunofluorescence staining revealed that MΦ accumulation into 
EP67-treated biofilms was significantly increased at day 3 post-infection compared to vehicle 
(Fig. 6.12A). Importantly, while only a few MΦs were recruited to the biofilm surface in vehicle 
treated mice, EP67 administration dramatically increased the numbers of MΦs that migrated into 
the biofilm (Fig. 6.12B). The ability of EP67 to augment MΦ infiltrates in MRSA biofilms was 
confirmed by FACS (Fig. 6.12C). Collectively, these findings demonstrate that EP67 induces a 
proinflammatory milieu by augmenting MΦ recruitment and cytokine/chemokine production, which 
effectively counteracts the anti-inflammatory environment elicited by MRSA biofilms. We also 
investigated whether EP67 treatment could impact established biofilms; however, the peptide did 
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not exert any beneficial effects in this setting, suggesting its optimal use as a prophylactic 
modality under the conditions used in this study. 
 Collectively, our results have identified a previously unappreciated role for signals 
provided by M1-activated MΦs in biofilm containments and bacterial clearance. By extension, it is 
not unexpected that MRSA biofilms have the capacity to thwart this response by skewing MΦs 
away from a pro-inflammatory M1 to an anti-inflammatory M2 phenotype, which ensures biofilm 
persistence in an immunocompetent host. 
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Figure 6.10 
 
 
The macrophage activating peptide EP67 attenuates S. aureus biofilm growth in vivo. Mice 
were infected with 10
3
 cfu of USA300 LAC in the lumen of surgically implanted catheters to 
establish biofilms. Animals were treated with vehicle, EP67, or a biologically inactive scrambled 
derivative peptide (sEP67), beginning at the time of infection and again at 24 and 48 h, 
whereupon catheters (A & C) and surrounding tissues (B & D) were recovered to quantitate 
bacterial burdens at days 3 or 14 after infection. Data are expressed as the number of cfu per ml 
for catheters or cfu per mg host tissue for normalization. Results are presented from individual 
animals from at least two independent experiments. Significant differences are denoted by 
asterisks (*p < 0.05). 
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Figure 6.11 
 
 
EP67 augments proinflammatory mediator expression in biofilm infected tissues. Mice 
were infected with 10
3
 cfu of USA300 LAC in the lumen of surgically implanted catheters to 
establish biofilms. Animals were treated with vehicle or EP67 beginning at the time of infection 
and again at 24 and 48 h, whereupon tissues were collected at day 3 to quantitate the effects of 
EP67 treatment on IL-12p40 (A), CCL5, (B), IL-17 (C), IL-1α (D) and IFN-γ (E) expression by 
MIlliplex analysis. Results were normalized to the amount of total protein recovered to correct for 
differences in tissue sampling size. Results are presented from individual animals combined from 
two independent experiments (n = 14 per group). Significant differences between EP67- vs. 
vehicle-treated tissues are denoted by asterisks (*p < 0.05). 
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Figure 6.12 
 
 
EP67 augments macrophage infiltration into MRSA biofilms. (A & B) Mice were infected with 
10
3
 cfu of USA300 LAC in the lumen of surgically implanted catheters to establish biofilms. 
Animals were treated with vehicle or EP67 beginning at the time of infection and again at 24 and 
48 h, whereupon tissues surrounding infected catheters were collected at day 3 and subjected to 
immunofluorescence staining with Iba-1 to identify macrophages (MΦs; red) and nuclear staining 
with DAPI (blue). Asterisks represent the original location of the catheter, which is non-adherent 
to glass slides. (C) Macrophage (F4/80
+
) infiltrates in tissues surrounding infected catheters from 
vehicle- or EP67-treated animals were quantitated by FACS. Results are expressed as the 
percentage of cells after correction for isotype control staining and are representative of three 
independent experiments with 8 mice per group (*p < 0.05; ***p < 0.001).   
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Supplemental Figure S6.1 
 
 
M1 macrophage polarization enhances co-stimulatory molecule and reactive oxygen 
species (ROS) production. Bone marrow-derived macrophages (MΦs) from C57BL/6 mice were 
stimulated with 10 ng/ml IFN- γ + 10 µg/ml PGN for 6 h to induce M1-activation or medium alone 
(non-activated MФs). Expression of the cell surface markers MHC Class II and CD86 was 
assessed by FACS analysis (A). MФs were also incubated with MitoSOX (B) or CM-H2DCFDA 
(C) to measure mitochondrial superoxide (mROS) and determine total cellular H2O2, respectively. 
Significant differences are denoted by asterisks (*p < 0.05; **p < 0.01; ***p < 0.001). 
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Supplemental Figure S6.2 
 
 
Neutrophils are capable of phagocytosing S. aureus biofilms but do not reduce bacterial 
burdens. (A) Neutrophils (PMN) were isolated from the bone marrow of C57BL/6 mice, labeled 
with CellTracker Orange (orange-yellow), and co-cultured with S. aureus-GFP (green) during 
biofilm or planktonic growth for 2 h and imaged to observe their phagocytic ability. (B) After 24 h, 
biofilms were sonicated to quantitate bacterial burdens to evaluate the ability of PMNs to 
attenuate biofilm growth. Biofilms without PMNs were used as untreated controls. White arrows 
indicate phagocytic cells. 
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Supplemental Figure S6.3 
 
 
Neutrophil infiltrates into catheter-associated biofilms are minimal compared to 
abscesses. C57BL/6 mice were infected with 5x10
5
 CFU USA300 LAC either in the lumen of 
surgically implanted catheters or s.c. in the absence of any indwelling device to establish biofilm 
and abscess infections, respectively. Animals were sacrificed at days 3, 7, or 14 following S. 
aureus exposure, whereupon tissues surrounding infected catheters or s.c. injection sites were 
collected to quantitate neutrophil infiltrates by FACS. Results are expressed as the percent of 
Ly6G
+
 neutrophils after correction for isotype control staining and represent the mean ± SEM of 
three independent experiments. 
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Discussion 
 S. aureus is a frequent etiological agent of biofilm infections on indwelling devices and 
orthopedic implants [36, 292] and recent reports by our group and others have demonstrated that 
biofilms can skew the immune response to favor anti-inflammatory and pro-fibrotic pathways, 
which likely contribute to biofilm persistence [32, 162]. To overcome this immune deviation and 
provide a novel treatment strategy for biofilm infections, we augmented antimicrobial activity 
through the local administration of classically-activated M1 MΦs or treatment with the CD88 
agonist EP67, which invokes MΦ proinflammatory responses. Early administration of M1-
activated MΦs or EP67 limited biofilm formation, and treatment of established biofilm infections 
with M1-activated MΦ also significantly reduced catheter-associated biofilm burdens. Based on 
this evidence, we have identified a novel therapeutic strategy to limit S. aureus catheter-
associated biofilm infections by targeting MΦ activation, which may extend to other artificial 
implants. 
 The greatest therapeutic benefit of both MΦ targeting strategies in this study was 
achieved with early interventions to boost proinflammatory activity against biofilm infections. By 
extension, targeting MΦ proinflammatory activity may prove useful when administered to patients 
undergoing orthopedic surgery or other device-related implants to prevent nosocomial infections, 
particularly for individuals who are at high-risk for developing infectious complications. Although 
our M1-activated MΦ therapy did not completely eliminate established biofilms on infected 
devices, this strategy may prove beneficial in combination with antibiotics for patients who are 
unable or unwilling to undergo additional surgeries to manage the infection and maintain the 
implanted device. The significance of this approach is even more pronounced against the 
backdrop of the rapidly increasing elderly population, which becomes progressively less immune 
responsive and represents the primary recipients of hip and knee replacements. To achieve 
enhanced efficacy against established biofilms we are currently refining our M1-acitvated MΦ 
delivery; nonetheless, these results clearly demonstrate proof-of-principle that induction of a 
proinflammatory milieu during MRSA biofilm infection is beneficial for bacterial clearance. 
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 The therapeutic potential of activated MΦs is supported by our results demonstrating that 
early treatment with proinflammatory M1-activated MΦs significantly limited S. aureus biofilm 
growth in vivo and provided long-term protection from biofilm colonization. Likewise, activated 
MΦs were also effective at reducing S. aureus burdens in established biofilms. The 
cytokine/chemokine milieu elicited following M1-activated MΦ transfer reflects products derived 
from both T cells (i.e. IFN-γ and IL-17) and MΦs (i.e. CXCL9, CCL5, and IL-1), suggesting the 
coordinate activity of both cell types. This complex profile was only significant in the early 
intervention paradigm with M1-activated MΦs and the functional impact of these mediators on 
biofilm burdens remains to be determined. When querying the inflammatory milieu associated 
with established biofilms following M1 MΦ injection, only IL-17 was significantly increased. 
Although the other mediators examined did not show statistically significant increases, the trends 
towards elevated production may translate into increased efficacy when considering their 
combined action. This may explain why bacterial burdens were decreased on the catheter itself 
but not in the surrounding tissue because heightened inflammatory mediator levels may be 
required to impact the latter. It was not feasible to measure all of the microbicidal effectors 
associated with biofilm infections; therefore, it is likely that alternative factors not examined here 
could be significantly elevated after M1 MΦ treatment to account for the decreased bacterial 
burdens observed on infected catheters. It was unexpected that M1-activated MΦ transfer had no 
effect on tissue burdens in established biofilms. One explanation to account for this finding is that 
the number of MΦs injected was not sufficient to effectively manage bacterial burdens within the 
infected tissue. It is clear that M1-activated MΦs limit biofilm growth on the catheter itself; 
however, it remains to be determined whether this results from direct killing of the biofilm and/or 
enhanced dispersal of organisms from the biofilm into the surrounding tissue. In the latter case, 
this would lead to increased tissue-associated bacteria, which would likely overwhelm the 
microbicidal capacity of M1-activated MΦs injected at the infection site. In future studies, it would 
be interesting to determine whether M1-activated MΦs display synergy with antibiotics to facilitate 
biofilm clearance, since the former facilitates the dispersal of organisms from the biofilm, which, in 
182 
 
turn, would restore their metabolic activity and potential susceptibility to antibiotics. However, this 
is beyond the scope of the current report. 
One interesting finding from this study was that non-activated MΦs demonstrated a trend 
towards reduced biofilm burdens in vivo, although most of these differences did not reach 
statistical significance. This suggests that MΦ activation signals are present at sites of biofilm 
infection; however, additional stimuli are required to achieve maximal MΦ microbicidal action. 
One such signal could be direct MΦ contact with the biofilm, which is impeded by the host-
derived fibrotic matrix deposited around the infected device. Another possibility is that the degree 
of endogenous MΦ recruitment is insufficient to prevent biofilm establishment and therefore, the 
injection of a large number of MΦs at the site of infection is sufficient to limit biofilm growth, 
regardless of their activation state. Nonetheless, the superior action of M1-activated compared to 
non-activated MΦs at thwarting S. aureus biofilm formation was demonstrated by the ability of the 
former to significantly reduce bacterial burdens in vivo. 
 The use of EP67 may overcome the principal issues of biofilm immune dysfunction, as 
EP67 appears to provide the correct activation signals to CD88
+
 MΦs (and perhaps other APCs) 
[293],  to engage a robust microbicidal response in the developing biofilm and surrounding 
tissues. Indeed, EP67 has been shown to enhance the immune status of aged mice by re-
establishing an immunologically productive Th1/Th2 balance [294], indicating that this peptide 
may be a valuable therapeutic option in the aged population where multiple surgeries to manage 
infected devices is not desirable. However, unlike M1-activated MΦ transfer, EP67 treatment did 
not impact established biofilms, suggesting that additional therapeutic obstacles are present. One 
such hurdle is the fibrotic capsule that typically surrounds biofilm infections [295-297]. Although it 
is presumed that biofilm encapsulation by the host represents a protective response to contain 
the infection, this process may inadvertently provide survival advantages to the bacteria [298, 
299]. The signals responsible for eliciting this fibrotic response are currently under investigation; 
nonetheless in the current study the injection of MΦs immediately adjacent to the biofilm 
bypasses this fibrotic barrier and enables MΦ activation to occur. 
183 
 
Neutrophils represent a first line of defense against bacterial infections and possess a 
potent arsenal of bactericidal compounds, including defensins, cathelicidins, and lysozyme [300, 
301]. In terms of their bactericidal activity, neutrophils are most notable for their ability to produce 
large amounts of reactive oxygen intermediates catalyzed by NADPH oxidase. In addition, 
neutrophils also degranulate and generate neutrophil extracellular traps (NETs), a meshwork of 
DNA and enzymes that lead to the extracellular killing of S. aureus and other bacteria [302]. 
Despite these microbicidal mechanisms, neutrophil transfer did not attenuate S. aureus biofilm 
growth even when higher numbers of cells were injected. One possibility to explain this finding is 
that neutrophils rapidly degranulated following in vivo transfer and did not survive long enough to 
provide a measurable effect on biofilm growth. Nevertheless, it is important to acknowledge that 
neutrophils may contribute to biofilm clearance at other sites of infection, which remains to be 
determined. The reasons responsible for differential neutrophil recruitment in various biofilm 
models may be influenced by the degree of tissue vascularization and/or extent of biofilm 
development. Another factor to consider is the type of device. For example, bacteria colonizing 
the lumen of a hollow catheter are initially shielded from immune recognition by the catheter wall, 
which may afford additional protection. In the case of a solid device, bacteria are immediately 
exposed to host tissues, in theory enabling an immediate proinflammatory response. We are 
currently investigating these possibilities utilizing other in vivo models of staphylococcal biofilm 
infection. 
Collectively, these studies have identified a previously unappreciated role for M1-
activated MΦs in biofilm containment and bacterial clearance. By extension, it is not unexpected 
that S. aureus biofilms have the capacity to thwart this response by skewing MΦs away from a 
pro-inflammatory M1 to an anti-inflammatory M2 phenotype, which ensures biofilm persistence in 
an immunocompetent host. The implementation of our “M1-activated MΦ Transfer" therapy would 
allow MΦs to be “on board” to neutralize potential device contamination from normal skin flora 
during surgical insertion. While conventional antibiotics are ineffective for treating biofilms, they 
are commonly used to control bacteria that escape the biofilm matrix to prevent their colonization 
of other tissue sites. Such use of antibiotics imposes mutational pressures on the bacteria and 
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portends the possibilities of developing antibiotic resistance. MΦ-based immune cell therapy is 
not only efficacious at controlling biofilm infections, but has the added advantage of doing so by 
utilizing the host’s endogenous innate immune cells, thus eliminating mutational pressures 
imposed directly on the bacteria and decreasing the likelihood of the emergence of antibiotic 
resistant strains. 
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Chapter 7: Discussion 
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Key Findings and Conclusions: 
 The innate immune system is the first line of defense against invading pathogens. 
Macrophages are a critical component of this response, as they exhibit potent antibacterial 
properties and link innate and adaptive immunity with the capability to present antigen to T cells. 
However, bacteria like S. aureus have developed sophisticated ways to evade traditional immune 
mechanisms of clearance by developing biofilms on native tissues and indwelling medical 
devices. A key component of this subversion is the induction of MDSCs. MDSCs use a variety of 
mechanisms to alter macrophage phenotypes, suppress T cell responses, and dramatically alter 
the biofilm milieu, all of which play a role in the chronicity of biofilm infection [59, 60]. 
 Our laboratory has found that when S. aureus is seeded at a low inoculum (i.e. 10
3
 CFU) 
onto either titanium implants or into subcutaneous catheters, bacteria is able to adhere and 
accumulate, forming a biofilm with the ability to persist for several months [59, 60]. There is a 
divergence between these two models though in the degree of the inflammatory response that 
occurs following infection. Catheter-associated S. aureus biofilms attenuate proinflammatory 
mediator expression compared to sterile catheter implantation [32], whereas we have now shown 
that S. aureus orthopedic implant infection elicits sustained cytokine and chemokine production 
[59](Heim et al 2015). In large part this can be attributed to the site of the implanted device. The 
subcutaneous catheter is implanted into the flank where more mature tissue-resident populations, 
such as macrophages, elicit initial responses [32]. Furthermore, it is known that S. aureus biofilms 
elicit exaggerated macrophage infiltrates compared to abscesses and soon after encountering 
biofilms macrophages acquire anti-inflammatory characteristics and readily die [32]. However, the 
orthopedic implant infection is being established in close proximity to the bone marrow, which is 
rich in progenitor cells that can elicit a rapid inflammatory response following bacterial assault. 
This is not without consequence though, as we have shown that these immature cells become 
stuck in their differentiation and develop immunosuppressive properties allowing the biofilm to 
establish itself on the device and persist for long periods of time [59, 60]. Indeed, MDSCs rather 
than neutrophils or monocyte/macrophage populations are the primary immune infiltrate to the 
site of orthopedic implant-associated infection. In addition, only a very small percentage of CD3
+
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T cells are observed in infected tissue [59, 60]. Although MDSCs also accumulate during 
subcutaneous catheter biofilm infection, their numbers are greater in the orthopedic model and 
therefore we chose to use it for the majority of our studies characterizing the mechanisms of 
MDSC immunosuppression.  
 To determine the clinical significance of this model, and determine whether similar 
patterns of leukocyte infiltration and inflammatory mediator production occur in mice and humans, 
these parameters were assessed in tissue samples from patients undergoing revision surgeries 
for PJIs or aseptic loosening as a control. MDSCs in humans can be identified as CD33
+
HLA-DR
-
, and a population with this MDSC-like phenotype was detected in tissues from a patient with a 
confirmed S. epidermidis PJI, whereas few of these cells were observed in aseptic samples [59]. 
The CD33
+
HLA-DR
-
 population recovered from the S. epidermidis-infected tissue expressed 
genes characteristic of MDSCs, including Arg-1, iNOS, and IDO-1. Although we did not recover 
enough CD33
+
HLA-DR
-
 cells from these tissues to confirm their suppressive ability in vitro; they 
do exhibit MDSC-like characteristics. In addition, T cell influx was minimal in infected tissues, 
while T cells represented the most abundant infiltrate associated with aseptic orthopedic revisions 
[59]. Ultimately these results demonstrate the utility of our mouse model for understanding 
mechanisms involved in evasion of host immunity during PJI and potentially identify therapeutic 
targets. To this point we have not seen major discrepancies between immune profiles of tissues 
infected with different pathogens, although this is something we are paying close attention to in 
an effort to determine whether staphylococcal species are unique in the responses they elicit or if 
this is a consistent response. 
In comparing the number of Gr-1
+
CD11b
+
MDSC infiltrates in sterile and S. aureus-
infected tissues and found sterile tissues contained cells resembling MDSCs even though 
numbers were significantly increased in the presence of an infection [60]. This was an important 
finding, because although MDSCs isolated from sterile implants were unable to inhibit T cell 
proliferation, it suggested that an immature myeloid population is recruited to sites of injury with 
the capability to differentiate into effector populations if needed. However, S. aureus-derived 
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products could elicit proinflammatory mediator production which then causes these immature 
cells to acquire immunosuppressive function and remain arrested in an immature state.  
 Early studies were performed using the Gr-1 Ab, as it is a common marker for mouse 
MDSCs. However, Gr-1 recognizes both the Ly6G and Ly6C epitopes and therefore cannot 
discern between subsets of MDSCs. Staining for Ly6G and Ly6C revealed three distinct 
populations, namely Ly6G
high
Ly6C
+
, Ly6G
low
Ly6C
low
, and Ly6G
-
Ly6C
+
, of which only the 
Ly6G
high
Ly6C
+
 cells significantly inhibited CD4
+
 T cell proliferation [60]. In addition, FACS-purified 
Ly6G
high
Ly6C
+
 infiltrates expressed genes characteristics of MDSCs, and cytospins revealed the 
Ly6G
high
Ly6C
+
 population of suppressive cells had immature granulocyte morphology, 
characterized by numerous ringed nuclei. Together, these results are highly suggestive of these 
cells as G-MDSCs. The Ly6G
-
Ly6C
+
 population displayed monocyte-like morphology, and the 
Ly6G
low
Ly6C
low
 cells had some characteristics of neutrophils, including multi-lobed nuclei [60]. 
Both G- and M-MDSC subsets are found in a variety of pathologic conditions, and are thought to 
arise due to differences in the cytokine milieu during differentiation. In our laboratory’s mouse 
model of S. aureus PJI large amounts of G-CSF are produced relative to sterile implants, while 
very low levels of GM-CSF are detected [59], which could account for the favored G-MDSC 
response in this setting. A recent study comparing the phenotype of MDSCs in sepsis patients 
found that G-MDSCs are favored in patients with gram-positive sepsis, while M-MDSCs are 
expanded during infection gram-negative bacteria [303]. Currently, it is unclear whether this 
observation is true for PJI, but would correlate with our observations thus far. 
 There is currently no direct way to deplete only MDSCs in vivo, due in large part to the 
surface markers shared with other myeloid populations. In our model, the immunosuppressive 
MDSCs express the highest levels of Ly6G, whereas the monocyte population was Ly6G
-
. 
Therefore, we attempted to assess the functional role of MDSCs by using the anti-Ly6G Ab 1A8. 
Ly6G
+
 cells were depleted during the entire course of S. aureus biofilm infection, which led to 
increased monocyte recruitment at days 7 and 14 post-infection, potentially as a compensation 
mechanism due to depletion. Interestingly, monocytes isolated from infected tissues of Ly6G 
depleted mice had increased expression of iNOS, IL-1β, IL-12p40 and IL-6 compared to 
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monocytes from IgG-treated mice (Heim et al 2014). This increased proinflammatory profile was 
concomitant with significantly reduced bacterial burdens in the tissue and knee joint of Ly6G-
treated mice. For the first time, we were able to show that MDSCs are negatively regulating 
innate immune responses to S. aureus biofilm infection, which includes the active inhibition of 
monocyte proinflammatory responses that contribute to bacterial clearance. These conclusions 
were confirmed when mice were treated with the Gr-1 Ab, which targets and depletes MDSCs, 
neutrophils and monocyte macrophage populations. With this strategy, higher bacterial burdens 
were observed in implant-associated tissues in the absence of MDSCs and 
monocyte/macrophage effector populations [60]. 
 Interestingly, during Gr-1 Ab treatment, we observed an increase in Gr-1
+
 (Ly6G/Ly6C) 
infiltrates [60]. This was likely, a compensatory mechanism in response to increased bacterial 
burdens at the implant site and systemically, as bacteria disseminated to the heart, kidney and 
spleen. In addition, there was extensive extramedullary hematopoiesis occurring in the spleens of 
mice treated with Gr-1 Ab, which could contribute to the compensatory increase in Gr-1
+
 cells 
during infection. Extramedullary hematopoiesis is a phenomenon that is common during chronic 
inflammatory diseases and cancer. During infection the requirement for myeloid cells dramatically 
increases and creates a need for emergency myelopoiesis and subsequent mobilization of 
immature cells from the bone marrow and spleen. Once again, this data suggests that the 
accumulation of MDSCs is a direct result of signals derived from the establishing S. aureus 
biofilm infection.  
 During the initial characterization of immune infiltrates to S. aureus orthopedic biofilm 
infection, we observed FACS-purified MDSCs had increased expression of IL-10 relative to 
monocytes [60]. In addition, IL-10 expression was increased in implant-associated tissues of S. 
aureus infected mice. IL-10 is an anti-inflammatory cytokine important in regulating immune 
responses and has been shown to be secreted by MDSCs to polarize macrophages toward an 
anti-inflammatory phenotype and induce Treg accumulation. IL-10-GFP reporter mice enabled us 
to demonstrate that Ly6G
high
Ly6C
+
 MDSCs are indeed a major source of IL-10 during infection, 
and the loss of IL-10 enhances monocyte/macrophage recruitment to implant-associated tissues. 
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Although during S. aureus biofilm infection MDSCs do not suppress T cell proliferation via IL-10, 
which agrees with another recent report using a different model of S. aureus infection [149], 
production of IL-10 does influence the phenotype and effector functions of monocyte/macrophage 
populations. We observed increased proinflammatory gene expression in Ly6G
-
Ly6C
+
 monocytes 
in IL-10 KO mice, which paralleled significantly reduced bacterial burdens by day 14 post-
infection. Adoptive transfer experiments revealed that the effects of MDSCs on bacterial burdens 
and leukocyte influx into S. aureus biofilm infections are only partially dependent on IL-10. It was 
not surprising that the effects of MDSCs were not mediated solely through IL-10. There are a 
number of other factors implicated in MDSC immunosuppressive function, including Arg-1 
expression which is currently an area of investigation in our laboratory. 
In addition to the function of MDSCs, we were also interested in understanding how host- 
or bacteria-derived factors influence the recruitment and activation of MDSCs that ultimately 
permit biofilm establishment and promote chronicity. The accumulation and subsequent activation 
of MDSCs is thought to occur in a two-step manner. The first process of MDSC expansion being 
induced by various cytokines and growth factors produced by tumors, cells responding to 
infectious agents, or chronic stimulation, and the second signal provided by proinflammatory 
molecules. In our model of S. aureus orthopedic biofilm infection, we observed significantly fewer 
MDSC infiltrates in IL-12p40 and p35 KO tissues compared to WT [59]. However, FACS-purified 
MDSCs from KO mice retained their ability to suppress CD4
+
 T cell proliferation in vitro, indicating 
that in this model IL-12 is not a proinflammatory signal associated with MDSC activation. Rather, 
IL-12 appears to regulate MDSC recruitment, and the absence of MDSCs in IL-12-deficient mice 
results in increased monocyte influx and significantly reduced bacterial burdens in implant-
associated tissues. Adoptive transfer of WT MDSCs into IL-12p40 KO animals worsened disease 
outcome and confirmed a direct role for MDSCs in the inhibition of biofilm clearance and 
suppression of monocyte/macrophage responses [59]. Importantly, these studies demonstrate 
that IL-12p70 is important for this organization of the biofilm permissive response. Similar 
phenotypes were observed in both p40 and p35 KO mice but not in p19 KO animals.  
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Although our findings do not exactly follow the two-step model for MDSC expansion and 
activation as proposed by Gabrilovich et al [121], IL-12 appears to play a key role in the 
recruitment of MDSCs into biofilm infection via a chemoattractant that remains to be identified. It 
is possible that the induction of a proinflammatory cytokine like IL-12 induces COX-2 production 
of PGE2 and subsequent generation of MDSCs. Once recruited, MDSCs are activated and 
produce significant amounts of IL-10 by day 5 post-infection, which plays a critical role in 
polarizing monocytes/macrophages toward an anti-inflammatory phenotype. It could be argued 
that IL-10 does not play a critical role because differences were only observed at two weeks post-
infection. However, IL-10 could be modulating inflammation in a manner that was not examined in 
these studies. Ultimately, the loss of either IL-12 or IL-10 during the early MDSC recruitment 
(days 3-7) or effector phases (days 7-14), respectively, promotes biofilm clearance and implicates 
a role for each cytokine at distinct stages of infection. Collectively, these findings point to the 
complexity in the MDSC response to S. aureus biofilms, and the identification of other 
mechanisms contributing to this response is ongoing in our laboratory.  
As our understanding of MDSCs and their immunosuppressive mechanisms during S. 
aureus biofilm infection develop, we hope to be able to identify potential therapeutic targets to 
treat these devastating and chronic infections. Of particular interest, is the manipulation of the 
innate immune response to promote clearance. Although complex, this approach would bypass 
the need to identify elusive S. aureus epitopes to induce a memory response and eliminate the 
evolution of more antibiotic resistant strains of bacteria. Previously, the Kielian laboratory 
demonstrated that upon co-culture with S. aureus biofilms in vitro macrophages acquired an anti-
inflammatory phenotype characterized by increased Arg-1 expression and were readily killed 
before any clearance could take place [32]. These results were also confirmed in vivo using the 
mouse model of subcutaneous catheter biofilm infection.  More recent experiments have shown 
that M1-activated macrophages stimulated with IFN-γ plus PGN were capable of phagocytizing 
biofilm-associated organisms resulting in significant reductions in bacterial burdens following 24 h 
of co-culture [100]. To assess the ability of M1-activated macrophages to attenuate biofilm 
formation in vivo, animals were treated with 10
6
 neutrophils, nonactivated macrophages, or M1-
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activated macrophages at 12, 24 and 48 h post-infection. The introduction of M1-activated 
macrophages at the site of biofilm infection significantly reduced bacterial burdens on catheters 
and in surrounding tissues at day 3 post-infection and perhaps more importantly, led to long-term 
effectiveness against biofilm formation, as catheters showed minimal evidence of biofilm growth 
at day 14 without any additional macrophage treatment [100]. This ability of M1-polarized 
macrophages to impair biofilm development is mediated by MyD88-dependent signals, further 
emphasizing that the production of proinflammatory cytokines is critical for bacterial clearance at 
early stages of infection. Addition of neutrophils had no impact on biofilm formation. These 
experiments indicate that the introduction of S. aureus near an implanted device rapidly alters the 
environment to promote a biofilm-permissive setting, which includes the skewing of macrophage 
phenotypes that prevent bacterial clearance. 
 Based on the efficacy of this early treatment paradigm, where animals received 
treatment at 12, 24 and 48 h post-infection, we wanted to determine whether the introduction of 
M1-activated macrophages could attenuate growth of established biofilm infections. Macrophages 
were administered on days 7 and 9 post-infection; however, significant reductions in bacterial 
burdens were only observed on infected catheters at day 10 post-infection, no effect was seen in 
surrounding tissues. The addition of M1 macrophages was associated with reductions in Arg-1
+
 
macrophages surrounding biofilms and augmented inflammatory cytokine and chemokine 
expression [100]. This suggests that the transfer of M1-macrophages is able to begin 
transforming the environment toward one that would promote bacterial clearance, but the biofilm 
is still a formidable force. We thought that perhaps this limited ability to clear bacteria could be 
due to exhausted cells following administration into the already established biofilm. However, 
labeling M1-activated macrophages with Quantum Dots showed that these cells remain localized 
at the site of biofilm infection 96 h and 4 days after being injected at the time of infection or day 7, 
respectively [100]. It is likely that the prolonged signal was due to quantum dots within 
macrophages, as they are relatively stable. However, it is possible that some of the continued 
signal is due to residual dots in the extracellular milieu following macrophage death.  
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Collectively, these studies demonstrate that S. aureus biofilm infections skew the local 
milieu to promote immunosuppression which favors bacterial persistence. This is achieved 
through the induction of MDSCs, which rapidly accumulate at the infection site following 
inoculation and skew the activation of monocyte/macrophage infiltrates toward an anti-
inflammatory phenotype that renders them unable to clear bacteria. Additionally, there is a 
paucity of T cell infiltrates associated with these biofilm infections, which could be a direct result 
of MDSC suppressive activity and have severe implications on the success of vaccines currently 
in development. We have found that manipulation of MDSCs by limiting their recruitment to the 
site of infection, or alternatively their function once accumulated, does allow for some degree of 
proinflammatory immune responses and clearance of biofilm-associated bacteria. Although the 
host immune system-biofilm interaction is multi-faceted and complex, these results demonstrate 
that targeting the host immune response to biofilm could lead us toward novel therapeutic 
interventions to treat these chronic infections. 
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